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 Protein misfolding diseases such as prion diseases, Alzheimer’s disease, and Parkinson’s disease, are fatal 
neurodegenerative diseases caused by a misfolded protein. There are no known therapeutics that extend survival 
times of afflicted individuals with these diseases. An attractive therapeutic option for protein misfolding disorder is 
RNA interference, which uses either short hairpin RNA or small interfering RNA (siRNA) to target a specific 
mRNA for degradation that results in a reduction of protein levels. The reduction of a target mRNA/protein can 
result in a decrease of misfolded protein in the central nervous system (CNS). However, crossing the blood-brain 
barrier remains the main challenge for developing RNA interference therapeutics to the CNS. Liposomes are 
commonly utilized to deliver siRNA to peripheral sites and are being investigated for their ability to deliver siRNA 
to the brain. We have previously reported on a new liposome delivery system that delivered siRNA targeted towards 
the cellular prion protein, PrP
C
, to mouse neuroblastoma cells. PrP
C
 is a normal host cellular protein that misfolds 
into a protease resistant isomer, PrP
Res
, which leads to the development of prion diseases. We call these siRNA 
delivery vehicles: liposome-siRNA-peptide complexes (LSPCs). LSPCs are targeted towards the CNS using a small 
peptide from the rabies virus glycoprotein, called RVG-9r. In the second chapter of this dissertation, we show that 
an intravenous injection of LSPCs results in a 40-50% reduction of neuronal PrP
C
. Upon injection of LSPCs, we 
observed that half of all treated mice had PrP
C
 siRNA targeted towards the area of the brain several hours after 
injection. However, we also observed a clearance of PrP
C
 siRNA by the kidneys in the other half of LSPCs-treated 
mice. Therefore, we designed two other liposomal delivery vehicles that would allow us to encapsulate the siRNA in 
the liposome and covalently link RVG-9r to the outside of the liposome. We also added PEG lipids to these new 
delivery vehicles to extend the circulation half-life of the liposomes. We call these additional delivery vehicles 
peptide-addressed liposome-encapsulated therapeutic siRNA (PALETS). The two PALETS formulations include 
one cationic (DOTAP [1,2-dioleoyl-3-trimethylammonium-propane]) PALETS and one anionic (DSPE [1,2-
Distearoyl-sn-glycero-3-phosphoethanolamine]) PALETS. We have utilized the cation protamine sulfate to 
encapsulate the siRNA within the anionic PALETS. The addition of protamine sulfate to the siRNA resulted in an 
encapsulation efficiency of 80-90% in DSPE PALETS. Four days after treatment with LSPCs and PALETS, LSPCs 
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have the biggest decrease in neuronal PrP
C
 on the cellular surface, while DOTAP PALETS have the greatest 
reduction of PrP
C
-positive cells. DSPE PALETS showed no statistical difference between the treated and untreated 
mice at this time point; however, two of the three treated mice did have a decrease in their neuronal PrP
C
, indicating 
that this delivery vehicle is able to deliver PrP
C
 siRNA to the brain. There was no reduction in mRNA levels of any 
of the treated mice in the brain but the DOTAP LSPCs and DOTAP PALETS resulted in a 2-fold decrease of PrP
C
 
mRNA levels in the kidney, while DSPE PALETS resulted in a 2-fold increase of PrP
C
 mRNA levels in the same 
organ.  





These therapeutics were successful in decreasing the amount of PrP
Res
 in vitro but they had limited success in vivo. 
Challenges of these therapeutics included toxicity, inability to cross the blood-brain barrier, strain specificity, and/or 
failure to affect survival times. PrP
C
 became an attractive therapeutic option when it was shown that PrP-null mice 
did not develop any outward phenotypic differences from the removal of PrP
C
. Our LSPCs, with PrP
C
 siRNA, 
reduced the amount of PrP
C
 protein and PrP
C
 mRNA levels in mouse neuroblastoma cells. This reduction in PrP
C
 
resulted in a concomitant decrease of PrP
Res
 and a ‘curing’ of the prion-infected cells. In the third chapter of this 
dissertation, we have treated two different mouse models with our LSPCs at different time points to assess the 
pharmacodynamics of the treatment. In vivo live imaging followed by flow cytometry revealed delivery of PrP
C
 
siRNA to the brain one hour after intravenous injection. The LSPCs resulted in a decrease of neuronal PrP
C
 in a 
C57Bl/6 mouse model at 24, 48 hours, and 4 days after treatment. A decrease in neuronal PrP
C
 was also observed in 
a CD1 mouse model at 4 and 15 days after treatment. Surprisingly, mRNA levels did not always concur with the 
protein level data. At certain time points, the mice with the biggest decline in PrP
C
 protein had the greatest increase 
of PrP
C 
mRNA. Off-target effects were observed in the kidney, which might have been caused non-specifically by 
LSPCs treatment and not by the PrP
C
 siRNA. We also show that PrP
C
 protein levels decrease by 70% in prion-
infected mice after three consecutive LSPCs treatments spaced two weeks apart. Analysis of mRNA levels of these 
mice after three treatments revealed a simultaneous reduction in PrP
C
 mRNA levels.  
 Several researchers have shown a reversal in prion neuropathology that results after decreasing the amount 
of PrP
C
, either by a Cre/loxP system or short hairpin RNA. Therefore, we treated prion-infected mice with our 
LSPCs treatment targeting PrP
C
. Two treatment studies were conducted to determine the optimal dosing regimen of 
LSPCs treatment. The first study treated prion-infected mice with LSPCs every two weeks starting at 120 days post 
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inoculation and the second study treated mice with LSPCs every 3-5 weeks starting at 120 days post inoculation. 
The mice were intraperitoneally inoculated with a low dose of RML-5 prions to simulate a more natural prion 
infection. Unfortunately, in the fourth chapter of this dissertation we show that neither of the dosing regimens 
resulted in an increase in survival times of prion-infected mice. The mice in these two dosing studies were also 
subjected to burrowing and nesting behavioral tests to determine if LSPCs treatment improves behavioral outcomes. 
We show that LSPCs treatment every two weeks improves behavior scores at 141 and 169 days post inoculation in 
some treated groups. This improvement in behavior indicates that, while the LSPCs treatment are not affecting 
survival times, they are improving behavioral outcomes of prion-infected mice. Surprisingly, three of the uninfected, 
treated controls died immediately after LSPCs treatment of an apparent Type III hypersensitivity. Therefore, we 
performed ELISAs to measure the immune response towards the RVG-9r peptide. Several groups of treated mice in 
the terminal dosing studies had increased levels of IgG against RVG-9r compared to the infected, untreated control. 
In another study, it was revealed that three total IgG levels against RVG-9r increased after three subsequent LSPCs 
treatments spaced two weeks apart. We also assessed the amount of PrP
Res
 in the brains and spleens of LSPCs-
treated mice. Using the protein misfolding cyclic amplification assay, we determined that LSPCs treatment causes 
an increase in PrP
Res
 levels in the brain after one to six LSPCs treatments. No trends can be seen in the spleen. 
 Taken together these results indicate that the current LSPCs formulation using RVG-9r and PrP
C
 siRNA 
result in an immune response that may interfere with any benefits of the treatment. Another explanation for these 
results is that PrP
C 
may be tightly regulated at the transcriptional level, so the cell may try to return the 
mRNA/protein levels to normal by increasing PrP
C
 mRNA when it detects a decrease in PrP
C
 mRNA or protein 
levels. The increase in PrP
C
 may be the cause of the increase of PrP
Res
 observed in these studies. Therefore, 
transiently decreasing PrP
C
 via siRNA may not be the best therapeutic option available. It is recommended that more 
studies are undertaken to further elucidate the transcriptional regulation and immune response towards the LSPCs 
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History: A new but old disease 
In Europe and England in the mid-18
th
 century, sheep farmers changed their breeding protocols to select for 
more desirable traits related to wool production and quality. This breeding protocol resulted in a massive increase of 
inbreeding among the sheep flocks. Shortly after the increase in inbreeding, sheep farmers started to notice that their 
flocks succumbed to a disease that the farmers had never seen before. The first reports of this disease were in 1732 
in Spain and England under the name 'rickets,' which would later be known as scrapie
1-3
. It is unclear if the 
inbreeding caused the scrapie epidemic, but some have speculated that while the farmers were selecting for wool 
production, they may inadvertently have selected for a genetic element that led to scrapie susceptibility
1
. 
An excerpt published in 1811 in the General View of the Agriculture of the County of Cambridge describes 
the clinical signs of rickets (scrapie) as seen by a sheep farmer of an affected flock during the 18
th
-century epidemic:  
At this time the animal appears extremely uneasy, constantly rubbing its head against the hurdles and 
fences, and scratching its back and sides with its horns, starting suddenly, running a few steps, then falling 
down, where it will remain a short time and then rise and begin feeding as in perfect health. The skin is 
perfectly free from eruption and other appearances of disease, nor are there any traces of the disorder 
discoverable by examination of the entrails, the body, or the head of the animal…
2
 
Clinical signs of scrapie during this epidemic included emaciation, paresis of hind limbs, trembling, ataxia, and 
excessive drinking. The clinical signs appeared in animals between 2-4 years of age and lasted between 10-12 weeks 
after the initial onset. As mentioned in the excerpt, necropsies of affected animals showed no anatomical 
abnormalities
1,2
. No defining pathological features of scrapie disease would be found until 1898 when Besnoit and 
colleagues discovered neuronal vacuolation in all affected sheep
4,5
. In 1936, scrapie was classified under a new 
disease group known as transmissible spongiform encephalopathies (TSE)
1-3,6,7
. 
The epidemic ended when farmers started breeding rams from scrapie-resistant breeds to ewes from 
susceptible breeds. At this time, researchers believed scrapie was hereditary since the altered breeding protocol 
resulted in sheep breeds that were resistant to scrapie. However, investigations in the 1930s revealed that the scrapie 
agent, while probably having a hereditary component, was also infectious. The Cuillé and Chelle experiments and a 
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louping-ill-vaccine-related scrapie outbreak, both occurring in the 1930s, revealed the infectious nature of the 
scrapie agent
3,6,8,9
. Cuillé and Chelle inoculated seventeen sheep through various routes with central nervous system 
(CNS) material from scrapie-infected sheep. Eight of the inoculated animals later developed scrapie. In a similar 
experiment, these same two researchers discovered that the scrapie agent could pass through a porcelain filter
8,9
. At 
the same time, a new scrapie outbreak, associated with vaccination of louping-ill vaccine, was affecting flocks in 
England and Scotland. Louping-ill vaccine is prepared using brain, spinal cord, and spleen from animals affected by 
the louping-ill virus, and formalin-fixed to inactivate the virus
3,6,8
. Researchers discovered that brain tissue used to 
generate a batch of the louping-ill vaccine in 1935 was contaminated with scrapie. Several important conclusions 
came from these studies: the scrapie agent is transmissible, it passes through a membrane that catches bacteria and 
larger microorganisms , and it is present in the brain, spinal cord, and/or spleen of infected animals
8
. Even with these 
breakthroughs, the scientific investigation into the cause of the scrapie epidemic/outbreaks did not intensify until 
after two human TSEs were discovered: Creutzfeldt-Jakob disease (CJD) and kuru.  
In 1920, Hans-Gerard Creutzfeldt described a 23-year-old female patient as having ataxia, dementia, 
tremors, and spasticity. The patient had several symptoms related to other neurodegenerative disorders, but she also 
had symptoms that did not fit these previously described diseases. Therefore, Creutzfeldt proposed that he had 
discovered a new disease
10
. A year later, Alfons Jakob described nearly identical symptoms in three additional 
patients. Autopsy findings of these three patients revealed astrocyte proliferation and severe neuronal degeneration 
in the cerebral cortex and basal ganglia. Jakob proposed that both his and Creutzfeldt’s patients were suffering from 
the same neurodegenerative disease
11
. This disease would later be referred to as Creutzfeldt-Jakob disease or CJD
12
. 
In a remote region of the Eastern Highlands of New Guinea, Carleton Gajdusek and Vincent Zigas 
discovered a new disease called kuru. Early symptoms of kuru included ataxia and tremors, and later symptoms 
included cerebellar ataxia, tremors, dysarthria, paralysis, dementia, and eventually death. Kuru affected children of 
all ages/gender and adult females but rarely affected adult males. There were no gross pathological findings upon 
autopsy of any affected individual
1,13-16
. However, microscopic examination of the CNS revealed neuronal 
degeneration, plaques, and astroglia proliferation in all patients
15
.  
 Later it was discovered that kuru was transmitted through the cannibalistic consumption of nervous system 
material during death rituals. The Fore people commonly performed rituals of respect for their dead relatives by 
consuming the flesh and organs of the individual. The women performed the dismemberment of the bodies during 
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the ritual and often had children crowding around them. Women and children also ate the nervous tissue of the dead 
individual more often than the males of the tribe. This gender task difference revealed why women and children had 




 In 1959, kuru, scrapie, and CJD were all proposed to be similar diseases based on epizootiological, 
etiological, and pathological characteristics. Hadlow suggested a link between scrapie and kuru. He noted that both 
diseases have a long incubation period, affect restricted populations, and have a similar clinical disease course. Kuru 
and scrapie also have the same neuropathological characteristics such as activated astrocytes and widespread 
neuronal degeneration
6,17
. Klatzo performed a pathological study on the brains of twelve kuru patients and noted that 
there were striking similarities between the pathological characteristics of kuru and CJD
6,18
. Experimental 
transmission of kuru and CJD into chimpanzees proved that these diseases not only share common 
neuropathological features, but they also share the infectious nature that characterizes scrapie
17,19,20
. These theories 
about relatedness would one day lead to the discovery that the same etiological agent causes all three diseases, and 
to the classification of all three diseases as TSEs. 
Discovering Prions: Characteristics of the scrapie agent 
 Scrapie research did not intensify until the 1960s-70s due to the lack of laboratory animal models for the 
disease. In the 1960s, R.L. Chandler successfully transmitted scrapie disease to laboratory mice inoculated 
intracerebrally with scrapie from a goat
21
. The results from these studies showed that the mice developed similar 
clinical signs and neuropathological characteristics of scrapie disease in goats and sheep
21,22
. Early research of 
scrapie in mice provided details about how the agent spread throughout the bodily organs. Peripheral exposure of 
scrapie demonstrated that the scrapie agent replicates in lymphocytic organs such as the spleen, then moves to the 
spinal cord where it can infiltrate the brain
23-25
. These early studies led to many hypotheses about the identity of the 
scrapie agent, which resulted in many discoveries on the characteristics of the scrapie agent. 




 centuries, researchers noticed that most of the scrapie-
afflicted sheep were also affected by sarcosporidiosis caused by the parasite Sarcosporidia. These researchers 
proposed that a heavy infection of Sarcosporidia was likely the cause of scrapie, and was the scrapie agent. 
However, not all sheep infested with Sarcosporidia also contracted scrapie
2
. Then in the 1930s, Cuillé and Chelle 
proved that the activity of the scrapie agent did not decrease when filtered through porcelain filters. They suggested 
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that the scrapie agent is a virus and cannot be a bacterium or a parasite due to its small size
8,9
. This result was 
confirmed when scrapie activity remained intact after filtration through 50 nm filters. Activity was significantly 
reduced when passed through 25 nm filters suggesting that the operational size of scrapie is around 50-30 nm in 
diameter
26
. The virus hypothesis was the most prevalent theory of the identity of the scrapie agent
27,28
, but the 
identity was far from solved. 
 The virus hypothesis was an attractive theory at the time but it could not explain many of the unusual 
biochemical characteristics of the scrapie agent. Experiments involving ultraviolet (UV) and ionizing irradiation
29-33
, 
and nucleic acid enzymes
29,34-37
 provided some of the most compelling pieces of evidence that scrapie is not a virus. 
Viruses store their genetic information within DNA/RNA and do not replicate without these molecules
27
. Nucleic 
acids are destroyed under UV and ionizing irradiation and using RNase and DNase treatment. Unlike viruses, the 
activity of the scrapie agent does not diminish under high concentrations of UV and ionizing irradiation, RNases, 
and DNases, suggesting that the main component of scrapie is not a nucleic acid
29-37
. Also, Alper et al. found the 
molecular weight of the scrapie agent to be 1.5-2x10
5
 Daltons, which indicates an impossibly small DNA/RNA 
genome of around 800 nucleotides. A genome of this size would be too small to encode anything useful
30
. 
Therefore, it was proposed that scrapie must not be a virus since it replicates without the use of a nucleic acid. 







, and replicating protein
29,40-42
 among others. Since there was such a wide range of 
hypotheses to describe the scrapie agent, researchers performed many biochemical experiments to try and deduce 
the identity of the scrapie agent. The agent does not have reduced activity when boiled. The activity of scrapie 
decreased only when temperatures of 100°C are reached
29,35
. The agent is resistant to formalin inactivation, which 
usually inactivates viruses
37
. Several chemicals that inactive other infectious agents have little to no effect on the 




, and treatment with fluorocarbons
29,35,44
. 
Some chemicals that did affect the titer of the scrapie agent include urea
29,44









. These characteristics excluded 
most of the hypotheses about the agent but also resulted in much confusion on the actual identity. 
 The intracellular location of the scrapie agent was of great interest to early scrapie researchers.  It became 
immediately apparent, with the advent of the mouse scrapie model, that the scrapie agent associates with 
membranes
29,45-49
. Differential centrifugation of scrapie-infected brain homogenate showed scrapie agent activity 
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located in every cellular fraction, with the crude mitochondrial fraction showing the greatest activity
45,46
. Techniques 
using ultrasonic vibrations and filtration revealed scrapie activity was highest in crude mitochondrial sub-fractions 
containing plasma membrane and endoplasmic reticulum
48
. Several years later, the advent of two techniques 
resulted in the discovery of the precise location of the scrapie agent. The two techniques were: a mouse scrapie cell 
line, SMB cells, was developed using brain homogenate from a mouse infected with the Chandler scrapie strain
50
, 
and the Bingham and Burke method of separating plasma membrane from endoplasmic reticulum
49
. Scrapie activity 
was isolated to the plasma membrane by separating it from the mitochondrial fraction using these two techniques
49
. 
 This discovery led to the membrane hypothesis, which stated that the scrapie agent does not contain nucleic 
acids but instead is a membrane-bound complex of macromolecules. The membrane hypothesis explains some of the 
unusual physicochemical properties of the scrapie agent, including that the agent is partially resistant to proteolytic 
enzymes and heat, and that all cellular fractions contain some scrapie activity
29,47
. However, questions remained 
whether the scrapie agent was a self-replicating membrane, or if the agent only associated with membranes. 
 In the late 1970s, Stanley Prusiner performed purification experiments on the scrapie agent that ultimately 
lead to the identity of the agent. He used differential centrifugation, detergent treatment, and a sucrose gradient to 
purify the scrapie agent from cell constituents. Using the purified scrapie agent, he determined that, while the 
scrapie agent associated with membranes, its infectious nature remained intact when isolated away from 
membranes
51-53
. The scrapie agent was also found to aggregate and be of a hydrophobic nature
52,54,55
. The agent was 
also inactivated and reactivated using carbethoxylation and hydroxylamine
56
. Prusiner postulated the scrapie agent 
was a protein because of the above conclusions, and because chemicals that disrupt/denature proteins inactivate the 
scrapie agent. He defined the agent as a proteinaceous infectious particle, aka prions
53,55
. 
 The prion hypothesis remained highly controversial for some time but the discovery of a protein that was 
purified from scrapie brains helped cement the hypothesis in the scientific field. A highly protease-resistant protein, 
PrP (aka the prion protein), was found upon proteinase K (PK) digestion of hamster brains infected with scrapie. 
This PK-resistant fragment has a molecular weight of 27,000-30,000 Daltons. PrP27-30 is only found in infected 
brains and is the only major protein found in these samples
57-59
. PrP27-30 is also found in patients with kuru, CJD, 
and another human TSE disease Gerstmann-Sträussler-Scheinker syndrome (GSS)
57,58,60
. Further analysis of PrP27-
30 revealed that it has 245 amino acids, and is highly enriched with glycine residues
61
. Electron microscopy images 
of PrP27-30 showed aggregation of the fragment into rod-shaped particles that were 100-200 nm in length. The rod-
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shaped aggregates stained with Congo red and showed a green birefringence, which along with glycine residues, 
indicates that PrP27-30 is an amyloid protein.  The authors of this study speculate PrP27-30 contains b-pleated 
sheets as this is another characteristic of amyloid protein
62
. PrP27-30 was also discovered to be a glycoprotein with 
multiple carbohydrate residues
63
. With the discovery of a short sequence of PrP27-30 in prion-infected samples, the 
next question became what biological process leads to the creation of this protein. 
Beyond the Discovery of Prions: The cellular prion protein (PrP
C
) 
History of the cellular prion protein 
 For many years, it was postulated that scrapie, kuru, and CJD were hereditary and possessed a genetic 
element of transmissibility. This hypothesis existed because some sheep were known to be resistant to scrapie 
infection, and Gajdusek had initially postulated a genetic basis of kuru transmissibility due to more women and 
children being afflicted with the disease
15,16
. However, this genetic element, much like the prion, was highly elusive. 
Scrapie mouse models provided an ideal model to study the genetic control of the scrapie agent quantitatively. 
Inbred strains of mice that were bred with half-inbred strains of mice revealed that an autosomal dominant gene with 
a single pair of alleles controlled the incubation period of the ME7 scrapie strain. The authors coined this gene sinc, 
with the s7 allele for short incubation periods and the p7 allele for long incubation periods
64,65
. Interestingly, even 
though the alleles correlated with short and long incubation times, the titer of the scrapie agent remained at the same 
concentration upon terminal disease in both the brains and spleens of scrapie-infected mice. These data indicated 
that the sinc alleles only determine the delay or time to initial replication of the scrapie agent, and not either the rate 
of replication or endpoint concentration of the agent
66,67
. Incubation periods influenced by different alleles of sinc 
also change depending on the scrapie strain utilized. Infections with the ME7 strain resulted in long incubation 
periods in mice expressing the p7 allele and short incubation periods in mice with the s7 allele. However, infections 
with the 22A strain in mice expressing the s7 allele resulted in long incubation times and short ones in mice 
expressing the p7 allele. This strain dichotomy implies that the interaction between the scrapie strain and the product 
of the sinc gene determines incubation periods
68,69
. 
 A gene that controls incubation time in sheep, sip, was found at the same time as sinc was found in mice. 
Using the SSBP/1 strain of sheep scrapie, the sip
sA
 allele in either homozygote or heterozygote form results in short 
incubation times, and the sip
pA
 homozygote results in extremely long incubation periods that extend beyond the 
animal’s lifetime
69,70
. However, just like sinc, the incubation periods are reversed when CH1641 scrapie strain is 
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used. Since both sinc and sip have this characteristic, it was assumed that they were homologs and that the same 
gene controlled incubation time in both sheep and mice
69
. 
 The sequencing of the NH2-terminal of PrP27-30 provided a template from which tissues could be screened 
for the scrapie agent. Two different laboratories found that PrP27-30 is part of a larger, PK-sensitive protein called 
PrP33-35. Uninfected tissues from mice and hamsters contain PrP33-35, which indicates that a host gene encodes 
the infectious form of scrapie
71-74
. Various tissues including brain, spleen, heart, lung, and kidney express this host 
gene, prnp, and its concomitant protein
71,75
. Prnp encodes two different alleles A and B for long and short 
incubation times, respectively
76
. PrP33-35 resembles PrP27-30 in that it has a hydrophobic NH2-terminus, and two 
N-glycosylation sites
71,73
. To differentiate the uninfectious from the infectious form of PrP33-35, the notations PrP
C
, 




, for the scrapie form/PK-resistant form, are utilized
75
. 
 Questions arose as to whether prnp was the only gene involved in scrapie infection or whether it was part 
of a complex. Along with sinc and sip, another gene, prn-i, was found to control incubation times. Prn-i was 
mapped close to the location of prnp on chromosome 2 in mice and was found to have two alleles N and I that 
controlled short and long incubation times, respectively
77,78
. It was proposed that prnp, prn-i, and sinc are congruent, 
instead of being separate genes acting in a prion protein complex, due to multiple shared characteristics
79,80
. To 




 alleles, which gives long incubation times, had shortened 
incubation times with mouse scrapie when the A allele was changed to a B allele. These results indicates that the 
prnp gene and its alleles is the sole determinants of incubation times
80
. 
Structure, Regulation, and Trafficking of PrP
C
 
5’-untranslated regions, non-coding exons (humans), introns (murine and bovine), and/or 3’-untranslated regions 
control gene expression of prnp. The prnp promoter doesn’t contain a traditional TATA box. Instead, the promoter 
is highly G/C rich and contains binding sites for several transcription factors including Sp1. The promoter also 
contains CpG islands near the transcription start sites. These characteristics of the promoter indicate that prnp is a 
housekeeping gene, and the protein may be involved in housekeeping functions
75,81-85
. 
 Most adult tissues express PrP
C
 mRNA and protein, with the highest levels being in neurons within the 
CNS. Specifically, PrP
C
 is highly expressed in anterior brain regions, synaptic layers of the hippocampus and 
dentate gyrus, and the molecular cell layer in the cerebellum
86
. Expression of PrP
C
 protein is lower in all other adult 
tissues compared to the brain. During embryogenesis, PrP
C
 mRNA and protein expression begins at E8.5-9 when the 
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embryo switches from an anaerobic to an aerobic state. Some researchers believe that this suggests PrP
C
 functions in 
the defense against antioxidants
87,88
. It is not known whether the embryonic expression continues until birth, or 
whether it stops during embryogenesis and then commences again after birth. After birth, there is a 4-fold increase 
in PrP
C
 protein levels in the brain until day 35
89
. 
 After day 35 in the postnatal mouse, PrP
C





 mRNA expression remains stable during scrapie infection
75,90,91
. However, several scenarios lead to an increase 
in PrP
C





. The activation of dendritic cells by lipopolysaccharide and CpG oligodeoxynucleotides also 
upregulated the expression of PrP
C93
. The increase in PrP
C
 in lymphocytes led to an increase in susceptibility to 
prion infection, indicating that more PrP
C




 mRNA and protein are also upregulated 
during heat shock response
95
. These results imply that PrP
C
 may modulate immune responses or provide a cell 
signaling/defense mechanism during cellular stress
92,93,95
. No instances of natural downregulation of PrP
C






Figure 1.1. Artistic representation of PrP
C
. 
A) Diagram of prnp gene structure. Nucleotide number locations are shown for the gene 
components. CC=Charged Clusters. HC=Hydrophobic Core. S-S=Disulfide bridge. B) 
Secondary structure of the PrP
C







 is a soluble protein and is highly sensitive to PK digestion. The prnp gene encodes for 
an immature 250-amino acid protein. A signal peptide on the NH2-terminus, encompassing residues 1-22, targets the 
immature protein to the endoplasmic reticulum (ER) for further posttranslational processing. This NH2-terminal 
signal peptide is eventually cleaved off. The hydrophobic peptide of the COOH-terminus is replaced with a 
glycosylphosphatidylinositol (GPI) anchor
96
. In mice, the mature protein is 208-amino acids, encompassing residues 
23-231
97
. The mRNA molecule encoding PrP
C
 is 2.1kb long
72
 and has an open reading frame that is contained 
within exon 2 (sheep and humans) or 3 (mice), depending on the species. The prnp gene is located on chromosome 2 





 contains a structured globular domain from residues 125-228, three a-helices and two b-sheets, and a 
disordered flexible NH2-terminus tail from residues 23-124 that contains four or five octapeptide repeat units
97-99
. 
While the cellular form of PrP
C
 contains mostly a-helices, the infectious form contains mostly b-pleated sheets. It is 
this conversion of secondary structure that allows PrP
C
 to become infectious and pathologic
100,101
. The COOH-
terminus globular domain of PrP
C
 also includes a disulfide bridge at Cysteine residues 179 and 214.  
 Post-translational modification of PrP
C
 occurs in the form of glycosylation in the Golgi apparatus. The N-
glycosylation sites take the form Asn-X-Thr. In human PrP
C
, the glycosylation sites are Asn-181-Ile-Thr and Asn-
197-Phe-Thr, and in the mouse asparagine residues 180 and 196 are glycosylated. These glycosylation sites can be 






 can exist as three 
separate isoforms due to the glycosylation: un-, mono-, or diglycosylated. At any one given time, all three forms are 
present in specific brain regions, but the primary form expressed in most brain regions is the diglycosylated form. 
The existence of these three isoforms suggests that each isoform may have a physiological role or may determine the 
efficiency of prion strain replication. For example, different glycoform ratios have been used to identify strains of 
PrP
Res
, such as variant CJD from bovine spongiform encephalopathy (BSE)
103,104
. 
 As discussed above, PrP
C
 enters the ER, via a NH2-terminus signal, where cleavage of the signal peptide 
and transfer of the GPI anchor occurs. PrP
C
 then migrates through the ER where it acquires its folded structure 
before moving on to the Golgi to be glycosylated
105
. Studies have shown that there are three different topologies of 
PrP
C
 that exist within the ER. The usual form of the protein, 
Sec
PrP, translocates to the plasma membrane. The other 
two topologies are transmembrane forms that span the ER membrane at residues 110-135: 
Ctm
PrP, which has its 
COOH-terminus in the ER lumen, and 
Ntm
PrP, which has its NH2-terminus in the ER lumen
106-108
. While the exact 
	 10	
function/relevance of these two transmembrane forms is unclear, 
Ctm
PrP does cause a prion-like disease without 
PrP
Res
, indicating that more than one topology of PrP
C
 can be involved in prion infection
106,108
. The ER-Golgi 
network is of particular importance for prion disease because if PrP
C
 exit from this network is blocked then no 
disease is apparent
109
. Also, in some inherited forms of prion disease, immature PrP
C
 misfolds in the ER and 




 is shown to associate with lipid components before its exit from the Golgi and 





 is found on the surface of the cell membrane after translocation from the ER-Golgi network
29,47
. In a 
seminal paper, Brown and Rose showed that GPI anchored proteins localize in specialized locations on the cell 
surface called lipid rafts
110
. These lipid rafts are highly-ordered lipid structures enriched in sphingolipids and 
cholesterol
111-114
. The saturated acyl chains of the GPI-anchored protein target it to lipid rafts because the acyl chains 
are highly attracted to the sphingolipids
113
. The importance of the lipid composition of lipid rafts was demonstrated 
when the lipid rafts became disorganized upon depletion of either cholesterol or sphingolipid
112
. Reduction of 









 on the cell surface in lipid rafts. However, there is also evidence that conversion takes place in 







 is translocated out of the plasma membrane and endocytosed in less than one hour
117
. Studies revealed 
that PrP
C
 moves out of lipid rafts into a non-lipid raft membrane region before being endocytosed
118
. This movement 
occurs due to the polybasic residues in the NH2-terminus. It is unknown whether the NH2-terminus sends a signal or 




 moves out of the lipid 
raft domain, it becomes internalized into clathrin-coated pits
117,118,120
. The binding of Cu
2+
 ions to the octapeptide 
repeats mediates the internalization but Cu
2+
 is not required. Binding of other ligands also causes increased 
endocytosis; however, again it is not known if the endocytic pathway is physiologically dependent on these 
ligands
117,121
. During endocytosis, PrP
C





 varies from 3-6 hours in established cultured cells to 1.5-2 hours in primary cell culture
119,123,124
. 
Function or lack thereof of PrP
C
 
 The first attempts to discover the function of PrP
C
 came from the generation of PrP-null mice. The Zürich I 
strain of mice replaced a small section of exon 3 of the prnp gene with a neo cassette, and the Edinburgh (Npu) 
strain of mice inserted a neo cassette into exon 3 after residue 93. The Zürich I and Edinburgh mice were on 
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C57Bl/6J x 129/Sv or 129/Sv only backgrounds, respectively. The mice in both PrP-null strains show no 
physical/gross abnormalities nor do they have any detectable outward behavioral differences
125,126
. The PrP-null 
strains do not have any PrP
Res
 accumulation upon prion infection and do not display any neuropathology related to 
prion disease
127,128
. The function of PrP
C
 remains elusive since these PrP-null mice showed no outward phenotypic 
difference compared to the wild-type.  
Subtle differences in circadian rhythms, behavior, memory, and neuronal organization do exist within these PrP-null 
mice. Zürich I and Edinburgh PrP-null mice have elevated circadian motor activity during the constant darkness 
cycle. Also, these mice are more sensitive to sleep fragmentation and deprivation compared to wild-type mice. The 
circadian differences return to normal after reintroduction of PrP
C
, indicating that the alterations are due to PrP
C
 
depletion. These data implicate a possible loss-of-function role of PrP
C
 depletion in a human prion disease with 
altered circadian patterns (FFI, discussed below)
129
. There is also mossy fiber reorganization in the hippocampus, 
which might contribute to changes in locomotor activity observed in PrP-null mice
130-132
. There are other 
hippocampal alterations noted within PrP-null mice including deficits in short- and long-term memory. The altered 
hippocampal synapses and neural circuits point to a function of PrP
C
 within the hippocampus, but none of these lines 
of evidence point to what that function is
133,134
. One hypothesis to explain the results of the PrP-null mice is that 
PrP
C
 interacts with a ligand for its normal function. Therefore, depletion of PrP
C
 might then either cause no 
signaling or an altered signaling through this ligand producing the small effects seen in PrP-null mice. However, 
since these mice display no overt phenotype, it is also suggested that the ligand interacts with another protein to 
abrogate the loss of PrP
C125,126
.  
 Many papers examining the function of PrP
C
, and of its conversion to PrP
Res
, have alluded to an accessory 
protein that either helps with the function of PrP
C




. Therefore, some 
researchers focused their attention on ligands or receptors of PrP
C
 to elucidate if this ‘protein X’ exists. There are 
numerous ligands/receptors of PrP
C
 that bind to it or that it binds to, including Synapsin Ib, Bcl-2, GFAP, Nrf2, 
NCAM, and Hsp60 among others. Perhaps the biggest contenders for the identity of protein X include the 
37kDa/67kDa laminin receptor, stress-inducible protein 1 (STI1), and copper (Cu
2+
). 
 Laminin is the major glycoprotein found in the extracellular matrix of the basement membrane. It is made 
up of three different subunits a, b, and g. Laminin functions in cell differentiation, proliferation, migration, and 
neurite outgrowth, and the 37 kDa/67 kDa laminin receptor (LRP) functions in cell signaling. PrP
C
 binds to the LRP 
	 12	
at residues 161-179. The LRP binding site on PrP
C
 encompasses residues 144-179. There is a secondary LRP 
binding site on PrP
C
 at residues 53-93 that requires co-binding of heparan sulfate
135
. Binding of PrP
C
 to LRP results 






 binds to laminin in a saturable manner with a 
dissociation constant (Kd) of 2x10
-8
 M. In primary rat hippocampal slices and PC12 cells, the interaction between 
PrP
C
 and laminin resulted in neurite outgrowth. Also, treatment with anti-PrP antibodies reduced but did not 
eliminate neurite outgrowth, indicating that there is a redundant protein to compensate for the loss of PrP
C137
. 
Treatment of rats with either anti-PrP antibodies or anti-laminin antibodies decreased the retention of fear memory 
in the animals. The authors speculate that the reduced memory retention is due to an inhibition of ERK1/2 and PKA 
signaling since PrP
C
 and laminin are known to bind to these signaling molecules
138
. Protein X is believed to aid in 




. The conversion is not optimal when residues 167, 171, and 218 are removed from 
PrP
C
, indicating that these sites might be the protein X binding sites. Since LRP binds to PrP
C
 at two of these 
residues, the authors conjecture that LRP could be the putative protein X
135,139,140
. 
 Stress-inducible protein 1 (STI1) helps PrP
C
 enter the endocytic pathway into early endosomes
141
. The 
main role of STI1 is to help regulate the heat shock response initiated by Hsp70, and it is a 66 kDa protein that 
colocalizes with PrP
C
 on the cell surface. STI1 colocalizes with PrP
C
 specifically in hippocampal neurons where it 
initiates both neuritogenesis and neuroprotective functions with PrP
C
 through the MAPK and PKA signaling 
pathways
142
. Another study found that STI1 and PrP
C
 provided protection from oxidative stress by modulating the 
activity of superoxide dismutase (SOD). STI1 and PrP
C




 The octapeptide repeat region in the NH2-terminus of PrP
C
 contains four Histidine residues, which bind 
Cu
2+
 ions with a Kd of 5 µM
144-146
. There is a fifth Cu
2+
 binding site either located at His 96 or His 111 with a Kd in 




 binding to PrP
C
 in wild-type mice showed that Cu
2+
 aids in the 
endocytosis of PrP
C
 by aiding movement of PrP
C
 to a non-lipid raft part of the membrane before it becomes 
endocytosed. Cu
2+
 might work in conjunction with either laminin or STI1 to aid in endocytosis of PrP
C117,118,148
. PrP-
null mice have excess free Cu
2+
 because of the inability to bind it at the cell surface due to the lack of PrP
C
. PrP-null 
mice also have a lower cellular membrane Cu
2+
 content in synaptosomal fractions due to a lack of PrP
C
 at synapses, 
which increases the susceptibility of these mouse lines to oxidative stress
146,148
. It is possible the increased 
susceptibility to oxidative stress is either caused by a decrease in Cu
2+
 metabolism or a decrease in SOD activity. 
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SOD facilitates the response to oxidative stress thru the reduction of Cu
2+
, which partitions a superoxide radical into 
O2 or H2O2. In PrP-null mice, lower cellular membrane concentrations of Cu
2+
 results in lower SOD activity and an 
increase in oxidative stress damage. Some studies have shown that PrP
C
 has its own SOD activity in primary and 
secondary cultures, which might aid in resistance to oxidative stress
149,150
. However, this putative function of PrP
C
 
remains highly controversial because it does not explain some of the other functional features of PrP
C
. Instead, it is 
thought that perhaps the SOD activity of PrP
C
 acts as a buffer system for excess Cu
2+
 at the synapse
148
.  
 The anti-oxidative stress function of PrP
C
 remains highly contentious because some groups reported 
adverse cellular effects due to the binding of Cu
2+145,147
. Binding of Cu
2+
 to the fifth binding site causes a 
conformational change in the secondary structure from a-helices to b-sheets. It is not known if this structural change 
results in infectious isomers
147
, but the conversion of cellular PrP
C
 to infectious PrP
Res
 is mediated by a 
transformation of a-helices into b-sheets. Also, duplication of more than one octapeptide repeat results in two 
human prion diseases, fCJD and GSS (discussed below)
147,151
. During oxidative stress, PrP
C
 is cleaved into a 28.5 
kDa NH2-terminal peptide. It is unclear what, if any, function this peptide might have, including if it retains any 
PrP
C
 function (known or otherwise) after cleavage
151
. There is more evidence pointing to a neuroprotective role 
against oxidative stress, but it is hard to reconcile some of these negative findings. Therefore, the exact reason of 
Cu
2+
 binding remains questionable. 
 The observation that PrP
C
 can bind to the anti-apoptotic protein Bcl-2 is evidence that supports an anti-
apoptotic role for PrP
C
. Bcl-2 associates with the Bax protein, and suppresses cell death in a homodimeric complex. 
When Bcl-2 no longer binds to Bax, and Bax forms homodimers, a pro-apoptotic signal is initiated. It was shown 
that PrP
C
 bound to the 37 amino acids of the COOH-terminus of Bcl-2
152,153
. The interaction between PrP
C
 and Bcl-2 
rescued serum-deprived PrP-null primary hippocampal neurons from apoptosis
154
. Analysis of the PrP-null serum-
deprived cells revealed DNA fragmentation consistent with apoptosis, suggesting that under certain conditions 
apoptosis is upregulated in these cells versus wild-type. Transfection of a PrP-expressing vector into PrP-null serum-
deprived cells rescued the pro-apoptotic phenotype of the cells
154
. Similar results were seen in hypoxic or ischemic 
mouse and cell line models. PrP-null cells or mice with hypoxic or ischemic damage had larger and more extensive 
lesions than wild-type counterparts. Again, suggesting that PrP-null tissues are more susceptible to injury caused by 
both oxidative stress and/or apoptosis
155-157
. Deletion of the octapeptide repeats abolishes the phenotype of rescuing 
primary human neurons from Bax-induced apoptosis
158
. The octapeptide repeats on PrP
C
 share homology with the 
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anti-apoptotic BH2 domain on Bcl-2, indicating that the octapeptide repeats might mediate the anti-apoptotic 
function of PrP
C
. By binding to Bcl-2, PrP
C




 There is also evidence that PrP
C
 either migrates to sites of damage or is upregulated in response to 
oxidative or apoptotic lesions. Studies have reported a 35% increase in PrP
C
 protein expression in the injured 
hemisphere eight hours after injury in a cerebral ischemia mouse model, whereas the uninjured hemisphere showed 
no increase
156
. In a perinatal case of hypoxic-ischemic injury, PrP
C
 mRNA increased and accumulated in damaged 
axons and neuronal somata. The authors note that the accumulation could be due to altered trafficking of neuronal 
proteins after injury, but it could also be due to an upregulation of PrP
C




 There are some conflicting reports on both the proposed antioxidant and anti-apoptotic functions of PrP
C
 
despite these conclusions on the possible neuroprotective function of the protein. If PrP
C
 does indeed have a 
neuroprotective effect either as an antioxidant or anti-apoptotic role, one would think that the more PrP
C
 expression, 
the better or, the less, the worse. However, overexpression of PrP
C
 in either cultured cells, primary cells, or mouse 
lines results in deleterious effects. Overexpression in cells results in a pro-apoptotic phenotype mediated by caspase 
3 activation. The overexpressing cells also displayed an increased sensitivity to a pro-apoptotic chemical called 
staurosporine
160
. Transgenic mice that overexpress PrP
C
 have a spontaneous neurologic disease characterized by 
spongiform degeneration and skeletal myopathy reminiscent of scrapie infection
161
. On the other hand, in PrP-null 




 does have 
a neuroprotective function, PrP-null neurons should either be in oxidative stress or apoptosis, unless there is a 
compensatory mechanism
162,163
. Due to these studies, the role of PrP
C
 as an anti-apoptotic protein is still 
questionable. Some argue that overexpressing PrP
C
 does not mimic the physiological nature of PrP
C
, and the damage 
caused by overexpression might be due to an overexpression of the protein. Another theory is that PrP
C
 may have 
slightly different functions in different cell lines. Some cell lines may display a pro-apoptotic role and some an anti-
apoptotic role. These differing responses might be due to available ligands/receptors for PrP
C
. If a ligand is not 
available, such as STI1, then perhaps PrP
C





 The role of PrP
C
 as a signaling molecule is much less debated than its antioxidant or neuroprotective 
functions. Besides the MAPK/ERK, PKA, and STAT1 cascades, PrP
C
 has also been implicated in Ca
2+
 
signaling/homeostasis, the tyrosine kinase pathway, and the PI3K pathway. Organotypic retinal explants showed an 
increase in neuroprotection due to PrP
C
 activating the MAPK/ERK and PKA pathways, and antibody clustering of 
PrP
C
 also activates these pathways
165-167
. However, antibody clustering was also shown to cause severe neuronal 
apoptosis in the brains of mice. One explanation for this dichotomy is that as a single molecule, PrP
C
 might signal 
through neuroprotective pathways, but as a dimer, it might signal through these pathways and result in neuronal 
damage
168
. The MAPK/ERK pathway is activated by the non-receptor Src-related family kinases, such as Fyn, 
during antibody clustering of PrP
C169
. The Src kinase family also interacted independently of MAPK/ERK using the 
PI3K/Akt pathway, resulting in neurite outgrowth and survival
166
. It is hypothesized that PrP
C
 activates the PKA and 
other signaling pathways through the binding of Cu
2+
 or by the regulation of intracellular levels of Ca
2+
 (mainly in 




 could be said to be a master regulator of multiple signaling 
pathways using a wide array of ligands/signaling molecules. Lastly, the PI3K/Akt pathway was shown to be 
activated for neurite outgrowth/survival and in response to reactive oxygen species. PrP
C
 overexpression leads to 
activation of this pathway, whereas PrP-null cells are more sensitive to reactive oxygen species due to a decrease in 
PI3K/Akt activity
166,173
. These discoveries were made using an array of either primary or cultured cells from a 
neuronal or non-neuronal origin, suggesting that the interaction between signaling pathways and PrP
C
 is universal. 
 PrP
C
 also directs signaling pathways within the immune system. PrP
C
 modulates the phosphorylation of 




 also associated with Fyn 
and Src tyrosine kinases upon antibody clustering. The interaction with Fyn was dependent on PrP
C
 interaction with 
ZAP-70 after CD8 and CD3 signaling. This process was found to be caveolin independent and led to the 
amplification and diversification of T cells
175
. Another study reported that, instead of Fyn, PrP
C
 interacted with Src  
tyrosine kinase for T cell activation
176
. The difference in results could be due to different cell lines or to different 
antibodies/methods used for antibody clustering of PrP
C
, as this approach does not mimic the real physiological 
state. 




 is also widely expressed 
on non-neuronal cells, such as cells of the immune system. PrP
C
 is found on hematopoietic stem cells (HSCs), which 




. The expression of PrP
C
 on differentiated leukocytes is highly regulated and depends on the maturation 
and activation state of the cells. The protein is expressed on lymphocytes, monocytes, dendritic cells (DCs) and 
platelets, but not erythrocytes or granulocytes
178,180,181
. T and B lymphocytes and DCs have the highest expression of 
PrP
C
 within the immune system, with DCs having the highest expression in the body besides neurons. Within DCs, 
CD8
+
 conventional DCs express the highest amount of PrP
C
, indicating that PrP
C
 is involved in Th1 immune 
responses
93,182
. Germinal centers of the spleen contain most of the PrP
C
 expression observed on lymphocytes
183
, 
which suggests a potential role of PrP
C
 in antigen activation of lymphocytes. 
 Indeed, PrP
C
 expression increases 4-fold after activation of lymphocytes with mitogens, such as 
lipopolysaccharide, concanavalin A, or CpG oligodeoxynucleotides
181,184
. A lack of PrP
C
 either in mice or on 
primary splenocytes results in a decrease in the proliferation of T lymphocytes in response to antigen presenting 
cells
174,182
. On the cell membrane, PrP
C





 with these complexes occurs due to clustering of PrP
C
 by localization of flotillin 1 and 2 and the 
rearrangement of PrP
C
 to the cellular ‘cap’, which results in recruitment of Fyn, Lck, and the TCR/CD3 complex. 




 also plays a significant role in the synapse between DCs and 
T cells, which could involve the flotillin activation of capping. When T cells are deficient in PrP
C
, proliferation in 
response to antigen presenting cells is not affected. However, dendritic cells deficient in PrP
C
 lead to a reduction in 
the proliferation of T cells by antigen presenting cells. Thus, PrP
C
 has an important function not only at the 
neurological synapse but also the immunological synapse
182
. 




 involves a change of the secondary structure from 
a-helices into b-sheets. This pathological conformer accumulates within the spleen, lymph nodes, Peyer’s patches, 
and tonsils upon initial peripheral infection. It does not cause any pathology within these tissues, only within the 
CNS. This pathology includes spongiform degeneration, activation of glial cells, neuronal loss, and accumulation of 
amyloid plaques
186,187
. It is unclear whether the accumulation of PrP
Res
 results in the pathology (gain-of-function 
hypothesis) or whether a loss-of-function of PrP
C
 caused by the accumulation of PrP
Res
 results in the pathology of 
prion diseases. An early study using prion-infected tissue grafted into the brains of PrP-null mice showed no clinical 
disease and no prion-related pathology, even though PrP
Res
 had moved into the surrounding tissues. This was the 
first study to indicate that perhaps PrP
Res
 was not neurotoxic, or at the very least did not fully contribute to the 
pathology of prion infection
188,189
. Another study by Mallucci’s group removed PrP
C
 using a Cre/loxP system after 
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establishing prion infection. They noted that the spongiform degeneration reversed upon removal of PrP
C
 even 
though deposits of PrP
Res
 remained in the brain tissue
190,191
. In two different human prion diseases (FFI and CJD), 
neuronal apoptosis does not correlate with deposition of PrP
Res192,193
. These conclusions have led to the highly 
controversial loss-of-function hypothesis, which states that the pathology observed in prion infection is due to the 
loss of the physiological function of PrP
C
. This would make sense if the physiological function were truly an 
antioxidant or anti-apoptotic role. Reducing neuroprotection in the CNS along with the deposition of PrP
Res
 could 
lead to the morphological characteristics seen in brain tissue of prion-infected individuals. However, since the 
function of PrP
C
 is not known, this explanation is mere speculation. Other causes of the neuropathology could 
include withdrawal of activation signaling mechanisms, selective vulnerability of neurons to PrP
Res
, or early axonal 





Prion and Protein Misfolding Diseases 
Scrapie 
 Natural scrapie disease is found in sheep and goats. It is usually characterized by weight loss, ataxia, and 
pruritus. Clinical signs in goats mimic that seen in sheep, but may also include hyperesthesia, bruxism, and 
regurgitation. There are two forms of scrapie: typical and atypical. The clinical signs described above indicate 
typical scrapie. Clinical signs of atypical scrapie include ataxia, weight loss, and behavioral changes, such as 
irritability and anxiety. Animals with atypical scrapie usually do not show pruritus
195
. The average age of onset of 
atypical scrapie is 6.5 years of age, whereas typical scrapie usually presents between 2-5 years with 3.5 years being 
the average. Both sexes are equally affected by both forms. Transmission of atypical scrapie is not well understood. 
Some suggest it is a spontaneous disease rather than an infectious disease. Transmission of typical scrapie usually 
occurs through the oral route, and frequently involves the eating of the placenta (one of the most infectious tissues 
for scrapie prions). Exposure to scrapie also occurs through contaminated milk (horizontal transmission), feces, and 
the environment where prions like to bind to the soil. After exposure, prions spread to the gut-associated lymphoid 
tissues (GALT), and then ascend to the CNS 10-12 months after exposure. A breeding protocol to select for sheep 
that carry the resistant genotype is still in effect in Europe to reduce the number of sheep affected by scrapie
196
. 
 Three different codons determine a sheep’s susceptibility to scrapie: A136V, R154H, and Q171R/H. These 
codons lead to five alleles and fifteen different genotypes of resistance/susceptibility. Sheep fall into Risk Groups 1-
5 based on their genotypes at these positions. The most resistant genotype (Risk Group 1) is ARR/ARR. The most 
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susceptible (Risk Group 5) genotypes are VRQ/VRQ, VRQ/ARQ, VRQ/ARH, and VRQ/AHQ. All the other 
genotypes fall in the intermediate susceptibility range
196
. 
Bovine Spongiform Encephalopathy (BSE) 
 BSE, or mad cow disease, was first diagnosed in a cow in 1986 in the United Kingdom and thereupon 
revealed a BSE epidemic that devastated cattle herds. Clinical signs of BSE include aggression, tremors, gait 
abnormalities, and hyperreactivity to stimuli. An E211K polymorphism, a 12 base pair insertion/deletion in the 1
st
 
intron, and a 23 base pair insertion/deletion in the prnp promoter confer susceptibility of cattle to BSE. Like scrapie, 
there is an atypical form of BSE that is thought to occur spontaneously. Unlike scrapie, BSE does not spread from 
animal to animal. Tissues (with the exception of the CNS) and excreta, such as milk, feces, and urine, are not 
infectious
195
. The leading theory as to the origin of BSE is that scrapie was naturally passaged through cattle enough 
times to break the species barrier
197
. The species barrier of prion disease occurs because one type of prion from one 
species usually does not transmit to another species. Thus, most prion diseases are confined to the species’ that they 
naturally infect. However, it is thought that cattle were fed meat and bone meal (MBM) that was contaminated with 
tissues from scrapie-infected sheep, and accumulated enough scrapie prions that the species barrier threshold was 
lowered
195
. In the early 1980s, the process of rendering carcasses in MBM production changed such that scrapie 
prions were not inactivated and were allowed to contaminate the MBM stock. It could have been possible that 
scrapie was able to pass the species barrier in the United Kingdom sooner/easier than other locations due to the 
higher prevalence of scrapie compared to other locations
198
. Alternative theories do exist as to the origin of BSE, 
such as cattle developing a genetic mutation that led to a spontaneous generation of prions or that BSE was already 
endemic in the UK just not recognized. However, these theories cannot explain how BSE emerged in one general 
location at one particular time and why it was never observed before. The most unusual aspect of the BSE epidemic 
is that it resulted in a unique prion with such an altered host range that not only does it infect cattle, but it also spread 
and infected humans (vCJD) and zoo animals (FSE) (discussed more below)
198,199
. 
Chronic Wasting Disease (CWD) 
 CWD was first recognized in 1967 at a Colorado research facility and was characterized as a TSE in 
1978
200
. The prevailing theory on the origin of CWD is that it is an altered form of scrapie (much like BSE). 







. CWD has been detected in almost half the states in the United States, two Canadian provinces, South Korea, 
and Norway. It affects both free-ranging and captive populations of the cervid family, such as mule deer, white- and 
black-tailed deer, Rocky Mountain Elk, Shira’s moose, and Norwegian reindeer
195,203
. Prevalence of CWD in these 
herds ranges from <0.1% to 100%. Clinical signs of prion disease include loss of body condition, ataxia, excessive 
salivation, and behavioral changes. In nature, CWD only affects animals from the Cervidae family; however, it can 
be transmitted experimentally to a wide range of animal models suggesting that perhaps it can cross several species’ 
barriers
195
. Several polymorphisms confer susceptibility to the disease: S96G, where S confers a delay of disease, 
M132L, where MM confers susceptibility, and S225F, where SS confers susceptibility
204
. Transmission of CWD 
can occur horizontally and environmentally, where it is known to persist in the soil for years. In oral exposure, it 
spreads to the GALT and lymphoreticular system (LRS) and ascends to the CNS with an incubation period of 16 
months to 5 years. Infectious CWD prions are detected in a wide range of tissues, including CNS, LRS, blood, 
muscle, pancreas, fat, urine and feces, and antler velvet
195
. 
Transmissible Mink Encephalopathy (TME) and Feline Spongiform Encephalopathy (FSE) 
 Two other prion diseases that were caused by consumption of prion-contaminated food products are TME 
and FSE. In 1947, TME was discovered in captive-farmed mink, while FSE developed in parallel with the BSE 
epidemic in the 1980s and affected wild and captive felines. It is well established that FSE developed from feeding 
felines BSE-contaminated products, while TME may derive from either scrapie or BSE contamination. Both 
diseases have similar clinical signs, such as aggression, depression, ataxia, and tremors. The incubation period for 
TME is 6-12 months, and 2-8 years for FSE
195
. 
Creutzfeldt-Jakob Disease (CJD) 
 CJD comes in a few forms: sporadic CJD (sCJD), familial or genetic CJD (f/gCJD), iatrogenic CJD (iCJD), 
and variant CJD (vCJD). Sporadic CJD and f/gCJD occur in middle to late age, while iCJD and vCJD occur in a 
variety of ages. For sCJD and f/gCJD, clinical signs include dementia and cerebellar dysfunction. Sporadic CJD 
accounts for 85% of all CJD cases, and f/gCJD accounts for most other cases. Iatrogenic CJD and vCJD have been 
on the decline since their identification, so they account for 1-2% of CJD cases. The V129M polymorphism 
increases the risk of developing any form of CJD and determines the specific clinicopathological phenotype seen in 
CJD patients. In f/gCJD, other polymorphisms, such as E200K, I210V, D178N, and V180I, contribute to 
susceptibility to disease. There does not need to be a familial connection in f/gCJD, which is why some refer to it 
	 20	
only as gCJD. Also, f/gCJD results with the insertion or deletion of octapeptide repeats. Sporadic CJD is a 
spontaneous disease, whereas iCJD results from the injection/implantation of contaminated tissues. Sources of tissue 




 There was a concern that if BSE did indeed come from scrapie, then it might have the potential to cross the 
species barrier again, potentially into humans. Therefore, to ensure identification of a new variant, surveillance of 
CJD increased during the BSE outbreak. In May to October of 1995, three cases of a new variant of CJD were 
identified, later called vCJD. These patients had early onset of disease symptoms (<50 years of age) with psychiatric 
indications and ataxia
198,199
. It was later found that the molecular and biological characteristics of vCJD matched 
those of BSE. Researchers believe that vCJD arose from the consumption of BSE tainted meat products
104,206
. In 
BSE, only nervous tissue has a high amount of prions, with muscle and milk containing none. However, the process 
of slaughter could lead to the contamination of muscle and milk products with CNS tissue contaminated with BSE. 
The V129M polymorphism is associated with an increased risk of vCJD, with nearly all cases being 129MM 
homozygotes. While vCJD is declining along with BSE, concern remains about ‘silent’ carriers and whether these 




The origin of kuru is still somewhat of a mystery. Theories include a new or existing neurotropic virus that 
evolved through the serial passage of brain material
16
, ingestion of scrapie or BSE that transmitted to humans
16
, or 
ingestion of an individual affected by CJD
16,207,208
. The most likely theory is that an individual from the Fore tribe 
was affected with a sporadic case of CJD, and the remains of that person were consumed upon death, which led to 
the evolution of the CJD agent into the kuru agent. Evidence to support this claim includes similarity of plaques 
from CJD and kuru cases
207
, comparable neuronal degeneration
207,208
, analogous transmission patterns, and similar 
strain characteristics between kuru and classical CJD
208
. 
As previously stated, the kuru epidemic waned after cannibalism declined among the Fore people. The last 
noted death was in 2005, and there are no known current cases of the disease
209
. A secondary cause of the decline of 
kuru was established upon examination of the prnp gene at codon 129 in susceptible and non-susceptible 
individuals. Susceptible individuals that contracted the disease early in the epidemic were almost always 
homozygous for Met at position 129. These individuals also displayed the shortest incubation time of the disease. 
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Following the deaths of the most susceptible population, the disease started to affect heterozygotes (Val/Met) at 
position 129, and very rarely Val homozygotes. Patients with the Val homozygote genotype had incubation periods 
of 20 years or greater, and most never showed clinical symptoms of the disease even after being exposed. The 




Fatal Familial Insomnia (FFI) and Gerstmann-Sträussler-Scheinker syndrome (GSS) 
 There are two other autosomal dominant human prion diseases: FFI and GSS. Insomnia, or lack of sleep, 
characterizes FFI, with ataxia, myoclonus, and seizures also common. Neurodegeneration within the CNS is 
predominantly within the thalamic nuclei with minimal PrP
Res
 deposition. The incubation period of FFI is 20-72 
years. FFI is linked to two polymorphisms D178N and 129MM. Early onset dementia around 30-60 years of age 
with a slow disease progression that includes ataxia, dysarthria, and Parkinsonian signs characterizes GSS. GSS is 
also associated with two polymorphisms of the prnp gene: 129MM and P102L
205
. 
Alzheimer’s and Other Protein Misfolding Diseases 
 In recent years, a controversy surrounding prion diseases and other protein misfolding diseases has 
emerged. Some say that prion diseases should be classified with other protein misfolding diseases and others claim 
that the protein misfolding diseases might all be prion diseases (albeit caused by different proteins). Protein 
misfolding diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), 
are diseases caused by a misfolded cellular protein. This misfolded protein is either infectious, like prion diseases, or 
the accumulation of the misfolded protein results in neuronal degeneration. Protein misfolding diseases usually 
cause neurodegeneration but can cause damage to other organ systems as well, such as Type II diabetes. Some 
proteins that are involved in these diseases include amyloid precursor protein (APP) in AD, a-synuclein in PD and 
other synucleopathies, and huntingtin in HD. These misfolded proteins share common characteristics with PrP
Res
, 
such as insolubility and adaptation of highly ordered fibrillary aggregates. Specifically, AD not only shares 
characteristics with PrP
Res
 but also has a connection with PrP
C212,213
.  
 Amyloid-b (Ab) and tau are the two proteins in AD that misfold and accumulate within neurons. Ab is 
derived from APP through cleavage by b- and g-secretase. This cleavage results in the generation of two toxic 
peptides: Ab1-40 and Ab1-42. In the search for PrP
C
 ligands, amyloid-like precursor protein 1 (APLP1) was found to 
precipitate with PrP
C
, indicating that it may be a PrP
C
 ligand. APLP1 is a member of the APP family and is thought 
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to concentrate with PrP
C







 was also found to be a receptor for the Ab1-42 peptide. The direct interaction between PrP
C
 and 
Ab1-42 mediates a decrease in long-term potentiation observed in AD neurons. The decrease in long-term 
potentiation of Ab1-42 infected cells is abrogated when PrP
C
 is not present or when anti-PrP antibodies are used
215
. 
Two independent studies have shown that PrP
C
 is also upregulated in Ab plaques of AD. Whether the upregulation 
is due to a functional role of PrP
C
 or just abnormal protein turnover is unclear, but these conclusions indicate 
perhaps PrP
C
 has either a functional role in AD or a functional role with APP/Ab
216,217
. Evidence for a functional 
role of PrP
C
 with APP/Ab was confirmed when PrP
C
 was found to regulate Ab levels through b-secretase activity. 
PrP-null mice showed an increase in Ab, suggesting that the amount of Ab is dependent upon the presence/absence 
of PrP
C
. Mice infected with scrapie also had increased levels of Ab. The authors found that the regulation of Ab by 
PrP
C
 occurred during the b-secretase processing step. This study indicates that it may not be wise to decrease 
cellular levels of PrP
C




The ‘Anti’ Therapeutic Group 
 The first therapeutics investigated for anti-prion activity were antivirals since the scrapie agent was thought 
to be a slow virus. Some antivirals tested for their anti-prion activity include b-propiolactone, adenine arabinoside, 
amantadine, rifampicin, and cytosine arabinoside. These antivirals were tested in mice inoculated with the Chandler 
scrapie
219,220
 or CJD mouse strains
221
. None of the antivirals had any effect on survival time of prion-infected mice. 
These results helped solidify the conclusion that the scrapie agent does not contain nucleic acid 
219-221
. Despite the 
lack of a benefit of antiviral therapy, several clinical studies of human prion disease with antiviral therapies were 
published. Acyclovir, amantadine, and vidarabine were all tested for their effectiveness in treating clinical stage 
human prion disease. A few patients presented with transient improvements in their clinical state. However, there 
was no benefit in survival times or permanent improvement in clinical state
222
. The polyene antibiotic amphotericin 
B (AmB) was evaluated for anti-prion activity due to its membrane association and low toxicity in animal models. 
Polyene antibiotics are used for the treatment of fungal infections. The antibiotic binds to ergosterol in the 
membrane of fungi and disrupts the membrane. AmB delayed the onset of clinical signs and prolonged survival 




. Early treatment (2.5 mg/kg) of AmB resulted in a 40-day increase in survival time in both intracerebral and 
intraperitoneal prion-inoculated hamsters and mice. Higher doses of AmB (25 mg/kg) with an intraperitoneal 
 
inoculation of prions resulted in a 60-day increase in survival time
224,225
. Hamsters inoculated with the TME strain 
Drowsy had no effect on survival times with AmB treatment
226
. An AmB derivative, MS-8209, also showed an 
increase in survival time with a decrease in toxicity compared to AmB
225
. Treatment of SCID mice with AmB 
further emphasized that these polyene antibiotics do not act directly on PrP
Res
, but instead interfere with the 
mechanism between PrP
C
 conversion to PrP
Res228
. Treatment of scrapie-infected cell cultures with polyene AmB or 
MS-8209 revealed an increase in PrP
C
 accumulation on the cell surface and an alteration of lipid content in lipid 
rafts. The alteration of lipid content suggests that the antibiotics are binding to cholesterol in lipid rafts and altering 
its composition, thereby providing a blockade for PrP
Res
 conversion. The treatment could also be altering trafficking 
of PrP
C
 to the cell surface
229,230
. One clinical study reported that 0.25-1 mg/day treatment of AmB to CJD patients 
did not affect symptoms or disease progression
222
. Polyene antibiotics are used safely in humans but can cause 
toxicity, have limited bioavailability in the brain, and are prion strain specific. Therefore, use of these compounds as 
therapeutics for prion diseases is limited. 
Figure 1.2. Mechanisms of prion therapeutics that have shown promise in animal 
models.  
A graphic depiction of the mechanisms of some of the compounds that have shown 
promise as anti-prion compounds 	
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 During a cell culture screening for anti-prion drugs in scrapie-infected N2a cells, the antimalarial drug 
quinacrine was found to reduce PrP
Res
 levels in vitro. Quinacrine showed some cellular toxicity but did not affect 
protein biosynthesis in these cells. At this point, quinacrine had been used for decades for the treatment of malaria, 
so it was approved for human use and was found to cross the BBB
231,232
. Therefore, quinacrine became the poster 
child for prion therapeutics. Multiple human clinical trials were started to evaluate its effectiveness in human prion 
disease. However, shortly after quinacrine’s in vitro anti-prion activity was reported, several discouraging reports 
about quinacrine’s activity were also published. Quinacrine did not prolong survival times in mice infected with 
scrapie either through an intraperitoneal drug regimen or an intraventricular drug infusion regimen
233,234
. 
Mefloquine, another antimalarial drug, was also found to reduce PrP
Res
 levels in vitro but had no effect in vivo
235
. 
Several human clinical trials reported transient clinical benefits with the treatment of both quinacrine and 
chlorpromazine at 300-600 mg/day, but there were no permanent improvements in clinical stage or elongation of 
survival times
236-238
. These studies have noted that the bioavailability of quinacrine in the brain is minimal, which 
could explain the results. However, one study that blocked the efflux of quinacrine, which resulted in much higher 
amounts of the drug in the brain, reported no prolonging of survival times in scrapie-infected mice. They did 
observe quinacrine-resistant conformers of PrP
Res
, indicating that prions can establish drug resistance
239
. Another 
study hypothesized that quinacrine may work in a strain dependent manner, and may be effective against mouse 
prions but not human prions
240
. Long term exposure and high doses of quinacrine cause liver toxicity, 
cardiomyopathy, and toxic psychosis. Therefore, quinacrine might be effective at treating early stage disease, but its 
efficacy at late clinical stage and its toxic properties make it an unsuitable candidate for prion therapeutics. 
Polycationic Compounds 
 Polycationic compounds contain multiple positively-charged groups on their terminal ends. A significant 
number of these compounds are used in gene transfection for the delivery of nucleic acids to cells. Polyamines are 
polycationic compounds that contain amine groups as the cationic groups. Some polyamines include 
polyethyleneimine (PEI), polypropyleneimine (PPI), and polyamidoamine. Polyamines are usually used in 
transfection reagents because they are hydrophilic and they contain some hydrophobic groups that associate with 
	 25	
cell membranes. Multiple generations of polyamines result in more primary amine groups being added to the 
compound (generation 1 has 4 primary amines, and generation 4 has 32 primary amines)
241-243
. 
 Supattapone’s group accidentally stumbled upon the anti-prion activity of polyamine compounds during 
their transfection studies. They found that the polyamine compounds in Superfect reduced the amount of existing 
PrP
Res
 within mouse neuroblastoma (N2a) cells. The polyamines PEI and PPI were the most effective when they had 
the most primary amines (generation 4.0)
241
. Further work of this group concluded that PPI had no effect on PrP
C
 
levels and that it rendered PrP
Res
 more sensitive to proteolytic digestion. Supattapone hypothesizes that the amines 
on the compounds rip apart oligomers of PrP
Res
, making them more susceptible to normal cellular protein 
degradation. One limitation observed using these polyamine compounds is that they are strain specific, so some 
strains are more resistant to the effects of these compounds than others. The strain specificity indicates that a drug-





 Polyanionic compounds contain at least one negatively-charged terminal moiety that is typically either a 
sulfate or a carboxylate group. Sulfated glycosaminoglycans (GAGs), which are also polyanionic, are present in 
amyloid plaques of prion diseases. Whether they function to impair or benefit polymerization is unknown. Multiple 
different polyanionic compounds have been investigated for their effect on prion disease after GAGs were found to 
bind to PrP
Res
 aggregates. The polyanion HPA-23 (ammonium 5-tungsto-2-antimoniate) is effective at increasing 
survival periods in mice inoculated with the 139A strain of scrapie. The effect was only produced when mice were 
treated four hours after inoculation. While the exact mechanism is unknown, it is thought that HPA-23 acts on the 
LRS to prevent peripheral accumulation of prions
244,245
. Similarly, dextran sulfate with a molecular weight of 500 
kDa (DS-500) was effective at decreasing PrP
Res
 levels in N2a cells, and in a scrapie mouse model. Unlike HPA-23, 
DS-500 increases survival time when administered either several weeks before or after inoculation due to its longer 
half-life
245-247
. DS-500 is known to decrease PrP
Res
 levels in the spleen early in infection, possibly by activating 
splenic immune cells. However, DS-500 is quite toxic in vivo. Another polyanion that is less toxic than DS-500 is 
pentosan polysulphate (PS), which results in complete protection of scrapie-infected mice when given at a 1 mg 
dose seven hours after inoculation
247,248
. In clinical trials, PS is well tolerated at high doses and leads to cognitive 
improvements with slow disease progression in a majority of patients
222
. Treatment with the above polyanions 
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results in increased endocytosis of PrP
C
 in vitro. While the polyanions don’t alter PrP
C
 synthesis, they seem to shift 
more PrP
C
 into late endosomes and lysosomes. It is not known whether this action is a result of direct or indirect 
contact with PrP
C
, but the decrease in PrP
C




. Other less 
toxic polyanions include heparan sulfate (HS) and HS mimetics. Two HS-like compounds, HM2602 and HM5004, 




 The histopathological stain congo red (CR) stains amyloid fibrils. Its ability to bind to amyloid, including 
PrP
Res
 deposits in the brain, made it an attractive therapeutic option. CR decreases levels of PrP
Res
 in mouse 
neuroblastoma cells
247
. It is also effective at prolonging survival times in hamsters intracerebrally or 
intraperitoneally inoculated with either 263K or 139H prion strains. In intracerebrally inoculated hamsters, 
pretreatment of 10 mg of CR one week before inoculation and 5 mg weekly afterward produced the largest benefit 
on survival times. Pretreatment of CR did not have any impact on intraperitoneally inoculated hamsters, but the 
treatment of CR and intraperitoneal inoculation on the same day produced a modest effect in elongation of survival 
times
251
. However, mice treated with CR had increased levels of splenic prions and did not have an increase in 
survival periods of scrapie-infected mice, suggesting that CR may be strain/animal dependent
252
. Multiple 
mechanisms for the activity of CR include increasing endocytosis of PrP
C249
, binding to PrP
C
 to cause competitive 
inhibition with endogenous GAGs
253
, and stabilizing the structure of PrP
Res252,254
. The stabilization of PrP
Res
 by CR 
may lead to either inhibition of denaturation that hinders conversion
254





. Whatever the mechanism might be, CR does not make a good therapeutic as it 
cannot cross the BBB and it is toxic, possibly even carcinogenic/mutagenic. 
Immunotherapeutics/Immunomodulation 
 Prions do not elicit an immune response because they are derived from a normal host cellular protein. 
However, therapeutic strategies toward eliciting an immune response against prions have increased over the last 




, active and passive immunizations, and 
immunostimulation/immunosuppression therapeutic strategies have all shown promise. The purification of PrP 27-





. Both polyclonal and monoclonal antibodies raised against PrP
C
 were shown to decrease levels of 
PrP
Res




hindrance to prevent conversion, or interference of binding of other proteins (protein X). Antibodies with epitopes in 
both the COOH- and NH2-terminus of PrP
C




. The 6H4 antibody operates 
like phosphoinositide phospholipase C cleavage of PrP
C
, which cleaves the GPI anchor from the cell membrane, 
indicating that this antibody directly occludes PrP
C
 and may increase turnover of the protein
260
. SAF34 and SAF61 
antibodies were shown to increase the clearance of PrP
C





. Most of the antibodies that have shown anti-prion activity can reduce PrP
Res
 levels to undetectable 
amounts. These studies indicate that the cells are ‘cured’. However, a few studies report that there is a hidden 
cellular reservoir of PrP
Res
 that allows its replication after treatment is suspended. These results suggest that PrP
Res
 is 
cleared through normal cellular degradation pathways, and antibody therapeutics may need to be given continuously 
throughout the animal’s/individual’s life. Several in vivo studies have shown efficacy of the 6H4 antibody and the 
ICSM18 and ICSM35 antibodies to increase survival periods. There was no sign of autoimmunity in any of the 
animals. The in vivo antibodies were efficacious against peripheral prion infections in the early stage of disease
262
. 
 The biggest challenge for the use of immunotherapies in prion diseases is overcoming tolerance to PrP
C
. 
Both active and passive immunization studies have been employed to overcome this problem. Passive immunization 
with ICSM18 or ICSM35, with no adjuvant, resulted in a 153% extension in survival time
263
. Active immunization 
with recombinant PrP
C
 and complete Freund’s adjuvant (CFA) also resulted in an increase in survival time by two 
weeks but was not effective in preventing disease
264
. Mucosal vaccination of a Salmonella PrP
C
 vector in an oral 
inoculation mouse model resulted in a 200-day increase of survival times, with no PrP
Res
 detected in the brain after 
500 days post-inoculation
265
. These studies led to an activation of Th2 immune responses and no activation of Th1 
immunity, which is important because vaccination of AD patients with an Ab peptide resulted in a massive Th1 
immune response, resulting in cessation of the trial
261,262,264,265
. Thus, there is a need for careful characterization of 
vaccination strategies towards prion diseases in mouse models before being used in human clinical trials. 
 Other immune system exploitations for prion disease include immunostimulation and immunosuppression. 
Immunostimulation with several adjuvants, namely CpG oligodeoxynucleotides and CFA, increased survival times 
of prion-infected mice. Use of CFA in both intracerebral and intraperitoneal prion inoculation proved effective at 
elongating survival times. The authors speculate since it is effective with both types of inoculation routes it must 
have a local effect on the CNS, perhaps by activating microglia for increased phagocytosis of PrP
Res262,266
. On the 
other hand, immunosuppression using anti-inflammatory drugs, such as prednisone and dapsone, have been proven 
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effective at increasing survival times. These two compounds were also shown to produce long-term survivors that 
showed no clinical signs of prion disease 200 days after non-treated controls died. It is thought that prednisone and 
dapsone cross the BBB and modulate neuronal inflammation during prion disease
267,268
. The exact mechanisms of 
how these techniques work to improve survival are not known but may provide insight into which cells/mechanisms 
to target with therapeutics. 
Targeting PrP
C 
 As discussed above, PrP-null mice are phenotypically normal
126,162
. They have some minor phenotypes 
associated with the knockout of PrP
C
, but they otherwise live healthy lives
129,132-134
. The loss of PrP
C
 in these mice 
allows them to be resistant to prion infection, while having no detrimental effects with the ablation of PrP
C127,190
. 
Some have suggested that there must be a compensatory mechanism during embryogenesis that counteracts the loss 
of PrP
C
. However, post-natal knockout of PrP
C
 in a Cre/loxP mouse also produced mice that were mostly 
phenotypically normal. PrP
C
 was eliminated in these mice by Cre recombinase at twelve weeks of age, which 
resulted in a decline of both medium and slow afterhyperpolarizations in hippocampal CA1 cells, indicating that 
there were some synaptic changes within these mice
163
. Also, when PrP
C
 was eliminated in the Cre/loxP mice after 
established prion infection, there was a reversal of the spongiosus and neuronal loss seen in prion infection even 
though PrP
Res
 continued to accumulate. The depletion of PrP
C
 in these mice after prion infection leads to an increase 
in survival time compared to the PrP-expressing counterparts
190
. These conclusions suggest that 1) reduction or 
elimination of PrP
C
 has no detrimental effects, 2) animals with no PrP
C
 are resistant to prion infection, and 3) 
removal of PrP
C
 during prion infection results in reversal of disease pathology. Therefore, PrP
C
 has become an 
attractive therapeutic target for the treatment of prion diseases. 
 Therapeutic targeting of PrP
C
 has occurred through the use of RNA interference (RNAi) technology, such 
as short hairpin RNA (shRNA) and small interfering RNA (siRNA) (mechanism of technology discussed later).  
Expression of shRNA in lentiviral vectors and treatment with siRNA in primary or cultured cells results in a 
substantial decrease in expression levels of PrP
C
 mRNA and protein. shRNA and siRNA are effective in multiple 
different types of cell lines with different expression levels of PrP
C
, suggesting that these therapeutics could be used 




 concentrations in the CNS but also in peripheral areas. Treatment of prion-infected 
cells with either shRNA or siRNA reduces the levels of PrP
Res









through normal protein processing mechanisms, such as the proteasome
269-274
. Some of these studies report that the 
levels of PrP
Res
 drop so substantially that the cells become ‘cured’ of prion infection. However, one study noted that 
even though PrP
Res
 levels were reduced to nearly non-detectable levels, de novo generation of PrP
Res
 was still 
occurring
271
. This study insinuates that perhaps the cell lines are not completely cured, and designation of such 
should be given carefully. 
 Stereotactic injection of shRNA or siRNA is standard practice when treating mice with these molecules. A 





 levels and reversed the early neuronal pathology of prion infection. This single treatment resulted in a 
24% increase in lifespan of these mice
275
. Generation of chimeric mice that express shRNA in 50% of their cells 
results in prolonged survival when infected with prions
276,277
. These results have led to attempts to generate livestock 
with reduced or eliminated levels of PrP
C
. The hypothesis being that cattle or goats with decreased levels of PrP
C
 
could be resistant to either BSE or scrapie, and could be bred to generate herds that withstand prion outbreaks
273,278
. 
A limitation of the stereotactic technique in mammalian models is that the injections cause damage to CNS 
tissue and only deliver the shRNA/siRNA to local areas around the injection. A recent study employed the use of 
liposomal technology (discussed later) to package siRNA with a neuronal targeting peptide so that the siRNA was 
delivered to the BBB with an intravenous injection. The authors reported a 70% reduction in PrP
C
 levels in N2a 
cells, and a concomitant reduction in PrP
Res
 of prion-infected cells. The liposomes protected the siRNA from serum 
degradation for transport through the bloodstream, and the peptide was specific to receptors commonly found on 
neurons. These liposome-siRNA-peptide complexes (LSPCs) crossed the BBB and selectively targeted neuronal 
cells in vivo. This delivery method has the potential to overcome the complications of previous delivery methods
272
. 
The success of RNAi technology in prion disease needs to be further addressed in mouse models. Limitations that 
need to be overcome include delivery methods, toxicity of double-stranded RNA or vectors, and some leakage of 
PrP
C
 expression that results in de novo PrP
Res
 propagation after treatment. 
 Other Therapeutic Approaches 
 Another RNA therapeutic option for prion diseases, besides shRNA and siRNA, are RNA molecules 
known as aptamers. Aptamers are oligonucleotides (RNA or DNA) that bind to a particular target molecule and 




 as target molecules, 
two RNA aptamers have been described to influence PrP
Res
 levels. DP7 is a 2’-aminopyrimidine-RNA aptamer that 
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binds specifically to the a-helix-rich PrP
C
 protein. It was generated from human PrP
C
 residues 90-141 and binds 




 levels decreased by 53% upon treatment with DP7 in scrapie-infected N2a 
cells. The authors speculate that the inhibitory effect is due to the aptamer blocking or interfering with 
polymerization of PrP
Res
, thereby making it more PK-sensitive
279
. SAF-93 is a 2’-fluoro-RNA aptamer that binds 
specifically to the b-sheet conformation of PrP
Res
. SAF-93, when bound to PrP
Res
, is PK-resistant, indicating that it 
binds to the infectious form in the PK-resistant core. As with DP7, there was inhibition of PrP
Res
 conversion with the 
treatment of SAF-93 in infected cells. The mechanism is not known, but the authors conjecture that the binding to 
PrP
Res




. In vivo efficacy is unknown for the above aptamers. 
 Other compounds discovered to have anti-prion activity include curcumin (a major component of the spice 
turmeric), statins such as lovastatin and squalestatin, inhibitors of cell signaling pathways, 2-aminothiazoles (IND24 
and IND81), and dimethyl sulfoxide. These compounds decreased levels of PrP
Res
, or inhibited the conversion of 
PrP
Res
 in vitro, but were unable to produce any meaningful effects in vivo or selected for drug-resistant prion strains. 





siRNA and Liposomes 
From RNA Interference Discovery to Mechanism 
 In the 1980s and early 1990s, experiments with plants revealed a mechanism that silenced exogenous and 
endogenous genes. Introduction of a purple gene for flowers into petunias resulted in white flowers produced from 
the gene silencing of both the exogenous and endogenous gene. This process became known as post-transcriptional 
gene silencing. The mechanism was unknown but it was accepted that both sense and anti-sense RNA silenced 
target gene expression, as observed in other models. In 1998, Fire and Mello discovered that the introduction of 
double-stranded RNA (dsRNA) into the nematode Caenorhabditis elegans (C. elegans) resulted in specific gene 
silencing. This silencing was more potent than using either sense or anti-sense single-stranded RNA (ssRNA). This 
phenomenon became known as RNA interference (RNAi)
286
. Gene silencing through RNAi is mediated by dsRNA 




and will bind the target gene. The sense strand, or passenger strand, eventually becomes degraded. When the guide 
strand associates with its target mRNA and an endonuclease, the result is cleavage of the mRNA, which causes a 
decrease in protein expression. Many organisms possess RNAi, from Drosophila melanogaster (fruit flies), plants, 
C. elegans, fungi, to mammals including mice and humans. RNAi evolved as an immune response towards any 
dsRNA, including endogenous (transposons) and exogenous (viruses) sources
287
. 
 The mechanism to induce RNAi starts with the introduction of a long dsRNA, short hairpin RNA (shRNA) 
or a small interfering RNA (siRNA) of 21-23 nucleotides into the cell. The long dsRNA is cleaved into smaller 21- 
23 nucleotide fragments, which is accomplished through the action of the Dicer RNase III (Dcr) protein. In D. 
melanogaster, Dcr works in concert with another protein, R2D2, to cleave the long dsRNA into 21-23 fragments 
through ATP hydrolysis
288-291
. After Dcr processing, the siRNA fragments load into the RNA induced silencing 
complex (RISC) by association with an Argonaute (Ago) protein. The main Ago protein utilized in siRNA gene 
Figure 1.3. RNAi pathway in humans for long dsRNA, siRNA, and 
shRNA. Qiagen 
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silencing is Ago2. SiRNA molecules are designed with 2-3 nucleotide 3’ overhangs so that the PAZ domain in Ago2 
can bind to the siRNA. In humans, Ago2 binds to the Tar RNA binding protein to complete the RISC complex. 
RISC remains inactive until the passenger strand has been removed
290,292-297
. The passenger strand is either removed 
when Dcr hands the siRNA to Ago2
296
 or by an ATP-dependent helicase
287,289
 that unwinds the siRNA when loaded 
into Ago2. RISC is activated when Ago2 has exposed the guide strand and can bind to its target mRNA. The target 
mRNA is cleaved by the PIWI domain of the Ago2 protein, which contains an endonuclease catalytic site. The 
mRNA is cleaved at a single site, which attracts endo- and exonucleases to digest the rest of the mRNA and results 
in reduced levels of protein translation
290,294,297
. 
Several factors are important to produce the optimal amount of gene silencing. Two modifications are 
required to load the siRNA in the correct orientation in Ago2. Synthetic or natural siRNAs need to possess a 5’ 
phosphate group. If synthetic siRNA does not already have the 5’ phosphate group, then the cellular kinase Clp1 
will immediately phosphorylate the RNA upon cell entry
289,297,298
. The 5’ phosphate along with a divalent cation 
enables the RNA molecule to bind to the PIWI domain of Ago2
297
. Second, a 2-3 nucleotide 3’ overhang is needed 
for the RNA molecule to bind to the PAZ domain of Ago2
290,299
. Also, mRNA cleavage is more robust when the 
siRNA has a low internal stability on the 5’ end of the anti-sense strand, and a reduced thermodynamic stability in 
the 10-14 nucleotide region of the siRNA. Thermodynamic instability is achieved with the addition of more A/U 
base pairs at the 5’ end. These characteristics are referred as the asymmetry rule of siRNA
289,300
. 
Challenges of RNAi Based Therapeutics 
 RNAi technology represents a novel gene therapy that can target any gene for downregulation. The use of 
this technology, not only in the research lab but also as a therapeutic, became extremely appealing. Therapeutic 
RNAi technology soon exploded leading to new developments in siRNA synthesis and expression, stability and 
efficacy, and delivery systems. 
Expression of RNAi 
 Expression of siRNA in mammalian cells can occur in multiple ways. A direct injection of long dsRNA 
leads to the formation of siRNA molecules. This practice is common in plants and nematodes but in mammals, long 
dsRNA activates the interferon response. Therefore, synthetic siRNA molecules are produced for the use of 
mammalian studies. Injection of siRNA into mammalian cells allows the siRNA to bypass the Dcr cleavage step of 
the RNAi pathway and proceed directly to Ago2 in the RISC complex. One disadvantage to the chemical synthesis 
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method is the problem of delivering the siRNA both systemically and across the plasma membrane because siRNA 
molecules are easily digested by serum nucleases and have a short half-life. They also do not cross the negatively-
charged plasma membrane due to the negatively-charged backbone of the siRNA
301
. Other popular expression 
methods include utilization of either a viral or non-viral vector. Viral and non-viral vectors offer an advantage over 
chemically synthesized siRNAs in that the vectors provide a more stable expression of siRNA, whereas the 
chemically synthesized siRNA is only transiently present and effective. Lentiviral and adeno-associated viral vectors 
are the most commonly used because they can be introduced into non-dividing cells. The siRNA is typically 
processed from a shRNA expressed from either a U6 or H1 promoter. These vectors integrate into the chromosome, 
which allows for stable expression of siRNA. However, this is also a drawback in utilizing this technology for 
human therapeutic use as chromosomal mutations are probably not the best therapeutic strategy
302-304
. Non-viral 
vectors include the use of plasmids that express shRNA from RNA polymerase II or III promoters. Non-viral vectors 
are not easily introduced into non-dividing cells, unlike their viral counterparts
305,306
. The choice of expression 
system is dependent upon the application of the siRNA therapeutic, such as cell type, expression duration, and 
delivery method. 
Delivery of siRNA in vivo: Considerations of stability and targeting 
 The in vitro use of siRNA has shown that it is capable of downregulating genes in a wide range of 
situations. Once the siRNA is intracellular, it decreases expression of any targeted mRNA. However, the challenge 
of getting it to the cell remains the biggest blockade for siRNA in vivo applications. The seminal studies that used 
synthetic siRNA in vivo used the hydrodynamic method of injection into mice. These studies injected close to one 
milliliter of naked siRNA into the tail veins of mice, which creates a high-pressure system to push the siRNA into 
cells. This method is extremely effective for the transfection of siRNA into hepatocytes. Naked siRNA in 
hepatocytes can reduce viral titers of hepatitis C virus
307
 and Fas protein
308
 to inhibit damage generated by hepatitis 
C infection and fulminant hepatitis, respectively. Also, siRNA targeted towards either caspase 3 or 8 within 
hepatocytes can reverse damage caused by hepatic ischemia
309
. SiRNA is found in the liver and kidney several 
minutes after hydrodynamic injection with lower concentrations found in the lung, spleen, and heart
310
. While this 
method is effective in delivering siRNA to the liver, hydrodynamic injection in humans results in tissue damage, so 
is it not an ideal method for clinical use. Other methods of delivery include non-hydrodynamic intravenous injection 
or site-specific injection. 
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 Non-hydrodynamic intravenous injection is an attractive alternative for systemic administration of siRNA 
as this administration can be used in a clinical setting. The major drawbacks of this method include siRNA 
degradation and lack of targeting. The half-life of siRNA depends on the thermodynamic stability of the 5’ end. Due 
to the asymmetry rule, the 5’ end is already thermodynamically unstable to allow RISC loading. This instability also 
allows attack from serum exonucleases. The half-life of any particular siRNA molecule can range from 15 minutes 
to several hours in 100% serum conditions
311-314
. Endonucleases also participate in siRNA degradation by attacking 
the 2’OH on the ribose sugar of the RNA. Nonetheless, nuclease stability can be achieved using modifications on 
the termini or the backbone of the siRNA.  
Typical modifications include phosphorothioate (PS), 2’-O-methyl, 2’-fluoro, locked nucleic acids (LNAs), 
and cholesterol. The addition of PS to the siRNA backbone results in an increase of half-life to 24 hours in 50% 
human serum. The addition of more PS groups confers more stability but too many groups causes toxic 
effects
309,312,315
. Maximal siRNA activity is retained when 2’-O-methyl modifications are incorporated on every third 
nucleotide and 2’-fluoro modifications are incorporated into the pyrimidine bases. 2’-O-methyl and 2’-fluoro also 
increased half-life to 24 hours in 50-100% serum. Neither of these modifications generates toxicity, but too many 
modifications on the backbone can abolish siRNA activity
309,312-314,316
. LNAs incorporate a methylene bridge into the 
siRNA to increase the stability of the backbone, which also increases nuclease stability. LNAs at the terminal ends 
retain maximal activity compared to incorporation into the core region of the siRNA
316
. Terminal cholesterol siRNA 
modification not only increases nuclease stability but also increases transfection efficiency of siRNA into 
hepatocytes. In the absence of hydrodynamic injection and any transfection reagent, cholesterol-siRNA was 
delivered to hepatocytes, where it decreased apoB protein levels
317,318
. This was one of the first studies that indicated 
siRNA could be targeted to specific cell types using a targeting peptide. Due to the importance of the 5’ phosphate 
on the anti-sense strand, any terminal modifications should be located on the 3’ end of the anti-sense strand or the 5’ 
and 3’ ends of the sense strand to retain maximal RNAi activity. 
 Several types of peptides are used for cell-specific delivery of siRNA: cell-penetrating peptides (CPPs), 
membrane-penetrating peptides (MPPs), and cell targeting peptides. MPPs are peptides that can readily cross 
membranes, from plasma membranes to endosomal membranes. Various viruses can cross membranes quickly due 





 to destabilize both plasma and endosomal membranes and deliver oligonucleotides to 
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the cytoplasm. Several polycations can also be used as MPPs, such as polylysine, the cationic polymer PEI, and the 
neutral lipid DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine)
321
. The MPPs penetratin and transportin also 
decreased GFP expression in COS-7, C166-GFP, and EOMA-GFP cell lines, which are resistant to siRNA 
transfection via liposomes
322
. CPPs, such as the TAT peptide from HIV-1, are more commonly used than MPPs for 
siRNA research, and result in more tissue-specific RNAi activity. The Tat peptide from HIV-1 was fused to a 
double-stranded RNA binding domain to aid in delivery of siRNA. SiRNA complexed to the TAT/RNA binding 
domain was directed towards multiple different cell types in vivo and had reduced off-target effects compared to 
lipid transfection of the same siRNA
316
. 
Common cell targeting peptides include cholesterol, aptamers, CpG oligodeoxynucleotides for Toll-like 
receptor (TLRs) expressing cells, a-tocopherol (Vitamin E), and some viral peptides such as TAT from HIV-1
316,323
. 
Aptamers are selected for their ability to bind to a cellular receptor on specific cell types. A 2’-fluoro modified 
aptamer for the PSMA cell surface receptor delivered siRNA directly to prostate cancer cells. The siRNA was 
targeted towards several anti-apoptotic mRNAs and resulted in tumor regression in a xenograft mouse model
324
. 
Another 2’-fluoro modified aptamer conjugated to anti-HIV siRNA showed a dual inhibition of HIV infection. The 
aptamer was targeted towards the gp120 cell surface receptor on HIV-infected T cells, and the siRNA was targeted 
towards the Tat/Rev mRNA. The aptamer-siRNA conjugate delivered the siRNA to HIV-infected cells only. It 
resulted in a decrease of Tat/Rev mRNA, and a reduction in HIV-infected T cells due to the blockade of gp120 
binding to CD4 due to the aptamer
325
. The CNS is especially difficult to deliver siRNA to due to the BBB. Several 
CPPs have managed to traverse the BBB and deliver siRNA to neuronal cells within the CNS. An intravascular 
injection of a-tocopherol conjugated siRNA resulted in receptor-mediated uptake in the brain. The siRNA was 
targeted toward beta-secretase 1, which led to a reduction of Ab peptides in a mouse model of AD. The a-
tocopherol-conjugated siRNA was also attached to serum high-density lipoprotein to mediate BBB crossing
326
. A 
small peptide of the rabies virus glycoprotein (RVG), which binds to nicotinic acetylcholine receptors, was shown to 
deliver siRNA to neuronal cells within the CNS. A nine-arginine residue stretch (RVG-9r) enabled RVG to bind to 
the anionic backbone of the siRNA for in vivo delivery. The siRNA decreased SOD1 mRNA in the brain, and 
protected neurons from Japanese encephalitis virus by reducing viral proteins. RVG-9r also increased serum stability 




Another way to protect siRNA from serum degradation is to use a vehicle delivery system. Vehicle delivery 
systems include polymers, dendrimers, and liposomes. Liposomes have become the most widely used siRNA 
vehicle since cationic liposomes were found to efficiently deliver plasmid DNA and other gene therapy products to 
cells. Liposome formulations include cationic, anionic, neutral, and ionizable lipids. Cationic lipids are the most 
widely used lipid for liposomes as they easily complex with siRNA through the negative charge of the phosphate 
backbone and the positive charge of the lipid
328-333
. However, other lipid formulations other than cationic lipids 
efficiently transfect different cell types. The application of the therapeutic determines which liposome formulation 
performs better. For example, it is extremely difficult to load some drugs into conventional cationic liposomes. 
Therefore, stable nucleic acid lipid particles (SNALP) were generated to possess a positive charge in acidic pH, to 
facilitate pH gradient loading, and a neutral charge at physiological pH to ensure drug retention. The charge 
difference of SNALPs is due to the mixture of cationic, neutral, and ionizable lipids within the liposome
334,335
. 
Cationic lipids (DOTAP [1,2-dioleoyl-3-trimethylammonium-propane (chloride salt)], DOTMA [1,2-di-O-
octadecenyl-3-trimethylammonium propane (chloride salt)]) used for RNAi purposes are often synthetically 
engineered. Anionic liposomes come from more natural sources as cell membranes are composed of anionic lipids. 
Therefore, anionic liposomes can evade the immune system more efficiently than cationic liposome. A positively-
charged molecule should be employed to condense the siRNA before loading into anionic liposomes if anionic lipids 
are used for RNAi purposes
336
. A helper lipid is usually included in liposome formulations, such as cholesterol or 
DOPE, to aid in liposome fluidity and to create a more rigid structure, so therapeutic drugs are retained within the 
liposome
337
. Liposomes, with either cationic or anionic lipids, are cleared by the mononuclear phagocyte system of 
the liver and spleen. Thus, they tend to have short half-lives in circulation. The incorporation of either PEG groups 
or GM1 ganglioside generates stealth liposomes with longer half-lives. Clearance kinetics with either of these 
moieties is dose independent
338
. CPPs can target liposomes towards a particular cell type. Targeting ligands are 
either attached via covalent bonds or electrostatic interactions. Thus, generating a targeted siRNA delivery vehicle 
that is resistant to nucleases. 
There is much speculation about how liposomes deliver siRNA into the cytoplasm of cells. Early 
experiments with fluorescent liposomes indicated that they fused to the plasma membrane and deposited their 
contents into the cytoplasm. However, any siRNA that is electrostatically attached to the outside of the liposome 
cannot enter the cell through this mechanism. This may not be a problem since it was shown that the addition of 
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DNA to liposomes resulted in destabilization of the liposomes, such that the DNA ended up on the inside of the lipid 
bilayer
339
. The same mechanism could occur with siRNA, leaving minimal amounts attached on the outside. Another 
mechanism of siRNA cytoplasmic entry is through endosomes. After transfection, liposomes are concentrated within 
cytoplasmic vesicles. It is believed that liposomes undergo endocytosis after interacting with the plasma 
membrane
340
. The mechanism of endosomal escape is still a little unclear. Some have speculated that the interaction 
between the negatively-charged endosomal membrane and the positively-charged liposome creates a destabilization 
effect of the membrane so siRNA can escape. However, this would imply that liposomes are no longer intact after 
endosomal escape, which seems not to be the case in some cell types
330,339
. Others have postulated that the bilayer 
phase properties contribute to endosomal escape such that a hexagonal bilayer more efficiently escapes the 
endosome than a lamellar bilayer
341
. Polymer vehicle delivery systems are not able to escape the endosome unless a 
membrane-disrupting peptide is used
330
. The exact cell entry mechanism, whether plasma membrane fusion or 
endosomal escape, may depend on cell type and liposome formulation. 
Liposomes as siRNA delivery systems are extremely efficient in delivering siRNA to cells; however, 
toxicity issues have arisen with their use. Cationic formulations become immunogenic when they interact with 
negatively-charged serum proteins, which leads to an increase in cytokines and complement production. Also, since 
cationic liposomes are exceptionally effective at delivering siRNA to cells, they may inadvertently deliver siRNA to 
immune cells allowing for more immune activation
342
. Cationic lipids can also lead to an increase in reactive oxygen 
intermediates leading to toxicity of cells. There is some debate as to whether the liposome or the whole 
liposome/siRNA complex leads to immune activation. Some studies have shown that empty liposome or naked 
siRNA do not induce immune activation
342,343
, while other studies have demonstrated that they do
324,344,345
. Immune 
activation may depend on the concentration of liposome, formulation of the liposome, concentration of siRNA, and 
cell type. Anionic lipids are less immunogenic since they are derived from naturally-occurring lipids and do not 
readily associate with serum proteins
336
. However, a complete toxicity profile for anionic liposomes is lacking due to 
little research on anionic lipids. 
Besides intravenous injection, intraperitoneal injections also deliver siRNA systemically. The exact 
mechanism of systemic delivery via intraperitoneal injection is not known but is thought to occur via diffusion 
directly into cells, uptake by vasculature and dissemination, or uptake by the lymphatic system. This injection 
method has shown promise in delivering siRNA to organs within the intraperitoneal cavity. In a mouse model of 
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septic shock, siRNA targeted towards TNFa resulted in protection against sepsis induced by lipopolysaccharide
346
. 
Intraperitoneal injections are efficient in delivering siRNA to abdominal tumors, specifically tumors caused by 
ovarian cancer. SiRNA directed towards either the tyrosine kinase receptor EphA2 or the integral membrane protein 
claudin 3 resulted in a decrease in tumor growth when the siRNA was injected intraperitoneally. Maximal delivery 
of the siRNAs was achieved through the complexation of lipid particles, either DOPC (1,2-dioleoyl-sn-glycero-3-
phosphocholine) lipids or a lipid-like particle (98N12-5). This route of systemic delivery is important because it is 
less evasive and less technically challenging than an intravenous injection, and it is a clinically relevant route as 
some chemotherapeutic drugs are already administered this way
346-348
.  
While systemic delivery shows promise in delivering siRNA to highly vascularized parts of the body, it 
does have a few limitations. Therefore, local delivery of siRNA has been investigated as an alternative. Nuclease 
stability of siRNA and cell-specific distribution is not as problematic in local administration as it is in systemic 
delivery. Also, local delivery decreases the risk of triggering an interferon response (discussed below) caused by the 
siRNA. Local delivery is attractive for delivering siRNA to tumors, or to privileged sites such as the eye and the 
brain. Intratumoral injections of siRNA have reduced tumor growth and angiogenesis in mouse xenograft models of 
melanoma, breast cancer, and cervical cancer. An increase in apoptosis and cytotoxicity in malignant cells 
developed by targeting various proteins (CSF1, Raf1, E6/E7) that have enhanced function in cancer cells, which 
resulted in reduction of tumors
349-352
.  
Pump infusion into the third ventricle or stereotactic injections has been employed for local delivery to the 
CNS. Stereotactic injections have been used for both prion diseases and HD. The prion disease RNAi therapeutics 
were discussed above, but, briefly, they resulted in reversal of neuropathology by targeting PrP
C
. A Huntington’s 
disease study, involving siRNA, targeted exogenous mutant huntingtin in an HD mouse model. The cholesterol-
modified siRNA using an intrastriatal injection resulted in a reversal of HD neuropathology and motor deficits
353
. 
Studies using siRNA against a-synuclein revealed that a one-month infusion into the substantia nigra of squirrel 
monkeys decreased a-synuclein without reducing the number of dopaminergic neurons or activating microglia
354
. A 
functional study to determine the physiological role of APP revealed that siRNA reduction of APP results in a 





Lastly, local delivery to the eye is so efficient that many RNAi ocular drugs are currently in Phase II/III 
clinical trials. Local delivery to the retina through an intravitreal injection was achieved using the transfection 
reagent TransitTKO. The retina is especially hard to deliver drugs to given the inner limiting membrane of the 
retina
356




 injection results in a reduction in 
choroidal neovascularization. Neovascularization is particularly damaging in age-related macular degeneration as it 
leads to blindness. However, in other reports the activation of TLR3 by RNAi was shown to decrease 
neovascularization in a siRNA sequence independent manner, indicating that RNAi within the ocular region results 
in an immune response. Nevertheless, RNAi drugs aimed at ocular targets are being developed
309,356
.  
Off-Target Effects and the Immune System 
 In the first years of RNAi technology, researchers were extremely excited that no off-target effects were 
observed. Most siRNA molecules were selected based on homology screens, such that any homology with an 
endogenous gene was excluded. Therefore, many publications reported that the expression of the few control genes 
that were monitored for off-target effects (OTEs) were not disrupted because there was no homology with the 
siRNA. However, a microarray analysis of hundreds of expression profiles revealed a dozen to several hundred 
genes are regulated by any one siRNA molecule
359
. This finding was a major setback for the field, and research into 
the exact cause of the OTEs intensified. It was found that the seed region of a siRNA or shRNA, which corresponds 
to the 2-7 or 2-8 bases in the core region, determines the OTEs of a specific RNAi molecule. One nucleotide change 
in this seed region results in a different set of OTEs. Specifically, complementarity between the seed region of the 
RNAi molecule and the 3’ untranslated region of mRNA determines which genes’ expression is affected. This 
mechanism is remarkably similar to how micro RNAs (miRNAs) function by repressing translation through the 
binding of the miRNA to the 3’ untranslated region of a particular gene. The mechanism of OTEs of siRNA indicate 
that it can mimic miRNA molecules, which results in a widespread alteration of gene expression
360,361
. Some 
chemical modifications, such as 2’-O-methyl, can be incorporated into the siRNA molecule to reduce OTEs. 
However, most of these modifications result in a reduced efficacy of the siRNA
309,316
. Researchers may never be 
able to abrogate OTE activity with RNAi completely, so design of siRNA molecules with the fewest and least 
deleterious OTEs needs to be considered for any siRNA translated to the clinic. 
 It is known that long dsRNA molecules elicit an innate immune response through TLRs. TLRs recognize 
pathogen-associated molecular patterns. One of the mechanisms of this immune pathway enables an organism to 
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defend itself against any exogenous RNA or DNA, usually from a viral infection. While this is a typical response to 
exogenous RNA, researchers thought that siRNA was incapable of stimulating an immune response due to its short 
length. Any DNA/RNA below 30 base pairs did not seem to activate the immune pathway. Early RNAi studies 
typically assessed one or two immune activation proteins, such as interferons and cytokines
308,311,325
. Just like the 
early attempts to deduce siRNA OTEs, attempts to find immune activation via siRNA were very narrow. Eventually, 
it was shown that treating a cell line that possessed immune system markers with siRNA resulted in immune 
activation. The activation occurred either through TLR-3 or TLR7/8. TLR-3 commonly recognizes dsRNA 
molecules, and TLR7/8 recognizes ssRNA molecules. TLR activation may occur through the endosomal pathway 
after endocytosis of the siRNA. Activation through TLR-3 or TLR7/8 increased interferon production
324,344
. 
Additionally, TLR-3 signaling leads to an increase in IL8, TNFa, and activation of NF-kB promoters. One 
consequence of immune activation is sequence-dependent gene suppression
324
. Immune activation by siRNA 
remained controversial for some time as the immune response was not seen in all cell lines or even animal models. 
Again, the animal model screens might have been too narrow or were looking at the wrong part of the immune 
system
362
. Differences in cell lines might account for the variabilities and might be attributed to genetic 
abnormalities or immune versus non-immune cell lines. A non-immune cell line revealed immune activation through 
the PKR pathway instead of the TLR pathway
345
. Use of transfection reagent or carrier also affects immune 
stimulation, as noted above with liposomes. Certain poly(U) or G/U rich sequences also contribute to an immune 
response, so siRNA should be designed without these sequence stretches
363
. Structural modifications of the siRNA, 
such as 2’-O-methyl and LNAs, decrease immune stimulation but modified siRNAs need to be verified that potency 
is not affected
316,344
. Like OTEs, careful design of the siRNA and carrier need to be made to reduce the amount of 
immune stimulation, especially in animal or human models.		
	
The Blood-Brain Barrier 
Structure and Function 
 The BBB remains the biggest obstacle in developing pharmaceuticals for diseases that affect the CNS. In 
physiological conditions, the BBB maintains ion homeostasis, prevents toxic substances from entering the brain, and 
aids in immune surveillance. Neurons and other cells in the CNS depend on ions and nutrients for support and 
maintenance. However, ions and nutrients must be provided to these cells in strict concentrations, too much or too 
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little of these molecules results in neuronal damage. The BBB provides the transport needed for the ions/nutrients 




 There are three main layers to the BBB that support its role in limiting access of substances to neurons. The 
first layer, the endothelial cells, provides a physical barrier for all compounds in the blood stream. Astrocytes 
support the endothelial cells of the BBB and make up part of the physical barrier. Pericytes also aid in support and 
maintenance of the BBB by changing vascular permeability of blood vessels. The endothelial cells are connected via 
tight junctions with little to no movement of nutrients occurring through these junctions
364,365
. Therefore, the 
majority of compounds use transcytosis for transport across the BBB to neuronal cells. Nutrients, such as glucose 
and amino acids, are transported across the barrier using various membrane transporters. Larger molecules use either 
adsorptive mediated transcytosis or receptor mediated transcytosis. Both of these transport pathways result in 
compounds being endocytosed into the endothelial cells via a clathrin-dependent mechanism. It is not clearly 
understood how transcytosis occurs using these pathways but it is clear that there is a mechanism that releases the 
molecules before they are deposited into lysosomes for degradation. These transport pathways represent the 
transport barrier of the BBB. This layer of the BBB also includes multiple different types of efflux pumps. If a 
molecule is able to bypass the physical barrier, it can be pumped out of the endothelial cells by the efflux 
pumps
365,366
. The last barrier of the BBB is the enzymatic barrier, which consists of intracellular and extracellular 
enzymes. These enzymes are capable of digesting molecules around or in the endothelial cell layer. It is difficult for 
any drug to remain intact after crossing the BBB due to these three barriers. Once a drug does pass through the 
barrier it does not have to travel far for its site of action as most neurons sit between 8-25 µm from a microvessel. 
There are a variety of ways to circumvent these layers of the BBB to deliver drugs to the CNS
364,365
. 
 The most common way to transport drugs across the BBB is by the ‘Trojan horse’ method. This method 
employs couples a therapeutic with a known molecule that is able to cross the BBB. These molecules are referred to 
as targeting peptides as they directly target a therapeutic to the CNS. Many of these molecules transport therapeutics 
across the BBB using receptor mediated endocytosis. While this method has proven effective in transporting 
therapeutics across the barrier, many of the therapeutics that employ this method alter the endocytic pathway in a 
way that a substantial portion of the therapeutic is shuttled to lysosomes for degradation. However, the argument 




 Some molecules that have been utilized in the ‘Trojan horse’ method include transferrin, leptin, insulin, 
thiamine, and small viral peptides and bacterial toxins. Researchers have commonly used transferrin or transferrin-
like molecules to transport oligonucleotides across the BBB. Early on in RNAi research it was found that 
phosphorothioate oligonucleotides (discussed above) utilized a specific transporter for delivery across the barrier
367
. 
That specific transporter was later identified as the transferrin receptor. Since then, multiple different groups have 
taken advantage of the transferrin/transferrin receptor transport system to deliver therapeutics to the brain. One 
example that exploits the transferrin receptor transport pathway used a monoclonal antibody, OX26, towards the 
transferrin receptor as a targeting peptide. The OX26 antibody was bound to polymersomes, which are vesicles 
made of copolymers that are stronger than lipid based vesicles, such as liposomes. The vasopression drug NC-1900 
was packaged within the polymersomes and targeted towards the brain using the OX26 antibody. OX26 allowed 
NC-1900 to cross the BBB and resulted in an improvement in memory deficits of a scopolamine rat model
368
. 
 Other monoclonal antibodies towards cell surface receptors are also used as targeting peptides. The human 
insulin receptor monoclonal antibody was fused with the tumor necrosis factor receptor, which suppresses tumor 
necrosis factor a (TNFa). TNFa is an inflammatory cytokine that can lead to neuronal damage in traumatic brain 
injuries and neurodegenerative conditions. By itself, the tumor necrosis factor receptor is not able to cross the BBB 
but coupled to the insulin receptor monoclonal antibody it is transported across the BBB and is selectively targeted 
to the brain in a rhesus monkey. A problem with utilizing certain cellular surface receptors is that they bind their 
ligands in a saturable manner. Both transferrin and insulin receptors have saturable binding domains. Therefore, 
only a certain amount of drug is allowed to bind to these receptors before all the active sites are blocked. Also, drugs 
that use these receptors must compete with the endogenous ligand for active binding sites. These two factors limit 
the amount of drug that can be transported across the BBB with these cellular receptors
369
. The thiamine receptor is 
also used to transport therapeutics to the brain but also has saturable binding and therapeutics have been shown to 
compete with the natural ligands for this receptor
365
. 
 Several groups have taken advantage of peptides from viruses or bacteria that can enter the CNS. As 
discussed above, Kumar et al. used the small peptide RVG-9r from the rabies virus glycoprotein to target siRNA 
towards the CNS
327
. Other groups have found that the C-terminal fragment of the tetanus toxin delivered superoxide 
dismutase to neurons in vivo by a number of routes, including intramuscular and intraperitoneal injections
370
. Based 
on this observation, the tetanus fragment was conjugated to nanoparticles, which delivered drugs to neuroblastoma 
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cells. One problem that remains with the use of the tetanus fragment is immunogenicity due to mass vaccination 
against tetanus. Therefore, several molecules identical to the tetanus fragment have been generated to overcome the 
immune system. One of these tetanus-like compounds, CRM197, was able to deliver polymersomes across the 
BBB
371
. More studies are needed to determine if these targeting peptides are useful in neurodegenerative disease 
models. 
 Other methods of crossing the BBB include the generation of analogs for cellular transporters, bypassing 
the barrier completely using either intrathecal or intranasal administration, and taking advantage of certain disease 
processes that make the BBB more permeable. While many of these methods have proven successful in transporting 
therapeutics to the brain, many obstacles of brain delivery remain before one of these methods is approved for 
pharmaceutical use. An ideal delivery method would not only transport therapeutics to the brain but would also be 
biodegradable and nontoxic, selective for neuronal cells, non-damaging to the BBB, and deliver therapeutic 




Introduction to Work in this Dissertation 
 The primary objectives of this research are to understand the pharmacological effects of transiently 
decreasing PrP
C
, due to a RNAi therapeutic, in prion diseases, and investigate the biodistribution and 
pharmacodynamics of novel in vivo liposomal delivery systems in the central nervous system (CNS). The overall 
hypothesis of this research is that the novel liposomal delivery systems will deliver PrP
C
 siRNA to neuronal cells in 
the CNS, which will decrease neuronal PrP
C
 and result in the extension of survival times of prion-infected mice. We 
employed various techniques such as flow cytometry, western blotting, digital drop PCR, protein misfolding cyclic 
amplification, and ELISA to investigate the following questions: 
Question 1: Can liposome-siRNA-peptide complexes (LSPCs) and peptide-addressed liposome-encapsulated 
therapeutic siRNA (PALETS) deliver PrP
C
 siRNA to neuronal cells using systemic in vivo administration? 
 Numerous studies have shown that many targets are decreased in vitro by siRNA using a mechanism that 
cleaves target mRNA. However, translating these studies in vivo remains a challenge. For efficient in vivo delivery 
of siRNA, the siRNA must be protected from serum nucleases and should be targeted to the proper cell type. 
Targeting siRNA to neuronal cells remains a challenge due to the blood-brain barrier (BBB). The BBB is a tightly 
regulated barrier that does not allow most therapeutic drugs to cross unassisted. Therefore, it is necessary to design 
	 44	
any drug delivery system with a CNS targeting peptide. We have developed three different liposomal drug delivery 
systems to the brain using both cationic and anionic liposomal formulations. These LSPCs and PALETS are directed 
towards the CNS using a small peptide from the rabies virus glycoprotein (RVG-9r) that targets nicotinic 
acetylcholine receptors. In chapter 2, we show that both LSPCs and PALETS effectively cross the BBB and deliver 
PrP
C
 siRNA to mouse neuronal cells in vivo. Each liposomal formulation that we created, demonstrated a unique 
pharmacodynamics profile. We speculate that the different profiles are due to either distinctive uptake efficiencies of 
the liposomes into the CNS or different efficiencies of siRNA unloading. 
Question 2: What are the pharmacodynamics properties of PrP
C
 siRNA in LSPCs delivered intravenously? 
 Gene therapy either results in a permanent or a transient decrease of protein levels of the targeted gene. 
Specifically, for this project, the use of RNAi leads to a transient decrease in protein levels, and because no two 
siRNAs are alike, this temporary decline is highly variable. Therefore, pharmacodynamics profiles are needed for 
every siRNA to determine its efficacy and viability as a therapeutic option. Here we are using the cellular prion 
protein (PrP
C
) as a target for siRNA due to its ability to misfold and cause disease. Since PrP
C
 is used as a template 
for the infectious form, a reduction in PrP
C
 protein levels decreases the amount of substrate available for conversion 
to the infectious form. In chapter 3, we show that our PrP
C
 siRNA targeted towards the 3’ UTR of the prnp gene 
results in a 40-50% reduction of cell surface PrP
C
 in two different mouse models. This decrease was seen to last as 
long as 21 days after siRNA treatment. The LSPCs did have some off-target effects in the kidney due to the presence 
of nicotinic acetylcholine receptors in that organ. We also demonstrate that PrP
C
 mRNA levels are reduced at certain 
time points after siRNA treatments. However, to our surprise, some mice showed an increase in PrP
C
 mRNA after 
siRNA treatment. 
Question 3: Do PrP
C
 siRNA-containing LSPCs increase the survival time of mice with established prion 
infection in a scrapie mouse model? 
 Many therapeutic options have been proposed for prion diseases. These options, discussed in more detail 
above, are effective at reducing PrP
Res
 in prion-infected cell lines. Some of these compounds are too toxic to be 
tested in vivo or cannot readily cross the BBB. Other compounds that have been investigated for efficacy in vivo are 
either effective only at the time of inoculation or only delay onset of clinical disease signs. Early RNAi studies in 
prion disease revealed that a decrease in PrP
C
 substrate for PrP
Res
 conversion leads to a reversal of prion disease 
neuropathology. Therefore, we have used our PrP
C
 siRNA-containing LSPCs to treat prion-infected mice. In chapter 
	 45	
4, we show that siRNA treatment every two weeks or every four weeks from the midpoint to late infection does not 
increase survival times of prion-infected mice. Consequently, the repeated siRNA treatments resulted in a Type III 
hypersensitivity response in the uninfected, treated control mice and total IgG levels increased after siRNA 
treatment. We also demonstrate that behavioral scores are improved with repeated LSPCs treatment, as shown with 
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Chapter 2:  







 The primary therapeutic challenge for any neurodegenerative disease, including prion diseases, remains 
delivery across the blood-brain barrier to neuronal cells. Here we generate three different delivery vehicles to the 
central nervous system: liposome-siRNA-peptide complexes (LSPCs) and peptide-addressed liposome-encapsulated 
therapeutic siRNA (PALETS) (two types). With these delivery vehicles, we can package small interfering RNA 
(siRNA) on the outside of the liposome or encapsulate it within the liposome. We utilize a small peptide, RVG-9r, 
from the rabies virus glycoprotein, to target these delivery vehicles to nicotinic acetylcholine receptors within the 
central nervous system. We show that the use of protamine sulfate increases the encapsulation rate of siRNA within 
anionic liposomes. We also show that LSPCs and PALETS protect the siRNA in the bloodstream long enough to 
cross the blood-brain barrier and deliver siRNA to neuronal cells resulting in a decrease of PrP
C
. These delivery 
vehicles represent a new tool for the delivery of siRNA and any small molecule drug to the central nervous system. 
 
Introduction 
 RNA interference (RNAi) is a potential gene therapy that is capable of regulating the expression of any 
gene through mRNA cleavage
2,3
. RNAi employs the use of small interfering RNA (siRNA) to activate the RNA-
induced silencing complex (RISC), which uses the Ago2 endonuclease to cleave mRNA
4-7
. Cleavage of mRNA is 
dependent on homology with the 21-23 base pair siRNA
8,9
. After mRNA cleavage, exo- and endonucleases degrade 
the mRNA, which results in a reduction of protein levels. Although siRNA has been investigated as a therapeutic for 
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 One of the difficulties of utilizing RNAi in mammalian models is nuclease sensitivity. Naked siRNA has a 
short half-life in circulation due to serum nucleases. RISC loading requires siRNA to have a thermodynamically 
unstable end, which is extremely attractive to exonucleases. Naked siRNA is also cleared from the bloodstream 
rapidly by the liver and kidneys, resulting in a short half-life. The half-life of siRNA can be increased by using 
chemical modifications that provide nuclease stability. Modifications include 2’-O-methyl and 2’-fluoro 
modifications on the ribose sugar, and phosphorothioate on the 3’ terminal end or a methylene bridge (locked 
nucleic acids, LNAs) on either the 3’ or 5’ termini. However, these modifications can decrease the potency of the 
siRNA and increase the synthesizing expense
13-17
. Another option to achieve nuclease stability of siRNA is to link 
the siRNA molecules to delivery vehicles, such as liposomes. 
 Liposomes have been widely used as delivery vehicles for gene therapy products in in vitro assays. They 
are also being investigated for use in animal and human models as delivery vehicles for siRNA as liposomes protect 
against serum nucleases and can be targeted towards specific cell types. Liposomes deliver siRNA directly into cells 
either through fusion to the plasma membrane or through endocytosis
18-20
. Liposomes with cationic lipids are the 
most commonly utilized liposome as the negatively-charged phosphate backbone electrostatically interacts with the 
positively-charged lipid. Cationic liposomes also readily interact with the anionic head groups of cell 
membranes
10,21,22
. Anionic liposomes are not commonly used, as the anionic lipid is thought to be incapable of 
passing the plasma membrane. Still, anionic liposomes are less immunogenic than cationic liposomes as they bind to 
fewer of the negatively-charged serum proteins. A limitation of anionic lipids is that the negative charge of the lipids 
repels the negative charge of the siRNA backbone. However, there have been reports that anionic liposomes can 
efficiently package and deliver DNA by using cations to condense the DNA and shield its negative charge
23-28
. The 
mononuclear phagocyte system (MPS) of the liver and spleen clears liposomes from the bloodstream but circulation 
times of liposomes can be increased using PEGylated lipid groups within the liposome. These groups make the 
liposomes invisible to serum proteins, which reduces uptake of the liposomes by cells of the MPS
29
. Liposomes can 
also be targeted to specific cell types using peptides that either electrostatically interact with or are covalently bound 
to the liposomes
30-33
. Thus, siRNA is protected from nucleases and can be targeted to specific cells or tissues to 
reduce off-target effects. 
 Prion diseases are neurodegenerative diseases caused by the misfolding of a cellular protein called PrP
C34-
37
. The conversion of PrP
C
 to the misfolded isomer, PrP
Res




. Currently, no known therapeutics alleviate clinical signs of prion disease in mammalian models. 
Decreasing or eliminating the substrate for conversion, PrP
C
, is an attractive therapeutic option because it may delay 
or abrogate the disease. Consequences of PrP
C
 knockdown are thought to be minimal as PrP-null mice show no 
abnormalities throughout their lifetimes.	Several research groups investigated the role of PrP
C
 expression levels in 
prion disease by creating transgenic mice with reduced levels of PrP
C
 or by injecting lentiviral vectors expressing 
short hairpin RNA directly into the brains of mice. These researchers found that by reducing the amount of neuronal 
PrP
C
, the life of infected animals could be extended and the neuropathology of prion diseases reversed
39-42
.	We have 





These studies suggest that the use of RNAi therapeutics, such as siRNA, to decrease PrP
C
 expression levels, may 
sufficiently delay the progression of prion diseases. However, for a RNAi therapeutic to be useful in the clinical 
setting, it needs to be coupled to a systemic delivery system.  
 Here we propose to use PrP
C
 siRNA, which is packaged into cationic and anionic liposomes, as a potential 
therapeutic for prion diseases. Liposome-siRNA-peptide complexes (LSPCs) are composed of liposomes with 
siRNA and a targeting peptide (RVG-9r) electrostatically coating the outer surface of the liposome. Peptide-
addressed liposome-encapsulated therapeutic siRNA (PALETS) are composed of siRNA encapsulated within the 
liposome, and RVG-9r linked to lipid PEG groups on the outside of the liposome. RVG-9r is a small modified 
peptide from the rabies virus glycoprotein that targets nicotinic acetylcholine receptors in the central nervous system 
(CNS). This peptide allows the liposome complexes to be targeted directly to the CNS to reduce siRNA off-target 
effects. For anionic PALETS, we also use the cation protamine sulfate to condense the siRNA so that it becomes 
encapsulated within the anionic liposomes. We show that LSPCs decrease surface PrP
C
 40-50% in neuronal cells, 
and that, although producing minimal effects, PALETS can cross the blood-brain barrier to deliver siRNA to the 
CNS.  
 
Materials and Methods 
Mice 
 FVB mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were euthanized using 
CO2. All mice were bred and maintained at Lab Animal Resources, accredited by the Association for Assessment 
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and Accreditation of Lab Animal Care International, in accordance with protocols approved by the Institutional 
Animal Care and Use Committee at Colorado State University. 
Generation of Liposomes 
DOTAP LSPCs 
 DOTAP LSPCs consist of a 1:1 DOTAP:cholesterol ratio in a 1:1 chloroform:methanol solution. Both 
lipids were purchased from Avanti Lipids (DOTAP - 1,2-dioleoyl-3-trimethylammonium-propane [chloride salt]). 
The solvents were evaporated using N2 gas and the resultant dry lipid film was placed under vacuum for a total of 8 
hours to remove any excess solvent. A stock solution of liposomes was made at an 8 mM (40 umole total lipid) 
concentration by resuspending the lipid film in 5 mL of 10% sucrose heated at 55°C. All components (lipid film and 
sucrose) were kept at this temperature during rehydration. The heated sucrose was added to the lipid cake 1 mL 
every 10 minutes. The lipid film was swirled every 3 minutes to promote lipid mixing. Resulting liposomes were 
stored at 4°C. 
DOTAP PALETS 
 DOTAP PALETS consist of a 55:40:5 DOTAP:cholesterol:DSPE-PEG ratio in a 1:1 chloroform:methanol 
solution. All lipids were purchased from Avanti Lipids. The solvents were evaporated using N2 gas and the resultant 
dry lipid film was placed under vacuum for a total of 8 hours to remove any excess solvent. A stock solution of 
liposomes was made at an 8 mM (40 umole total lipid) concentration by resuspending the lipid film in 5 mL of 10% 
sucrose heated at 65°C. All components (lipid film and sucrose) were kept at this temperature during rehydration. 
The heated sucrose was added to the lipid cake 1 mL every 10 minutes. The lipid film was swirled every 3 minutes 
to promote lipid mixing. Resulting liposomes were stored at 4°C. 
DSPE PALETS 
 DSPE PALETS consist of a 55:40:5 DSPE:cholesterol:DSPE-PEG ratio in a 1:1 chloroform:methanol 
solution. All lipids were purchased from Avanti Lipids (DSPE - 1,2-distearoyl-sn-glycero-3-phosphoethanolamine). 
The solvents were evaporated using N2 gas and the resultant dry lipid film was placed under vacuum for a total of 8 
hours to remove any excess solvent. A stock solution of liposomes was made at an 8 mM (40 umole total lipid) 
concentration by resuspending the lipid film in 5 mL of 1X PBS heated at 70-75°C. All components (lipid film and 
1X PBS) were kept at this temperature during rehydration. The heated PBS was added to the lipid cake 1 mL every 
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10 minutes. The lipid film was swirled every 3 minutes to promote lipid mixing. Resulting liposomes were stored at 
4°C. 
Generating LSPCs or PALETS 
PrP
C
 1672 siRNA sequence: ACATAAACTGCGATAGCTTC (Qiagen).  
RVG-9r peptide: YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGrrrrrrrrr (ChemPeptide) 
DOTAP LSPCs 
 The DOTAP LSPCs liposomes were diluted 1:100 in 1X PBS and sonicated 4X with 2-3 minute rests in 
between. 50 uL (4 nmole total) of diluted/sonicated liposomes was mixed with 100 uL (4 nmole total) of 1672 
siRNA. The siRNA/liposome solution incubated for 10 minutes at 4°C. Then, 80uL (40 nmole total) of RVG-9r 
peptide was added to the solution and allowed to incubate for 10 minutes on ice. 
DOTAP PALETS 
 The DOTAP PALETS liposomes were diluted 1:100 in 1X PBS. Single use aliquots were generated by 
lyophilizing 50 uL of the 1:100 liposome dilution (4 nmole total) for 15 minutes. The lipid cake was then 
resuspended using 100 uL (4 nmole total) of 1672 siRNA. The solution is incubated for 5 minutes, which 
encapsulates the siRNA. A carbodiimide reaction was used to covalently bond the RVG-9r to the COOH-terminus 
of the DSPE-PEG lipids. 10 µL of a 60 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) 
solution and 10 µL of a 150 mM N-hydroxysulfosuccinimide (sulfo-NHS) was added to the liposome/siRNA 
solution. The solution incubated for 10 minutes at room temperature. 80 uL (40 nmole total) of RVG-9r was added 
to the solution and allowed to incubate for 2 hours at room temperature. 
DSPE PALETS 
 The DSPE PALETS liposomes were diluted 1:100 in 1X PBS. Single use aliquots were generated by 
lyophilizing 50 uL of the 1:100 liposome dilution (4 nmole total) for 15 minutes. 1.4 uL of a 26.6 uM solution of 
protamine sulfate (Sigma Aldrich) was incubated with 100 uL of a 40 uM stock solution of the 1672 siRNA for 10 
minutes at room temperature. The lipid cake was then resuspended using 100 uL (4 nmole total) of the 1672 
siRNA/protamine solution and incubated for 10 minutes at 4°C to encapsulate the siRNA within the liposomes. 
Then, 80 uL (40 nmole total) of RVG-9r peptide was added to the solution and allowed to incubate for 10 minutes 
on ice. 
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Treating Mice with LSPCs or PALETS 
 Mice were placed under a heat lamp for 5 minutes and anesthetized with 1.5-2% isofluorane (VetOne). The 
mouse tails were disinfected using 70% EtOH. LSPCs or PALETS were injected into the tail veins of mice using a 
29-gauge insulin syringe. 
Measuring Encapsulation Efficiency 
 The encapsulation efficiency of the siRNA within DSPE PALETS using the cation protamine sulfate was 
determined by separating encapsulated from unencapsulated siRNA. The 1672 siRNA was encapsulated with the 
help of protamine within the DSPE PALETS using the above protocol to assemble DSPE PALETS. After 
encapsulation, the liposome/siRNA complex was incubated for 10 minutes on ice. The encapsulated siRNA was 
separated from the unencapsulated siRNA by its retention on a 50 kDa centrifugal filter. The concentration of 
siRNA was measured using a spectrophotometer (Nanodrop, ThermoFisher) at 260 nm. 
Flow Cytometry 
 Mice treated with either LSPCs or PALETS were euthanized 4 days after treatment for protein analysis via 
flow cytometry. Half a hemisphere of brain and one kidney from each mouse was pressed through a 40 µm cell 
strainer (Falcon, VWR) using the plunger from a 5 mL syringe and 5 mL of FACS buffer (1X PBS, 1% fetal bovine 
serum, 10 mM EDTA). The cell suspension was transferred to a 15 mL conical, of which 450 uL of each cell 
suspension was used for flow cytometric analysis. Cells were washed 3X by centrifugation at 2000 rpm (250 x g) 
and resuspension of the cells with 1 mL of FACS buffer. Fc receptors were blocked using 100 uL of a 1:100 dilution 
of a 0.5 mg/mL rat anti-mouse CD16/CD32 Fc block (BD Pharmingen) in FACS buffer with 7% goat serum for 20 
minutes on ice. The cell pellet was washed once as above. The cells were stained with 100 uL of a 1:100 dilution of 
a 20 µg/mL solution of the PrP
C
 antibody BAR-224 conjugated to Dylight 650 (per manufacturer’s instructions) in 
FACS buffer for 40 minutes at room temperature. Red blood cells were lysed with 1 mL of RBC lysis buffer (1X 
PBS, 155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA) for 3 minutes and then centrifuged at 2000 rpm for 3 
minutes. Cells were washed 2X with 1 mL of FACS buffer. Cells were stained with propidium iodide (FisherSci) 
10-15 minutes before analyzing a 1:2 dilution of the cells on a DakoCytomation Cyan ADP flow cytometer. Results 
were evaluated using FlowJo version 10. 
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In vivo Live Imaging 
 LSPCs were assembled as described above. siRNA labeled on the 5’ end with Alexa Fluor 488 (Qiagen) 
and RVG-9r labeled with Dylight 650 (per manufacturer’s instructions) (ThermoFisher) were used. Mice were 
anesthetized with 2% isofluorane, injected intravascularly with LSPCs, and then immediately imaged for up to one 
hour after treatment using an IVIS Spectrum in vivo live imaging system. Autoexposure settings were used. siRNA 
signal was viewed on 500/540 nm filter and RVG-9r signal was viewed on 640/680 nm filter. 
Digital Droplet PCR (ddPCR) 
 RNA was extracted from the cell suspensions using a RNeasy minikit (Qiagen). DNase digestion was 
performed off-column using RQ1 RNase-free DNase (Promega) per manufacturer’s instructions. The RNA was 
purified from the DNase using EtOH precipitation. A 1:10 volume of 2 M NaAcetate and 2.5X volume of 100% 
EtOH was added to the RNA after DNase digestion. The RNA was stored at -20°C for at least 24 hours. The 
samples were then centrifuged at 13,000 rpm (16,060 x g) for 45 minutes. The RNA pellet was washed with 200 uL 
of 100% EtOH and centrifuged again at the same conditions. The RNA pellet was allowed to dry for 1 hour and was 
resuspended in 40 uL of molecular grade H2O. RNA concentration was assessed via spectrophotometer (Denovix) at 
260 nm. Approximately 150 ng of RNA was used to generate cDNA using the High Capacity cDNA Reverse 
Transcription kit from ThermoFisher. A final concentration of 0.035 ng of cDNA was used for ddPCR reactions. A 
final concentration of 1.25 uM of the following PrP primers was used in the final ddPCR reaction: forward primer 
5’CCTTGGTGGCTACATGCTGG-3’ and reverse primer 5’-GGCCTGTAGTACACTTGG-3’. A final 
concentration of 125 nM of the following actin primers was used in the final ddPCR reaction: forward primer 5′-
GACCTGACAGACTACCTCAT-3′ and reverse primer 5′-AGACAGCACTGTGTTGGCAT-3′. The cDNA/primer 
solution was mixed with 10 uL of Supermix (BioRad) to generate a final reaction volume of 20 uL. Droplets were 
generated by combining the reaction mix with 60 uL of droplet generator oil (BioRad) using a QX-100 droplet 
generator. The droplets were then transferred to a 96-well plate and sealed with pierceable sealing foil sheets 
(BioRad). The PCR amplification was performed using a C1000 Touch Thermal Cycler (BioRad) with the following 
cycling parameters: enzyme activation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, 
annealing/elongation at 57°C for 1 minute for 40 cycles, signal stabilization at 4°C for 5 minutes and 95°C for 5 
minutes, and hold at 4°C. Following amplification, the droplets were transferred to a QX100 droplet reader and 
analyzed using Quantasoft (BioRad) software. PrP
C
 was normalized to actin. Fold change was determined by 
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dividing the treated sample by the untreated control (set as 1) and by the mRNA upregulation seen in control 
experiments that is caused by the LSPC treatment. 
Statistical Analysis 
 Statistical analysis was performed using a combination of Excel and GraphPad Prism. All error bars 
represent standard error of the mean (SEM) to show how closely the data resembles the population mean 
 
Results  
The experimental setup is shown in Figure 2.1. The thin lipid film hydration method was used to generate 
the liposomes as described (Figure 2.2). Figure 2.3 shows an artistic rendition of the differences between LSPCs and 
PALETS. For LSPCs, the siRNA is bound to the outside of the liposome with RVG-9r. For PALETS, the siRNA is 
encapsulated within the liposome, with RVG-9r attached to the outside either through a covalent modification or 
electrostatic interaction. Protamine is utilized in DSPE PALETS to condense the siRNA and give it an overall 





















Figure 2.3. Protocol of the thin lipid film hydration method.  
Figure 2.2. Schematic representation of LSPCs and PALETS.  
For LSPCs, PrP
C
 siRNA electrostatically interacts with the cationic liposome. The RVG-9r also 
electrostatically interacts with the PrPC siRNA due to the nine arginine residues. For PALETS 
(both formulations), the PrP
C
 siRNA is encapsulated in the liposome. DSPE PALETS utilize 
protamine sulfate to aid in siRNA encapsulation. PALETS also contain PEGylated lipids to 
increase circulation time and to allow the covalent modification of the RVG-9r.	
Solvents are used to thoroughly mix the lipids. The solution is then dried into a thin lipid cake 
using N2 gas. The resultant thin lipid film is rehydrated using either 10% sucrose or 1X PBS 
depending on the lipid composition of the liposomes.	
LSPCs PALETS
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Protamine sulfate efficiently encapsulates siRNA within DSPE PALETS 
The siRNA was mixed with varying concentrations of protamine, 0.7:1 to 2:1 protamine:siRNA molar 
ratio, to determine the optimal protamine concentration for siRNA encapsulation within DSPE PALETS. PALETS 
were formed as described in the methods section. The concentration of siRNA was measured before and after DSPE 
PALETS formation. Molar ratios 1.5:1 (29.26 nM protamine concentration) and above resulted in precipitation of 
protamine:siRNA complexes, which could not be encapsulated in the anionic liposomes (Figure 2.4A). 
Protamine:siRNA molar ratios from 0.7:1 to 1.3:1 (13.3 nM to 26.6 nM protamine concentration) encapsulated 80-
90% of the siRNA. There was a 60-65% encapsulation efficiency of siRNA in DSPE PALETS without the use of 
protamine (Figure 2.4A and C). A protamine concentration of 18.6 nM (0.9:1 protamine:siRNA ratio) was chosen to 
be used throughout the rest of the experiments as it is the mean concentration that gives an 80-90% encapsulation 
efficiency of siRNA (Figure 2.4C). 
Similarly, the concentration of the siRNA was measured during each step of PALETS formation to assess 
the effect of protamine on siRNA concentration and the amount of siRNA that became encapsulated. After the 
addition of protamine to the siRNA there is a decrease in the concentration of the siRNA; however, the level 
remains stable afterward (Figure 2.4B). PALETS were then filtered through 50 kDa centrifugal filters. Any 
encapsulated siRNA is found within the retentate with the liposome complexes, while any unencapsulated siRNA is 
located in the filtrate. After filtering, 90-95% of the siRNA is associated with the liposome retentate, while 5-10% of 
the siRNA is ‘free’ in the filtrate (Figure 2.4B).  No siRNA is detected in protamine or liposome only samples 
(Figure 2.4C).  
Neuronal PrP
C
 is decreased in mice treated with LSPCs 
To assess the efficacy of LSPCs, one FVB mouse was injected with 1X PBS (untreated control) and three 
mice were injected with LSPCs. Four days after treatment, mice were euthanized, and brain and kidney samples 
were removed for protein and mRNA analysis. Protein analysis was determined via flow cytometry using BAR-224 
conjugated to Dylight 650. All treated mice are compared to untreated controls for statistical analysis. Treatment 
with LSPCs resulted in a significant decrease in neuronal PrP
C
. The amount of PrP
C
 positive cells stayed the same, 
but cell surface PrP
C
 dropped 40-50% (Figure 2.5A and 2.6A and B). Results in the kidney suggest there is 
substantial binding of RVG-9r to kidney nicotinic acetylcholine receptors. Cell surface PrP
C
 and the number of PrP
C
 
positive cells are decreased in the kidney, although not statistically significant (Figure 2.5B and 2.6 C and D). Live 
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animal imaging was performed to determine the biodistribution of the siRNA and the peptide. Again, one mouse 
was injected with PBS (untreated control) and four mice were injected with LSPCs containing siRNA labeled with 
Alexa 488. Mice were imaged over a one-hour period after injection. Flow cytometric analysis was performed on 
both the brain and kidneys of all mice to determine the number of cells with siRNA. This experiment was repeated 
three times. In half of all mice treated across the three experiments, one hour after injection the PrP
C
 siRNA is 
concentrated in the brain (data not shown), but in the other half of treated mice, the siRNA and peptide are pooled 
 
Figure 2.4. Encapsulation of siRNA within DSPE PALETS using the cation protamine sulfate.  
A) After assembly of DSPE PALETS, protamine:siRNA ratios of 0.7:1 to 1.3:1 resulted in 80-90% 
encapsulation of the siRNA within DSPE PALETS. B) siRNA concentration was measured at all steps during 
DSPE PALETS assembly. There was a slight decrease in siRNA concentration after the addition to protamine, 
possibly due to masking of the siRNA. After separating free siRNA from siRNA associated with liposomes 
with a 50 kDa filter, 90-95% of the siRNA was associated with the liposomes while 5-10% was free siRNA in 
the filtrate. C) Protamine and liposome only controls do not contain any measurable amounts of RNA. 60-65% 
of the siRNA is encapsulated without the use of protamine and 80-90% of the siRNA is encapsulated within 
DSPE PALETS with protamine. Error bars indicate standard error of the mean (SEM). *p<0.05 and 
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Figure 2.5. Protein analysis and biodistribution of LSPCs treatment in vivo.  
A) Median fluorescent intensity (MFI) of PrP
C
 is decreased 40-50% in the brains of all three LSPCs-treated mice 
four days after treatment during one experiment. The amount of neuronal PrP
C
+ cells remains unchanged at this 
time point B) PrP
C
 MFI and amount of PrP
C
+ cells are slightly decreased in the kidney four days after LSPCs 
treatment, although not statistically significant. C) The four day LSPCs treatment was repeated three times. In a 
subset of the treated animals in those three repeated experiments, In vivo live imaging one hour after LSPCs 
treatment revealed a substantial portion of peptide around the bladder. D) Flow cytometric analysis of the brains 
of the treated mice in panel C showed very little siRNA in neuronal cells compared to the untreated control. E) 
Flow cytometric analysis of the kidneys of the mice shown in panel C revealed a large portion of the siRNA 
within the kidneys. Error bars indicate SEM. ** p<0.01 **** p<0.0001. t test.	
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within the area of the bladder with minimal amounts present in the brain (Figure 2.5C, D and E). PrP
C
 mRNA levels 
in the brains of mice treated with DOTAP LSPCs were not statistically different than the untreated mouse (Figure 
2.7A). However, mice treated with DOTAP LSPCs have a significant decrease in PrP
C





Figure 2.6. Comparison of PrP
C
 protein levels between LSPCs and PALETS treated mice.  
Three mice were used as untreated controls and injected with 1X PBS. Each treatment group has a total of three 
treated mice injected with one of the three liposomal PrP
C
 siRNA formulations. The brains and kidneys of all 
mice were harvested four days after treatment and flow cytometry was performed to assess PrP
C
 protein levels. 
A) Surface PrP
C
 is decreased 40-50% in the brains of mice treated with DOTAP LSPCs. Grouped together there 
is no statistical difference of either of the PALETS formulations compared to untreated control but at least one 
mouse in each of the PALETS formulations had decreases in surface PrP
C
. B) Neither the DOTAP LSPCs or the 
DSPE PALETS resulted in a decrease of PrPC positive cells but the DOTAP PALETS did result in a slight 
decrease. C. Surface PrP
C
 is decreased in mice treated with DOTAP LSPCs and DSPE PALETS, although it’s 
not statistically significant. D) No statistical difference is seen in the number of PrP
C
+ cells in the treated mice 
compared to the untreated mice but mice treated with DOTAP LSPCs do have a decrease in PrP
C
+ cells. Error 






























































































































































































































 siRNA to the brain 
 PALETS and LSPCs were assembled as described and injected intravenously into the tail veins of mice to 
determine if treatment with PALETS and/or LSPCs results in a significant decrease in PrP
C
 protein and mRNA 
levels. Three mice were treated for each delivery vehicle group, and three mice were given PBS as an untreated 
control. Mice were euthanized four days after treatment, and brain and kidney samples were taken to assess PrP
C
 
mRNA and protein levels. Protein levels were determined using flow cytometry staining with the anti-PrP
C
 antibody 
BAR-224, and mRNA levels were measured using ddPCR. Treated mice were compared to untreated controls for 
statistical analysis. While DOTAP LSPCs treatment showed the greatest reduction in the amount of PrP
C
 on the 
surface of neuronal cells as shown by median fluorescent intensity, DOTAP PALETS showed the most significant 
decrease of PrP
C
-positive neuronal cells (Figure 2.6A and B). At least one mouse treated with either DOTAP 
PALETS or DSPE PALETS had decreased surface PrP
C
, but no significant difference was found between the 
untreated and all three-treated combined (Figure 2.6A). There were no statistically significant results seen in the 
kidney, but trends are present. Both DOTAP LSPCs and DSPE PALETS reduced the amount of cell surface PrP
C
, 
with DSPE PALETS having the greatest reduction (Figure 2.6C). Only DOTAP LSPCs decreased the number of 
PrP
C
-positive cells in the kidney (Figure 2.6D). Digital drop PCR was optimized to detect PrP
C
 mRNA in wildtype 
mice with PrP
C
 mRNA levels of PrP-null mice measured below the limit of detection for the assay (Figure 2.7A). 
Analysis of mRNA levels in the brain shows no difference between the mRNA levels of the untreated mice versus 
the treated mice (Figure 2.7B). In the kidney, DSPE PALETS showed an almost 2-fold increase in mRNA levels. 
DOTAP LSPCs and DOTAP PALETS showed a 2-fold decrease in PrP
C
 mRNA levels in the kidney compared to 
the untreated control (Figure 2.7C). 
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Figure 2.7. mRNA analysis of LSPCs and PALETS treated four days after treatment.  
A) Optimization of ddPCR for PrP
C
 mRNA levels reveled mRNA levels below the limit of detection in PrP-null 
mice compared to PrP-expressing mice. B) PrPC mRNA levels remained unchanged in the brain four days after 
treatment with any of the LSPCs or PALETS formulations containing PrP
C
 siRNA. C) DOTAP LSPCs and 
DOTAP PALETS showed a two-fold decrease in mRNA levels in the kidneys four days after treatment. Mice 
treated with DSPE PALETS had a two-fold increase in PrP
C
 mRNA levels at this time point. Error bars indicate 

































































































































































 At the beginning of the 21st century, small interfering RNA (siRNA) was considered to be the biggest 
breakthrough in gene therapy in a generation
2
. Scientists worked quickly to discover its mechanism of action so that 







, and chronic viral infections
50-52
. However, it quickly became apparent, that even though the mechanism 
was fully elucidated, there were several enormous obstacles to overcome before siRNA could be used as a 
therapeutic option. The two biggest challenges included how to evade the immune system and how to target naked 
siRNA towards distinct cell populations to reduce off-target effects. 
 Escaping the immune system and targeted delivery, while separate concepts, remain intimately entwined in 
utilizing siRNA as a therapeutic. A targeted delivery system will only be effective if it can successfully hide the 
siRNA from the double-stranded RNA (dsRNA) response of the immune system, and similarly, one of the only 
ways to bypass the immune system is to use a delivery system that conceals the siRNA from immune cells. Thus, 
these two challenges could be overcome by using the right form of a delivery system. An effective delivery system 
becomes especially important when trying to utilize siRNA as a therapeutic for neurodegenerative diseases, such as 
prion diseases, as the blood-brain barrier remains the most challenging obstacle to overcome in therapeutic delivery. 
Direct injection of siRNA into the central nervous system (CNS) remains an option, but should not be used as a first 
choice in the clinical setting as the damage caused by an injection could be worse than the disease trying to be cured. 
 Liposomes are widely used as delivery vehicles for gene therapy, including siRNA, for a number of 
reasons. First, they protect the siRNA from degradation by efficiently hiding the siRNA from the various nucleases 
within the bloodstream
21
. Similarly, liposomes also conceal siRNA from serum proteins and cells that might result 
in a triggering of the dsRNA immune response. The lipid composition of the liposome determines the circulation 
time of the siRNA, which is controlled by the amount of serum proteins the liposome binds to. Some lipids, such as 
sterols, decrease the circulation half-life of siRNA by making the liposomes more attractive to the Kupffer cells of 
the liver
53,54
. While other lipids, such as pegylated (PEG) lipids increase circulation time by making the liposomes 
invisible to serum proteins
29
. Liposomes can also be easily targeted to any cell population with the addition of a 
targeting molecule, whether it’s a small peptide, antibody, or cellular protein
55
. So, liposomes represent a versatile 
delivery system that, when optimized, has the potential to overcome the challenges of siRNA therapeutics. 
Liposome-siRNA-peptide complexes (LSPCs) and peptide-addressed liposome-encapsulated therapeutic siRNA 
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(PALETS) were generated to determine the capability of siRNA to treat a neurodegenerative disease model and to 
evaluate the efficiency of a liposomal drug delivery system to the CNS. 
 LSPCs were described previously
43
. LSPCs decreased PrP
C
 protein levels in neuroblastoma cells by more 
than 70%, and the liposome component delivered PrP
C
 siRNA to these cells without the use of transfection reagents. 
The neuro-targeting peptide, RVG-9r, was shown to be specific in cell lines that possessed nicotinic acetylcholine 
receptors, which included neuroblastoma cells. Any cell line that did not possess these receptors did not have a 
notable decrease in PrP
C
 protein levels. Due to the reduction of PrP
C
, the treatment of prion-infected neuroblastoma 
cells by LSPCs resulted in a reduction of PrP
Res
 within the cells. This decrease was so dramatic that the cells were 
eventually ‘cured’ of prion infection. Since the LSPCs worked in vitro, the next step became characterizing their in 
vivo activity. 
 Treatment of mice with LSPCs resulted in a 40-50% reduction in the amount of cell surface PrP
C
 four days 
after treatment. There was not a concomitant decrease in the number of PrP
C
-positive cells at this time. It is not 
known whether reducing total cellular surface PrP
C
 or decreasing the number of cells that express PrP
C
 is more 
important. Regardless, a reduction of PrP
C
 across all cells, even with no difference in cell number, should also 
decrease the amount of PrP
Res
 being converted during prion disease. These data demonstrate that LSPCs deliver 
PrP
C
 siRNA across the blood-brain barrier to neuronal cells. However, it was noted that some mice did not respond 
to the LSPCs in the CNS but rather had a decrease of PrP
C
 within the kidneys. While all mice were shown to have 
some off-target effects in the kidney, some mice did not have any response to the siRNA within the brain and had an 
even more dramatic reduction of PrP
C
 within the kidney. Also, in vivo live imaging showed that in some mice the 
siRNA would immediately end up within the bladder one hour after injection. Therefore, two other delivery vehicles 
were designed to assess whether the circulation time and CNS targeting could be improved upon in vivo.  
 The short circulation half-life in some mice treated with DOTAP LSPCs could indicate several things: the 
LSPCs are being targeted towards the kidney, serum proteins are disassembling the LSPCs (such as the siRNA and 
RVG-9r), or binding of serum proteins is increasing the clearance of LSPCs. DOTAP PALETS were generated to 
address these concerns. DOTAP PALETS differ from DOTAP LSPCs by encapsulating the siRNA and 
incorporating PEG lipids. Serum proteins should not be able to remove the LSPCs elements so easily by 
encapsulating the siRNA and covalently linking the RVG-9r to the terminal PEG groups. Also, the addition of PEG 
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lipids to any liposome formulation increases the circulation time of the liposomes, which helps with circulation half-
life. 
 Four days after treatment with DOTAP PALETS, treated mice showed a reduction in the number of PrP
C
-
positive cells in the CNS by 7%, but not a decrease in cell surface PrP
C
. More studies are required to determine if 
this reduction is biologically significant. There were no changes in PrP
C
 mRNA levels within the brains of mice 
treated with DOTAP PALETS, but there was a 2-fold decrease in mRNA levels in the kidney. It was expected that 
DOTAP PALETS would reduce cell surface PrP
C
 as there are only minor differences between DOTAP PALETS 
and DOTAP LSPCs. However, only one time point was assessed in this report. Due to the PEG groups, it is possible 
that the circulation half-life increased and that this time point is not the optimal time to be assessing this particular 
vehicle. But it is just as likely that the addition of a chemical reaction resulted in an alteration of the activity of 
RVG-9r. If the carbodiimide reaction altered the RVG-9r peptide, it could have led to a malformed peptide with 
reduced activity. Thus, the LSPCs would not be efficiently targeted to the CNS. More experiments assessing the 
pharmacodynamics of DOTAP PALETS treatment with or without the covalent modification of the RVG-9r need to 
be performed to tease out whether the DOTAP PALETS require more optimization to target the CNS or if this is 
their optimal activity. It should be noted that DOTAP PALETS did not affect the kidneys. One of the reasons for 
generating a new vehicle was to increase circulation half-life so that the siRNA was not going directly to the 
kidneys. It seems that DOTAP PALETS have that effect as no reduction in either cell surface PrP
C
 or number of 
PrP
C
-positive cells was seen in treated mice.  
 One concern on the clearance of LSPCs was that immune cells were increasing the clearance of the 
delivery vehicle. It is well known that cationic lipids attract more serum proteins than anionic lipids, and are more 
toxic due to the activation of the immune system
56,57
. On the other hand, anionic lipids are derived from natural 
lipids, which shields them from the immune system. Therefore, the last delivery vehicle iteration employed an 
anionic lipid as its core lipid to reduce toxicity and clearance by serum proteins. DSPE PALETS also encapsulates 
the siRNA on the inside of the liposome to further protect it from serum proteins/nucleases.  
Anionic lipids are not typically used as delivery vehicles for gene therapy as it is harder to encapsulate the 
negatively-charged siRNA within the negatively-charged lipid, and toxicity profiles of anionic liposomes are 
lacking. Encapsulation of siRNA can be achieved with anionic liposomes by mixing small cations with the siRNA to 
condense it and give it an overall positive charge
23-25
. DSPE PALETS employ the use of the cation protamine 
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sulfate. which is a safe, non-toxic chemical that is routinely used in clinical settings to reverse the effects of heparin 
treatments. The protamine sulfate effectively condensed the PrP
C
 siRNA and encapsulated it within the DSPE 
PALETS. The small decrease in siRNA concentration after the addition of protamine sulfate is most likely due to the 
condensation and masking of the siRNA, rather than an actual loss of siRNA. One concern using protamine sulfate 
is that it will bind too tightly to the anionic lipids of the liposome so that the siRNA would never be released. If this 
is the case, then the protamine sulfate can be excluded from the DSPE PALETS as without protamine sulfate 60-
65% of the siRNA is still encapsulated.  
Anionic liposomes, especially DSPE liposomes, are harder to generate than their cationic liposome 
counterparts. Anionic lipids can produce insoluble lipid masses upon rehydration because they are extremely 
attracted to other anionic lipids. Therefore, careful consideration is needed when selecting rehydrating conditions of 
anionic lipids. The rehydrating temperature should always be above the phase transition temperature (Tm) of the 
lipids so that there is constant mixing and reorganizing of the liposomes during rehydration. In this protocol, a 
rehydration temperature of 70-75°C was used as it is around the phase transition temperature of DSPE, which is 
74°C. Also, the rehydration buffer was changed from 10% sucrose to 1X PBS for DSPE PALETS, as anionic lipids 
are more soluble in salt-containing buffers. Rehydration using either 10% sucrose or water resulted in insoluble lipid 
masses. The main lipid component of DSPE, phosphatidylethanolamine, hydrates poorly when used at a 60% molar 
concentration or higher. Salt rehydration buffers aid with the hydration at this molar concentration, but the buffer 
doesn’t solubilize all the lipid when used at greater than 60% molar concentration. Since anionic lipids like to 
aggregate, a significant loss is seen when sizing these liposomes through either syringe or extruder filters. Therefore, 
this protocol employed the use of sonication to size the DSPE liposomes to 200 nm. 
Treatment of mice with DSPE PALETS did not result in a statistically significant decrease in PrP
C
 when all 
three treated mice are compared to the untreated mouse. However, one mouse had a 50% reduction in cell surface 
PrP
C
, while another had a 15-20% decrease in surface PrP
C
 levels. Therefore, DSPE PALETS did effectively deliver 
the PrP
C
 siRNA to neuronal cells in a subset of treated mice. Similar to DOTAP PALETS, the use of PEG lipids in 
DSPE PALETS could have increased the circulation half-life of the vehicle such that the four-day time point is not 
the optimal time to assess protein levels using this delivery vehicle. More pharmacodynamics experiments are 
needed to determine the activity of DSPE PALETS. There wasn’t a concomitant decrease in mRNA levels in the 
brain in DSPE PALETS treated mice; however, none of the treatments using any of the delivery vehicles resulted in 
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a reduction in mRNA levels in this organ. One explanation for the lack of a decrease in PrP
C
 mRNA concentrations 
in the brains of any of the treated mice is that there is a compensation mechanism for decreases in PrP
C
 mRNA 
levels. When there is a reduction in PrP
C
, perhaps transcription factors increase transcription of PrP
C
 mRNA to 
normal or even greater than average values. Transcription regulation might explain why the treatment of DSPE 
PALETS resulted in a 2-fold increase of PrP
C
 mRNA levels in the kidney. There are instances of PrP
C
 mRNA and 
protein upregulation in the literature. Nerve growth factor was shown to increase PrP
C





 mRNA and protein levels also increase in response to heat shock or activation of Toll-like 
receptor ligands by lipopolysaccharide or CpG oligodeoxynucleotides
59-61
. Thus, regulation of PrP
C
 mRNA and 
protein levels seems to be tightly controlled. Protamine sulfate, when complexed with oligoribonucleotides, also 
results in activation of the immune system by Toll-like receptors 7 and 8
62
. It is possible that the use of protamine in 
the DSPE PALETS activated the Toll-like receptors and indirectly resulted in an increase of PrP
C
 mRNA in the 
kidney. Lastly, treatment with DSPE PALETS decreased the amount of cell surface PrP
C
 in the kidney, indicating 
that there is targeting and/or clearance of this delivery vehicle to the kidney. 
These three siRNA delivery vehicles represent new tools for the delivery of siRNA to the CNS for the 
treatment of neurodegenerative diseases. More studies are needed to determine the pharmacodynamics and 
pharmacokinetics of the PALETS systems. Depending on the results of future experiments, modifications and 
optimization might be necessary for them to deliver siRNA to the CNS effectively. The results shown here indicate 
that, using the current formulations, DOTAP LSPCs are the best choice as they result in a 40-50% decrease in PrP
C
 
compared to untreated controls. LSPCs may be further optimized by utilizing a different targeting peptide that is 
specific to the CNS. A CNS-specific targeting peptide would reduce the off-target effects seen, and could result in 
an even larger decrease in PrP
C
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Chapter 3:  
Intravenous injection of LSPCs delivers PrP
C








 The prion protein, PrPC, is a normal host cellular protein that becomes misfolded into an infectious isomer 
during prion disease. Early drug compounds targeting the infectious isomer have proven unreliable in treating prion 
disease in vivo. Therefore, PrP
C
 has become an attractive target for anti-prion therapeutics, as decreasing or 
eliminating PrP
C
 has no known detrimental effects and has the potential to reduce the amount of infectious isomer in 
prion-infected tissues. This report describes using siRNA as a therapeutic to target neuronal PrP
C
. We have 
packaged this PrP
C
 siRNA into our liposome-siRNA-peptide complexes (LSPCs) to improve serum stability and to 
target the siRNA towards neuronal cells using a small peptide from the rabies virus glycoprotein (RVG-9r). We 
show that LSPCs can cross the blood-brain barrier and decrease the amount of neuronal surface PrP
C
 by 40-50% 
within the central nervous system, while total PrP
C 
protein levels remain mostly unchanged. We demonstrate PrP
C
 
knockdown in two mouse models, with each model responding slightly differently to the PrP
C
 siRNA. Neuronal 
surface PrP
C
 and mRNA levels are decreased up to 21 days after LSPC treatment. Surprisingly, mRNA levels 
increased in some LSPC-treated mice. We observed off-target effects in the kidney, which resulted in a decrease of 
PrP
C
 protein and some mRNA levels. Treatment of mice with either LSPCs with control peptide or LSPCs with 
scrambled siRNA had minimal effect on neuronal PrP
C
 protein levels. We also show that repetitive two-week 
treatments of our siRNA results in a 70% decrease in PrP
C
 protein levels by the 3
rd
 treatment in prion-infected mice. 
mRNA analysis of these mice also shows a reduction in mRNA levels at the 3
rd
 time point. These LSPCs represent a 
new delivery method for siRNA to the central nervous system that could affect the outcome of prion disease. 
 
Introduction 
 Prion diseases are neurodegenerative diseases that have an impact on a broad range of species from sheep 
(scrapie) and cattle (bovine spongiform encephalopathy [BSE]) to humans (Creutzfeldt-Jakob disease among 
	 84	
others). Plaque deposits, neuronal vacuolation, glial activation, and neuronal cell death characterize these diseases. 
Prion diseases result when a normal host cellular protein, PrP
C
, misfolds into an infectious isomer, PrP
Res1-4
. 
Currently, there are no known clinical therapeutic interventions that lead to an elongation of survival periods in 
individuals or animals infected with prions. However, the literature discusses many compounds with anti-prion 
activity. 





. Antivirals were the first group of therapeutics investigated for prion diseases when 
the agent of scrapie was still considered to be a virus
5-7





 and an anti-cancer drug (IDX)
18
 have also shown anti-prion activity. Other compounds with anti-
prion activity include drugs within the polycationic and polyanionic categories. Polycationic drugs include 
polyamine compounds that contain positively-charged amino groups on their terminal ends, which are the active 
groups that confer anti-prion activity
19-23
.  On the other hand, some polyanionic compounds, which contain a 
negatively-charged terminal group, have anti-prion activity such as HPA-23
24,25





, and congo red
31-33
. In recent years, anti-PrP antibodies administered as either active or passive 
immunization have also shown promise
34-37
.  
These compounds can ‘cure’ prion-infected cells, and some are even able to prolong the survival times of 
animal models infected with prion disease. However, many challenges remain before large-scale clinical trials are 
considered. Most of the drugs do not cross the blood-brain barrier and do not specifically target neuronal cells. 
Therefore, delivery vehicles would need to be employed to target these molecules. Quite a few of the polyanionic 
and polycationic compounds are toxic and cannot be given in large doses or over an extended period. Some drugs 
only have anti-prion activity for specific prion strains. Most of the above compounds have a pronounced effect on 
survival times with early-stage treatment either before or directly after prion inoculation, but few have shown any 
promise when given at late or clinical stages. Because of these limitations, researchers are now focusing on targeting 
PrP
C
 to affect clinical stages of prion disease. 
 Mallucci’s group demonstrated the usefulness of targeting PrP
C
 when they used a Cre/loxP system to 
eliminate PrP
C
 after the establishment of prion neuropathology in a mouse model. After PrP
C
 was removed in mice 
with prion disease, the neuropathology was reversed, and the mice did not succumb to clinical stages of prion 
disease
38,39
. Another benefit of targeting PrP
C
 is that PrP-null mice live relatively healthy lives
40
. PrP-null mice show 
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some long-term potentiation changes,
41-43
 circadian rhythm alterations
44
, and reorganization of neuronal 
circuits
43,45,46
, but do not display an overt phenotype due to the loss of PrP
C
. It is thought that either the function is 
non-essential or that, more likely, there is a redundant protein or pathway that performs the function in the absence 
of PrP
C
. Thus, gene therapies targeting PrP
C
 are being investigated for their use in treating prion disease. 
 RNA interference is a pathway that utilizes RNA molecules to decrease mRNA levels of a particular 
protein. These RNA molecules, short hairpin RNA (shRNA) or small interfering RNA (siRNA), activate the RNA-
induced silencing complex that cleaves mRNA. The cleavage enables endo- and exonucleases to degrade the 
targeted mRNA resulting in a decrease in protein levels
47-52
. Both shRNA and siRNA treatment targeted towards 
PrP
C
 can reduce the level of PrP
Res
 in cultured and primary cells by decreasing the amount of PrP
C
 available for 
conversion
53-55
. Treatment of mice into the brain with either shRNA or siRNA is typically achieved through a 
stereotactic injection. A single injection of shRNA into the hippocampus of prion-infected mice resulted in an 
increase in survival times and a reversal of prion neuropathology
56
. Chimeric mice that expressed 50% less PrP
C
, 
due to the expression of shRNA in their cells, also have prolonged survival periods when infected with prions
57
. 
However, these methods are unrealistic as therapeutic options because stereotactic injections cause damage to the 
brain and generating chimeric humans is unethical. Still, these molecules are considered relatively safe as toxicity is 
achieved at much higher levels than is needed to decrease protein levels, and these molecules are relatively small so 
they can easily be packaged within delivery vehicles for targeting to the central nervous system. One report has 
demonstrated the usefulness of using liposomes as delivery vehicles for siRNA, as they protect the RNA and can be 
targeted towards neuronal cells
58
. 
Here we show that a single intravascular injection of siRNA results in a 40-50% decrease in neuronal PrP
C
 
levels in two different mouse lines. We have packaged our PrP
C
 siRNA into liposome-siRNA-peptide complexes 
(LSPCs) that are targeted towards nicotinic acetylcholine receptors (nAchRs) using a small peptide from the rabies 
virus glycoprotein (RVG-9r). We also show that our LSPCs can effectively cross the blood-brain barrier and deliver 
siRNA to neuronal cells resulting in a decrease of PrP
C
. The response of the mice to the siRNA lasts up to 21 days 
after injection. Also, repeated doses of our LSPCs every two weeks results in an even larger decrease in neuronal 
PrP
C
 levels. Our LSPCs represent a new method of delivering PrP
C
 siRNA in vivo to the central nervous system. 
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Materials and Methods 
Mice 
 CR1 KO and CR2 KO were kindly provided by Dr. John Weis at the University of Utah
59,60
. CR1/2 
hemizygous mice were generated by crossing CR1 KO and CR2 KO mice. The CR1/2 hemizygous mice contain one 
allele of CR1 and one allele of CR2. FVB mice were purchased from The Jackson Laboratory (Bar Harbor, ME). 
Mice were euthanized using CO2. All mice were bred and maintained at Lab Animal Resources, accredited by the 
Association for Assessment and Accreditation of Lab Animal Care International, in accordance with protocols 
approved by the Institutional Animal Care and Use Committee at Colorado State University. 
Generation of Liposomes 
DOTAP LSPCs 
 DOTAP LSPCs consist of a 1:1 DOTAP:cholesterol ratio in a 1:1 chloroform:methanol solution. Both 
lipids were purchased from Avanti Lipids. The solvents were evaporated using N2 gas and the resultant dry lipid 
film was placed under vacuum for a total of 8 hours to remove any excess solvent. A stock solution of liposomes 
was made at an 8 mM (40 umole total) concentration, by resuspending the lipid film in 5 mL of 10% sucrose heated 
at 55°C. All components (lipid film and sucrose) were kept at this temperature during rehydration. The lipid film 
was swirled every 3 minutes to promote lipid mixing. The heated sucrose was added to the lipid cake 1 mL every 10 
minutes. Resulting liposomes were stored at 4°C. 
Generating LSPCs and Treating Mice with LSPCs 
PrP
C
 1672 siRNA sequence: ACATAAACTGCGATAGCTTC (Qiagen).  
RVG-9r peptide: YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGrrrrrrrrr (ChemPeptide) 
LSPCs 
 The DOTAP LSPCs liposomes were diluted 1:100 in 1X PBS and sonicated 4X with 2-3 minute rests in 
between. 50 uL (4 nmole total) of diluted/sonicated liposomes was mixed with 100 uL (4 nmole total) of 1672 
siRNA. The siRNA/liposome solution was incubated for 10 minutes at 4°C. Then, 80 uL (40 nmole total) of RVG-
9r peptide was added to the solution and allowed to incubate for 10 minutes on ice. Mice were placed under a heat 
lamp for 5 minutes and anesthetized with 1.5-2% isofluorane (VetOne). The mouse tails were disinfected using 70% 
EtOH. LSPCs were injected into the tail veins of mice using a 29-gauge insulin syringe. 
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Flow Cytometry 
 Mice treated with LSPCs were euthanized after certain time points and assayed for protein levels using 
flow cytometry. Half a hemisphere of brain and one kidney was pressed through a 40 µm cell strainer (Falcon, 
VWR) using the plunger from a 5 mL syringe and 5 mL of FACS buffer (1X PBS, 1% fetal bovine serum, 10 mM 
EDTA). The cell suspension was transferred to a 15 mL conical, of which 450 uL of each cell suspension was used 
for flow cytometric analysis. Cells were washed 3X by centrifugation at 2000 rpm (250 x g) and resuspension of the 
cells with 1 mL of FACS buffer. Fc receptors were blocked using 100 uL of a 1:100 dilution of a 0.5 mg/mL rat 
anti-mouse CD16/CD32 Fc block (BD Pharmingen) in FACS buffer with 7% goat serum for 20 minutes on ice. The 
cell pellet was washed once as above. The cells were stained with 100 uL of a 1:100 dilution of 20 µg/mL solution 
of the PrP
C
 antibody BAR-224 conjugated to Dylight 650 (per manufacturer’s instructions) in FACS buffer for 40 
minutes at room temperature. Red blood cells were lysed with 1 mL of RBC lysis buffer (1X PBS, 155 mM NH4Cl, 
12 mM NaHCO3, 0.1 mM EDTA) for 3 minutes and then centrifuged at 2000 rpm for 3 minutes. Cells were washed 
2X with 1 mL of FACS buffer. Cells were stained with propidium iodide (FisherSci) 10-15 minutes before 
analyzing a 1:2 dilution of the cells on a DakoCytomation Cyan ADP flow cytometer. Results were evaluated using 
FlowJo version 10. 
Western Blots 
 Mice treated with LSPCs were euthanized after certain time points and assayed for protein levels using 
western blot. After dissection, brains were kept at -20°C until processed. Brains were thawed on ice for 1 hour, 
weighed and transferred to new tubes containing 2.5mm glass beads. 1X PBS was added to each brain to obtain a 
20% weight/volume (w/v) homogenate. Brains were homogenized using a Bead Blaster 24 (Benchmark). The brain 
homogenates were further diluted to 10% w/v with the addition of an equal volume of 1X PBS with 1% Triton X. 
Samples were immediately prepared for PrP
C
 western blot by further diluting the brain homogenates to 1% with 1X 
PBS and 3X sample loading buffer (Invitrogen). 1% samples were heated at 95°C for 10 minutes and frozen at -
20°C until western blots were performed. Samples were prepared in triplicate for two repeated experiments. Before 
starting western blots, samples were thawed on ice for 30 minutes and reheated at 95°C for 3 minutes. Proteins were 
electrophoretically separated using 12% sodium dodecyl sulfate polyacrylamide gels (Invitrogen). Proteins were 
then transferred to a polyvinylidene difluoride membrane (Millipore). Membranes were blocked using 5% non-fat 
dry milk for 1 hour. Membranes were washed 2X for 10 minutes each using 1X PBS with 0.2% Tween. Membranes 
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were incubated with horseradish peroxidase-conjugated BAR-224 (SPI Bio) anti-PrP
C
 antibody diluted 1:20,000 for 
overnight at 4°C. Membranes were washed again 6X for 10 minutes each, and incubated with enhanced 
chemiluminescent substrate (Millipore) for 5 minutes. Membranes were photographed using an ImageQuant LAS 
4000 (GE). The membranes were then stripped with restore stripping buffer (ThermoFisher) for 10 minutes at room 
temperature. Membranes were again blocked as above, but this time incubated with 1:10,000 anti-actin antibody 
(Santa Cruz) overnight at 4°C. Protocol proceeded as above for washing and imaging. Densitometric analysis was 
performed using ImageJ. 
In vivo Live Imaging 
 LSPCs were assembled as described above. siRNA labeled on the 5’ end with Alexa Fluor 488 (Qiagen) 
and RVG-9r labeled with Dylight 650 (per manufacturer’s instructions) (ThermoFisher) were used. Mice were 
anesthetized with 2% isofluorane, injected intravascularly with LSPCs, and then immediately imaged for up to one 
hour after treatment using an IVIS Spectrum in vivo live imaging system. Autoexposure settings were used. siRNA 
signal was viewed with a 500/540 nm filter and RVG-9r signal was viewed with a 640/680 nm filter. 
Digital Droplet PCR (ddPCR) 
 RNA was extracted from brain and kidney cell suspensions using a RNeasy minikit (Qiagen). DNase 
digestion was performed off-column using RQ1 RNase-free DNase (Promega) per manufacturer’s instructions. The 
RNA was purified from the DNase using EtOH precipitation. A 1:10 volume of 2 M NaAcetate and 2.5X volume of 
100% EtOH was added to the RNA after DNase digestion. The RNA was stored at -20°C for at least 24 hours. The 
samples were then centrifuged at 13,000 rpm (16,060 x g) for 45 minutes. The RNA pellet was washed with 200 uL 
of 100% EtOH and centrifuged again at the same conditions. The RNA pellet was allowed to dry for 1 hour, and was 
resuspended in 40 uL of molecular grade H2O. RNA concentration was assessed via spectrophotometer (Denovix) at 
260 nm. Approximately 150 ng of RNA was used to generate cDNA using the High Capacity cDNA Reverse 
Transcription kit from ThermoFisher. A final concentration of 0.035 ng of cDNA was used for ddPCR reactions. A 
final concentration of 1.25 uM of the following PrP primers was used in the final ddPCR reaction: forward primer 
5’CCTTGGTGGCTACATGCTGG-3’ and reverse primer 5’-GGCCTGTAGTACACTTGG-3’. A final 
concentration of 125 nM of the following actin primers was used in the final ddPCR reaction: forward primer 5′-
GACCTGACAGACTACCTCAT-3′ and reverse primer 5′-AGACAGCACTGTGTTGGCAT-3′. The cDNA/primer 
solution was mixed with 10 uL of Supermix (BioRad) to generate a final reaction volume of 20 uL. Droplets were 
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generated by combining the reaction mix with 60 uL of droplet generator oil (BioRad) using a QX-100 droplet 
generator. The droplets were then transferred to a 96-well plate and sealed with pierceable sealing foil sheets 
(BioRad). The PCR amplification was performed using a C1000 Touch Thermal Cycler (BioRad) with the following 
cycling parameters: enzyme activation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, 
annealing/elongation at 57°C for 1 minute for 40 cycles, signal stabilization at 4°C for 5 minutes and 95°C for 5 
minutes, and hold at 4°C. Following amplification, the droplets were transferred to a QX100 droplet reader and 
analyzed using Quantasoft (BioRad) software. ddPCR results are presented as copy number/µL and fold change. 
PrP
C
 was normalized to actin. Fold change was determined by dividing the treated sample by the untreated control 
(set as 1) and by the mRNA upregulation seen in control experiments that is caused by the LSPC treatment. 
Intraperitoneal Inoculations 
 RML-5 prions were prepared as previously described61. 10% brain homogenates were diluted 1:100 in 1X 
PBS supplemented with 100 units/mL of Penicillin and 100 µg/mL of Streptomycin (Gibco) immediately before 
inoculation. Mice were scruffed and flipped upside down for inoculation. 100 µL inoculum was injected in the left 
or right bottom quadrant of the intraperitoneal cavity with a 29-gauge insulin syringe (BD). 
Statistical Analysis 
 Statistical analysis was performed using GraphPad Prism. Standard deviation (SD) error bars are used to 
show the variability between technical replicates of individual treated mice. When mice are grouped together, 
standard error of the mean (SEM) is used to show how closely the mean of the treated mice represents the 





 siRNA to the brain 
 Mice were injected with LSPCs and monitored via in vivo live imaging. Mice were monitored up to 48 
hours after injection of LSPCs with Alexa 488-labeled siRNA and Dylight 650-labeled RVG-9r LSPCs. While 
RVG-9r was not visible under these conditions (data not shown), labeled siRNA was visible directly after injection 
into the tail veins of mice. The untreated control (PBS) showed no signal for PrP
C
 siRNA, while the LSPCs and the 
liposome+siRNA (L+S) only control showed a signal for PrP
C
 siRNA using a 500/540 nm filter one hour after 
injection (Figure 3.1). The LSPCs treated mouse has most of the siRNA signal concentrated towards the area of the 
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brain on the dorsal side, while the L+S control shows minimal amounts of siRNA signal concentrated in the area 
around the brain one hour after injection. Both LSPCs treated and L+S control mice show siRNA signal distributed 
throughout the entire ventral side (Figure 3.1A). Nearly two hours after injection, more PrP
C
 siRNA signal is present 
in the area surrounding the brains of both the LSPCs and L+S treated mice. Flow cytometric analysis was performed 
on these same mice to determine if the siRNA signal in the area of the brain corresponded to siRNA in neuronal 
cells. This analysis revealed that a significant amount of PrP
C
 siRNA is found in neuronal cells in LSPCs-treated 
mice (Figure 3.1B). No siRNA signal was detected in the brains of any treated mice 24 hours after LSPCs treatment 
(Figure A.1).  
Injection of LSPCs containing control peptide or scrambled siRNA results in an increase in neuronal PrP
C
 
mRNA levels and a slight reduction of cellular PrP
C
 
 To determine if scrambled siRNA or the RVM control peptide changes PrP
C
 protein or mRNA levels, FVB 
mice were treated with either no LSPCs, 1672 LSPCs, LPSCs with scrambled 1672 siRNA or LSPCs with the RVM 
 control peptide. One FVB mouse was injected with one treatment in each experiment, with the experiment being 
repeated for a total of two mice in each treatment group. The scrambled siRNA has no homology with the prnp gene 
and the RVM peptide does not specifically target any cellular receptors. Protein and mRNA levels were assessed in 
the brain and kidney four days after treatment using flow cytometry and ddPCR, respectively. Normalized median 
fluorescent intensity (MFI), calculated as treated/untreated, is reported for flow cytometry to evaluate surface PrP
C
. 
Fold change of ddPCR results was calculated by dividing copy number/µL of treated mice with copy number/µL of 
untreated mice. All treated mice were compared to untreated mice for statistical analysis. Flow cytometry analysis of 
the brain revealed that surface PrP
C
 levels are slightly but significantly decreased relative to the untreated control in 
mice treated with scrambled LSPCs (Figure 3.2A). However, the 14% reduction of PrP
C
 using scrambled LSPCs did 
not equal the 40-50% reduction in PrP
C
 using 1672 LSPCs. The opposite is true for mice treated with RVM peptide 
LSPCs as they have a slight increase in MFI in the brain (Figure 3.2A). Protein analysis in the kidney revealed that 
scrambled LSPCs decrease surface PrP
C
 levels as much as 1672 LSPCs, indicating that the treatment alone without a 
specific siRNA or peptide causes a decrease in surface PrP
C
 (Figure 3.2C). Scrambled LSPCs also reduce the 
number of PrP
C
-positive kidney cells (Figure A.2). mRNA analysis of both brain (Figure 3.2B) and kidney (Figure 
3.2D) cells revealed that both the scrambled LSPCs and RVM peptide LSPCs increased the amount of PrP
C
 mRNA 










































































Figure 3.1. LSPCS injected intravascularly deliver PrP
C
 siRNA to the brain. 
	
One mouse was used as an untreated control and injected with 1X PBS. Two mice were injected with either full 
LSPCs or liposome+siRNA only (no peptide). In vivo live imaging was performed one to two hours after 
injection to determine biodistribution and flow cytometry was performed on all mice 24 hours after injection to 
determine if PrP
C
 siRNA was delivered to neuronal cells. A) in vivo live imaging shows that the LSPCs are 
delivered to the area around the brain one to two hours after injection. More PrP
C
 siRNA is observed in the area 
around the brain using the RVG-9r neuro-targeting peptide than is without (liposome+siRNA only) B) Flow 
cytometry analysis revealed that PrP
C
 siRNA is found in neuronal cell 24 hours after injection in these treated 
mice compared to the untreated. 
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Figure 3.2. Scrambled LSPCs and control peptide LSPCs cause an increase in PrP
C
 mRNA levels. 
One mouse was injected with one treatment group for each experiment. The experiment was repeated 
for a total of two mice for each treatment group. All mice across the experiments were treated with 
either PBS or LSPCs for four days. A) Flow cytometry analysis of PrP
C
 protein levels in the brains of 
treated mice revealed a 10-15% decrease in protein levels with the use of scrambled siRNA LSPCs and 
an increase in protein levels using RVM LSPCs. Normalized median fluorescent intensity (MFI) of 
PrP
C
 levels in the brain of treated mice to untreated control. B) Neuronal PrP
C
 mRNA analysis of 
treated mice showed an increase in PrP
C
 mRNA levels in all LSPCs-treated mice compared to untreated 
control. C) Surface PrP
C
 levels in the kidney were significantly decreased using scrambled siRNA 
LSPCs. D) mRNA analysis of PrP
C
 levels in the kidney of treated mice also revealed a 1- to 2-fold 
increase in PrP
C
 mRNA levels in this organ. Error bars indicate SEM. * p<0.05, ** p<0.01, *** 








































































































































































































































































Analysis of cells that bind RVG-9r within the brain and kidney of wild-type mice 
 To assess the number of cells that contain nAchRs and that the LSPCs target, both in the brain and kidney, 
primary cells were incubated with anti-PrP antibody BAR-224 and RVG-9r labeled with Dylight 650. Flow 
cytometry analysis was performed. In this experiment, BAR-224 bound to 96.4% of neuronal cells, while RVG-9r 
bound to on average about 87% of neuronal cells (Figure 3.3A). Within neurons that bound RVG-9r, 51% express 
PrP
C
. In the kidney, BAR-224 recognizes less than 5% of the cells as PrP-positive (Figure 3.3B). RVG-9r, on the 
other hand, binds to 95% of kidney cells. Within the 95% RVG-9r positive cells, 52% are positive for BAR-224 
staining (Figure 3.3B). The discrepancy between the BAR-224 binding alone and BAR-224 binding RVG-9r 
positive cells in the kidney is not understood. 
  
Figure 3.3. RVG-9r binds to the majority of neuronal and kidney cells. 
A) About 90% of cells in the brain have surface PrP
C
 as shown by binding of the anti-PrP
C
 antibody 
BAR-224. A slightly smaller portion (80%) of cells bind RVG-9r, indicating that these cells have 
nAchRs. Within the cells that bind RVG-9r, about 50% express PrP
C
. B) Only about 5-10% of cells 
within the kidney have PrP
C

















































































Study design of LSPCs treatments with CR1/2 hemi mice and CD1 wild-type mice 
 Two mouse lines, CR1/2 hemizygous (hemi) and CD1 wild-type, were utilized to assess the 
pharmacodynamics of LSPCs over time (Figure 3.4). CR1/2 hemi mice, on a C57Bl/6 background, were used to 
ensure that the results we obtained using the CD1 mice were not due solely to the background genetics of that mouse 
line. The transgenic nature of the CR1/2 hemi mice does not affect neuronal PrP
C
 levels (Figure A.3). Both CR1/2 
hemi mice and CD1 mice were intravenously treated once through the tail vein with LSPCs. At each time point for 
each mouse line, there was one untreated mouse injected with 1X PBS and three treated mice injected with LSPCs. 
Protein and mRNA levels were assessed at varying time points after treatment using flow cytometry, western blots, 
and ddPCR. PrP
C
 protein and mRNA levels of CR1/2 hemi mice were measured 24 hours, 48 hours, and 4 days after 
a single treatment, whereas levels of CD1 mice were measured at 48 hours, 4, 15, and 21 days after treatment. Total 
protein was calculated using western blots with an anti-PrP
C
 antibody conjugated to horseradish peroxidase and 
surface protein was measured using flow cytometry using the same anti-PrP
C
 antibody conjugated to Dylight 650. 
Analysis of PrP
C
 mRNA levels employed ddPCR. Flow cytometry results are presented as median fluorescent 
intensity (MFI), as a measure of surface PrP
C
, amount of PrP
C
 positive cells, and fold change of treated MFI divided 
by untreated MFI. ddPCR analysis is presented as copy number/µL, fold change and grouped fold change. Copy 
number/µL is shown to illustrate the true physiological conditions at time of sampling. Fold change was calculated 
as treated divided by untreated, and divided again by the increase observed in control LSPCs experiments using 
scrambled and control  
  
Figure 3.4. Study design of pharmacodynamics experiments of CR1/2 hemi and CD1 mice. 
0
24 Hours 48 Hours 4 Day
21 Day15 Day4 Day48 HoursTreatment of CD1 
Mice
Treatment of CR1/2 
Hemi Mice
Protein Analysis
• Western Blot – Total Protein
• Flow Cytometry – Surface Protein
mRNA Analysis
• Digital Drop PCR (ddPCR)
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peptide LSPCs. Fold change was calculated this way to show the effect of only the PrP
C
 siRNA. Grouped fold 
change is presented to show biological significance. For all statistical analyses, all treated mice were compared to 
untreated controls. 
Total protein analysis reveals a decrease in total protein at various time points in both CR1/2 hemi and CD1 mice 
 After CR1/2 hemi or CD1 mice were treated, brain and kidneys were collected at different time points. 
Total protein analysis of PrP
C
 was conducted on ½ a hemisphere of the brain at these time points. The hemispheres 
were homogenized at 20% w/v and electrophoretically separated using a western blot at a 1% w/v. Actin and total 
protein were used as loading controls to ensure that the same amount of protein was loaded in each sample and to 
normalize PrP
C
 levels. Densitometry was performed using ImageJ software provided by the NIH. The Y-axis on 
each fold change graph was log transformed to guarantee that a 2-fold increase was viewed aesthetically like a 2-
fold decrease. The right Y-axis shows the actual fold change values.  
Unfortunately, the western blots reveal little statistical significance of either CR1/2 hemi or CD1 mice. 
Figure 3.5A shows representative western blots of the PrP
C
 and actin samples for each sample. At 48 hours after 
treatment in CR1/2 hemi mice, total neuronal PrP
C
 protein levels are reduced in two out of the three treated mice 
(Figure 3.5C). The reduction equates to a 1- or 2-fold decrease in PrP
C
 levels compared to untreated control. No 
statistical significance was found between untreated and treated mice in CR1/2 hemi mice at 24 hours (Figure 3.5B) 
or 4 days after treatment (Figure 3.5D). For the CD1 mice, there is a statistical difference in total neuronal PrP
C
 
levels at 21 days after LSPCs treatment in two out of the three mice. PrP
C
 is decreased 5-fold in two of the treated 
mice compared to the untreated control (Figure 3.6D). No statistical significance is seen in PrP
C
 levels in CD1 
treated mice at any other time points compared to the untreated control (Figure 3.6A-C). 
CR1/2 hemi mice treated with LSPCs have decreased surface PrP
C
 with variable mRNA levels at 24, 48 hours, 
and 4 days after treatment 
 To determine the pharmacodynamics of the PrP
C
 siRNA and LSPC treatment in C57Bl/6 mice, CR1/2 hemi 
mice were anesthetized and injected with either 1X PBS (one mouse) or 1672 LSPCs (three mice) at various time 
points. Surface PrP
C
 and total mRNA levels in the brain and kidney were assessed using flow cytometry and ddPCR 
analysis, respectively. Expression in the kidney was assessed due to some off-target effects observed in previous in 
vitro experiments, so kidney levels were measured to evaluate any potential adverse effects of the LSPCs treatment.  
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mRNA levels are shown for each treated mouse as copy number/µL and fold change. Fold change was calculated as 
discussed in the study design section. The time points were not repeated. 
Figure 3.5. Western blot analysis of PrP
C
 levels in the brains of CR1/2 treated mice. 
A) Representative western blot analysis of PrP
C
 and Actin blots of LSPCs-treated mice. Unt = Untreated control 
B) At 24 hours after treatment, two out of the three treated mice have decreases in total PrP
C
 levels (not 
statistically significant). C) Two out of the three LSPCs-treated mice at 48 hours after treatment had decreases in 
the amount of total PrP
C
 in the brain, although it was not statistically different than untreated. D) All CR1/2 
treated mice had increased levels of total PrP
C
 four days after LSPCs treatment. Error bars represent SD. The 
fold change graphs do not contain error bars as each technical replicate was averaged into one mean before fold 
change calculation. The fold change graph is only a visual representation of the changes in total PrP
C
 protein in 
the brains of treated mice so no statistical analyses were performed on the fold change graphs. One-way 








































































































































































































































































































































































































































































































































































































































































































































Figure 3.6. Western blot analysis of PrP
C
 levels in the brains of CD1 treated mice. 
A) Total PrP
C
 analysis of the brain 48 hours after LSPCs-treatment in CD1 mice revealed no statistical 
difference between untreated controls, with perhaps a 1-fold decrease in all LSPCs-treated mice. B) Two out of 
the three LSPCs-treated mice at 4 days after treatment showed a 2-fold decrease in total PrP
C
 levels in the brain. 
C) No statistical difference is observed 15 days after LSPCs treatment with one mouse having a 1-fold or less 
increase in total PrP
C
 levels. D) Total neuronal PrP
C
 levels are significantly decreased in two out of the three 
mice 21 days after LSPCs treatment of CD1 mice. Error bars represent SD. The fold change graphs do not 
contain error bars as each technical replicate was averaged into one mean before fold change calculation. The 
fold change graph is only a visual representation of the changes in total PrP
C
 protein in the brains of treated mice 
so no statistical analyses were performed on the fold change graphs.  ** p<0.01. One-way ANOVA with 
Dunnett’s multiple comparisons. 
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All mice treated with LSPCs had a decrease in surface PrP
C
 levels in the brain at 24 hours after treatment 
(Figure 3.7A). There was no effect on the number of PrP
C
-positive cells, but the median fluorescent intensity (MFI) 
of the brain samples was reduced in all treated mice compared to the untreated control. The 35-40% decrease in 
brain MFI was more significant than the 14% reduction observed with scrambled LSPCs. The opposite was true in 
the kidney where the MFI was not decreased compared to the untreated controls (Figure 3.7C). When the MFI of the 
treated mice is normalized to the MFI of the untreated control, one out of the three mice does have a decrease in 
surface PrP
C
. The reduction in the kidney might be due to the siRNA treatment in general as the scrambled siRNA 
LSPCs resulted in a decline of MFI in the kidney. The number of PrP
C
-positive cells in the kidney was also 
significantly reduced; however, again, this could be due to an effect of just the treatment and not the PrP
C
 siRNA as 
this effect was seen using scrambled siRNA (Figure 3.7C). PrP
C
 mRNA levels in the brain in two out of the three 
mice were also significantly decreased when analyzed individually but there is no difference when grouped (Figure 
3.7B). Interestingly, the mouse with the lowest surface PrP
C
 MFI had the highest copy number/µL of PrP
C
 mRNA. 
mRNA levels were also increased 2-fold in the kidney across all treated mice. When grouped, the treated mice had 
significantly higher PrP
C
 mRNA levels in the kidney compared to the untreated control (Figure 3.7D). 
At 48 hours post-treatment, flow cytometry data is only available for the brain due to a staining error in the 
kidney. Surface neuronal PrP
C
 levels are decreased significantly in all three treated mice (Figure 3.8A). The number 
of PrP
C
-positive cells also decreased in the brain at this time point. When normalized to the untreated mouse, the 
three treated mice have a 20-25% reduction in surface PrP
C
 levels (MFI) (Figure 3.8A). mRNA analysis shows that 
all three treated mice have a 1- to 2-fold decrease in fold change of PrP
C
 mRNA levels in the brain compared to the 
untreated mouse (Figure 3.8B). When grouped, PrP
C
 mRNA levels in the brain of treated mice is statistically 
different than the untreated control (Figure 3.8B). Two out of the three treated mice have decreased PrP
C
 mRNA 




 levels are decreased in both the brain and the kidney four days post-treatment in all three 
treated CR1/2 hemi mice. The MFI in the brain is decreased 25-50% (Figure 3.9A), and the MFI in the kidney is 
reduced 10-50% (Figure 3.9C) in the treated mice compared to the untreated control. The number of PrP
C
-positive 
cells is not statistically different for either the brain or the kidney at this time point (Figure 3.9A and C). While the 
group fold change of PrP
C
 mRNA levels of all treated mice is not statistically different from the untreated control 
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 Figure 3.7. Flow cytometric and ddPCR analysis of CR1/2 hemi mice 24 hours after LSPCs treatment. 
A) Surface PrP
C
 but not the amount of PrP
C
+ cells decreased in the brains of CR1/2 mice treated with LSPCs 24 
hours after treatment. The decrease equated to a 25% decrease in surface PrP
C
 levels. B) One LSPCs treated 
mouse had an increase in neuronal PrP
C
 mRNA levels 24 hours after treatment, while the other two treated mice 
had a 2-fold decrease in PrP
C
 mRNA. C) Only one mouse had a decrease in surface PrP
C
 levels in the kidney at 
this time point. All mice had a significant decrease in the number of PrP
C
+ cells in the kidney. D) All mice had 
an increase in PrP
C
 mRNA in the kidney 24 hours after LSPCs treatment. Error bars for graphs with individual 
treated mice indicate SD. Error bars for graphs with grouped treated mice indicate SEM. * p<0.05, ** p<0.01, 













































































































































































































































































































































































































































































































Figure 3.8. Flow cytometric and ddPCR analysis of CR1/2 hemi mice 48 hours after LSPCs treatment. 
A) All three CR1/2 hemi LSPCs-treated mice had a decrease in surface PrP
C
 in the brain 48 hours after 
treatment, with a slight but statistically significant decrease in the number of PrP
C
+ cells. B) Two out of the three 
treated mice had significant decreases in PrP
C
 mRNA, 1- to 2-fold, in the brain at this time point. C) mRNA 
analysis of CR1/2 LSPCs-treated mice shoed slight changes in PrPC mRNA in the kidney 48 hours after LSPCs 
treatment but no statistical significance is seen when the mice are grouped. Error bars for graphs with individual 
treated mice indicate SD. Error bars for graphs with grouped treated mice indicate SEM. * p<0.05, ** p<0.01, 



















































































































































































































































































































































































Figure 3.9. Flow cytometric and ddPCR analysis of CR1/2 hemi mice four days after LSPCs treatment. 
A) At 4 days after treatment, all three CR1/2 LSPC-treated mice had a decrease in surface PrP
C
 levels in the 
brain. This was a 25-50% decrease across all three treated mice. There was no decrease in the number of PrP
C
+ 
cells in the brain at this time point. B) Two out of the three LSPCs treated mice had decreased levels of neuronal 
PrP
C
 mRNA 4 days after treatment. This decrease was 1.5- to 2-fold lower than controls. C) All three LSPCs-
treated mice also had a decrease (10-50%) in surface PrP
C
 in the kidney 4 days after treatment. D) Kidney PrP
C
 
mRNA levels varied in the three CR1/2 treated mice. One LSPCs-treated mouse had a 2-fold decrease but 
grouped the mice do not have a significant decrease in kidney PrP
C
 mRNA levels. Error bars for graphs with 
individual treated mice indicate SD. Error bars for graphs with grouped treated mice indicate SEM. **** 
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in either organ, there are some mRNA expression differences between the individual treated mice. In the brain, two 
out of the three treated mice have decreased levels of PrP
C
 mRNA, while the third treated mouse has an increase in 
PrP
C
 mRNA levels (Figure 3.9B). Again, the mouse with the lowest PrP
C
 MFI also has the highest PrP
C
 copy 
number/µL levels in the brain. In the kidney, two out of the three treated mice have a decrease in PrP
C
 mRNA 
levels, a <1- to 2-fold reduction. The other mouse has a < 1-fold increase in PrP
C
 mRNA levels (Figure 3.9D). 
LSPCs treatment results in a reduction of surface PrP
C
 protein levels and PrP
C
 mRNA levels in CD1 wild-type 
mice 
 CD1 mice were also treated with LSPCs intravenously to assess whether the LSPCs are efficacious in mice 
on different backgrounds. For each time point, one mouse was treated with 1X PBS as an untreated control and three 
mice were treated with LSPCs. Brain and kidney samples were collected at 48 hours, 4, 15, and 21 days post-
treatment. Protein analysis was performed using flow cytometry, and mRNA levels were analyzed using ddPCR. 
Fold change of ddPCR analysis was calculated as explained in the study design section. The time points were not 
repeated. 
 CD1 mice responded differently than the CR1/2 hemi mice at 48 hours post-treatment. Unlike the CR1/2 
hemi mice, CD1 mice did not have a decrease in surface PrP
C
 levels in the brain at this time point. There was also no 
reduction in the number of PrP
C
-positive cells in this organ (Figure 3.10A). Even though the MFI was not decreased 
in the brain, mRNA analysis revealed that all three treated mice had reduced levels of PrP
C
 mRNA (Figure 3.10B). 
This decrease was between a 1- and a 2-fold decrease in mRNA levels. Grouped the 1672 siRNA-treated mice had a 
statistically significant reduction in fold change of PrP
C
 mRNA levels in the brain compared to the untreated control 
(Figure 3.10B). The kidney at 48 hours post-treatment in CD1 mice had a different response than the brain by flow 
cytometry. Two out of the three treated mice have a decrease in MFI, and the number of PrP
C
-positive cells is 
reduced to numbers seen in PrP-null mice. The reduction in surface PrP
C
 of these two mice is greater than 50% in 
one mouse and around 75% in the other (Figure 3.10C). The decline of PrP
C
 in the kidney could be due to LSPCs 
treatment in general; however, this reduction is more than what was observed with scrambled siRNA. mRNA 
analysis of the kidney revealed that PrP
C
 mRNA copy number was increased in two out of the three treated mice. 
Grouped all three treated mice had no statistical difference to the untreated control (Figure 3.10D). 
At four days post-treatment in CD1 mice, the MFI is not significantly decreased in the brain nor the number 
of PrP
C
-positive cells. However, when the treated mice are normalized to the untreated control, there is a statistically  
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Figure 3.10. Flow cytometric and ddPCR analysis of CD1 mice 48 hours after LSPCs treatment. 
A) None of the CD1 LSPCs-treated mice had a significant decrease in either neuronal surface PrP
C
 levels or the 
number of PrP
C
+ cells in the brain at 48 hours after treatment B) All three LSPCs-treated mice had ~2-fold 
decreases in PrP
C
 mRNA levels at this time point, with statistical significance when grouped. C) Two out of the 
three treated mice had decreased surface PrP
C
 in the kidney, while all three mice had significant decreases in the 
number of PrP
C
+ cells in this organ. D) PrP
C
 mRNA varies with LSPCs treatment 48 hours after treatment in 
CD1 mice, with two out of the three mice showing extremely slight increases in PrP
C
 mRNA levels. No 
difference in mRNA levels observed when mice are grouped. Error bars for graphs with individual treated mice 
indicate SD. Error bars for graphs with grouped treated mice indicate SEM. * p<0.05, ** p<0.01, **** 


















































































































































































































































































































































































































































































































significant drop in surface PrP
C
 in the brain in all three treated mice (Figure 3.11A). PrP
C
 mRNA levels in the brain 
in two out of the three mice are slightly decreased compared to controls (Figure 3.11B). The third treated mouse has 
slightly increased PrP
C
 mRNA levels than the untreated control. Grouping the treated mice show no statistical 
significance. The mouse with the lowest neuronal MFI also has the highest PrP
C
 mRNA copy number and fold 
change (Figure 3.11A and B). In the kidney, again there is not an appreciable difference in MFI of PrP
C
 between the 
untreated control and the treated mice. However, when the MFI of the treated mice is normalized to the untreated 
control, all three treated mice have a decrease in kidney surface PrP
C
 (Figure 3.11C). Analysis of mRNA levels 
concurs with flow cytometry data in that all three treated mice have about a 2-fold or less decrease in PrP
C
 mRNA in 
the kidney at this time point (Figure 3.11D). Grouping the treated mice is statistically significant (Figure 3.11D) The 
number of PrP
C
-positive cells in the kidney is not statistically different from untreated control (Figure 3.11C). 
PrP
C
 protein and mRNA levels were analyzed at 15 days to try to determine when the LSPCs treatment 
stops affecting CD1 mice. To our surprise, neuronal surface PrP
C
 was decreased in two out of three mice at 15 days 
post-treatment (Figure 3.12A). Neuronal PrP
C
 was reduced by 25%. There was no effect on the number of PrP
C
-
positive cells in the brain at this time point. One treated mouse had an increase in PrP
C
 mRNA levels in the brain, 
and two treated mice had a very slight decrease in mRNA levels, but when grouped the treated group was not 
statistically significant from the untreated control (Figure 3.12B). Again, the mouse with the greatest increase in 
PrP
C
 copy number/µL levels had the most significant decrease in PrP
C
 protein levels in the brain. Flow cytometry of 
surface PrP
C
 in the kidney revealed that all three treated mice had decreased levels of PrP
C
 (Figure 3.12C). MFI was 
reduced between 30% and 75% compared to the control. There was also a significant decline in the number of PrP
C
-
positive cells in the kidney. The LSPC treatment alone, without PrP
C
 siRNA, could have produced these results in 
the kidney. All treated mice had decreases in the fold change of PrP
C
 mRNA levels in the kidney, with statistical 
significance when grouped (Figure 3.12D). 
Since 15 days post-treatment showed significant decreases in PrP
C
 levels, CD1 mice were treated out till 21 
days to determine an endpoint of the treatment. Protein levels of neuronal PrP
C
 are unchanged from the untreated 
control at this time point (Figure 3.13A), but, interestingly, the mRNA copy number is decreased in all three mice at 
21 days post-treatment (Figure 3.13B). Fold change analysis shows that one treated mouse had a 3-fold decrease in 
PrP
C
 mRNA levels in the brain, while the other two treated mice had less than a 2-fold decrease in mRNA. Grouped  
	 105	
	   
Figure 3.11. Flow cytometric and ddPCR analysis of CD1 mice 4 days after LSPCs treatment. 
A) There is no statistical difference between PrP
C
 MFI in the brains of untreated and treated mice at four days 
after LSPCs treatment but when the data is normalized to the untreated control all three treated mice have 
between 25-40% decrease in surface PrP
C
. B) Two LSPCs-treated mice have increased copy number compared 
to the untreated control. When the treated mice are normalized to treatment controls one LSPCs-treated mouse 
has a 1-fold decrease and one has a 1-fold increase in PrP
C
 mRNA levels. Grouped the treated mice have no 
statistical difference in PrP
C
 mRNA levels C) When PrP
C
 MFI in the kidney of the treated mice is normalized to 
untreated controls, all three LSPCs treated mice have a decrease in surface PrP
C
 levels in this organ at four days 
after treatment. D) All three LSPCs-treated mice have a decrease in PrP
C
 mRNA levels, 2-fold or more, at four 
days after LSPCs treatment. Grouped there is a significant difference between the untreated and treated mice. 
Error bars for graphs with individual treated mice indicate SD. Error bars for graphs with grouped treated mice 
indicate SEM. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. One-way ANOVA with Dunnett’s multiple 




























































































































































































































































































































































































































































































































Figure 3.12. Flow cytometric and ddPCR analysis of CD1 mice 15 days after LSPCs treatment. 
A) Two of the LSPCs-treated had had a 25% decrease in neuronal surface PrP
C
 levels 15 days after LSPCs 
treatment. B) Corresponding to the flow cytometry data, two of the three LSPCs-treated mice had a decrease in 
PrP
C
 mRNA levels in the brain when normalized to the untreated and treatment controls. Copy number analysis 
of PrP
C
 mRNA revealed that all three LSPCs-treated mice had an increase in PrP
C
 mRNA levels, which could be 
due to the treatment alone and not the PrP
C
 siRNA. C) All three LSPCs-treated mice also had a decrease (30-
75%) in surface PrP
C
 in the kidney at this time point and a decrease in the number of PrP
C
+ cells in this organ. 
D) Two of the three LSPCs-treated mice had elevated PrP
C
 copy number but when normalized to the untreated 
and treatment controls each treated mouse had a slight decrease in PrP
C
 mRNA levels up to 1.5-fold lower. Error 
bars for graphs with individual treated mice indicate SD. Error bars for graphs with grouped treated mice 
indicate SEM. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. One-way ANOVA with Dunnett’s multiple 



























































































































































































































































































































































































































































































































Figure 3.13. Flow cytometric and ddPCR analysis of CD1 mice 21 days after LSPCs treatment. 
A) None of the LPSCs-treated mice had either a decrease in neuronal surface PrP
C
 or a decrease in the number of 
PrP
C
+ cells in the brain 21 days after treatment. B) All three LSPCs-treated mice had a decrease in copy number 
and fold change (~2-fold decrease) to untreated and treatment controls at 21 days after LSPCs treatment in the 
brain. C) Surface PrP
C
 levels in the kidney are decreased (25-55%) in all the LSPCs treated mice, as well as the 
number of PrP
C
+ cells. D) PrP
C
 mRNA analysis in the kidney also revealed a decrease in PrP
C
 mRNA levels in 
the kidney 21 days after LSPCs treatment. Error bars for graphs with individual treated mice indicate SD. Error 
bars for graphs with grouped treated mice indicate SEM. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
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Othe treated mice have a statistically significant reduction in PrP
C
 mRNA levels in the brain (Figure 3.13B). Both 
protein levels and mRNA copy number are decreased in the kidney 21 days post-treatment, with protein levels being 
reduced in one mouse about 50% (Figure 3.13C). The number of PrP
C
-positive cells is also still decreased in the 
kidney but could be due to non-specific reduction by LSPCs treatment. Fold change analysis revealed a less than 2-
fold change in one treated mouse and less than 1-fold change in the other two treated mice of PrP
C
 mRNA levels in 
the kidney (Figure 3.13D). Grouped the treated mice are statistically different than the untreated control. 
Repeated siRNA treatments in prion-infected mice result in ever decreasing levels of PrP
C
 
 FVB mice were treated with LSPCs every two weeks, for a total of twelve weeks, to determine the effect of 
a repetitive two-week dosing regimen on PrP
C
 protein and mRNA levels. The mice were inoculated with 0.1% 
RML-5 prions. One PBS and one LSPCs-treated mouse were sacrificed every week after treatment. The ‘1 
treatment’ mice received one LSPCs treatment, the ‘2 treatment’ received two LSPCs treatments, and so on until the 
last group which received a total of six LSPCs treatments. Brains and kidneys were harvested at each time point. 
Protein analysis was performed using flow cytometry and western blot. mRNA analysis was performed using 
ddPCR. 
Flow cytometry data revealed that three repetitive siRNA treatments result in a decrease in PrP
C
 MFI in the 
brain, indicating that surface PrP
C
 is consistently dropping till this time point (Figure 3.14A). Subsequent treatments 
after the 3
rd
 treatment result in a steady increase in MFI, indicating that PrP
C









 treatments and then steadily decrease 
in subsequent treatments (Figure 3.14B). Analysis of relative PrP
C
 expression and fold change in the brain using the 
western blot technique did not reveal any statistical difference between the untreated and treated mice at each time 
point (Figure 3.14C and D). mRNA analysis of the brain concurs with flow cytometry in that PrP
C
 mRNA levels are 
consistently decreased till the 3
rd
 siRNA treatment (Figure 3.14E). Three repetitive siRNA treatments result in a 3-
fold reduction in PrP
C
 mRNA levels in the brain. The 4
th
 siRNA treatment results in a 2-fold increase in neuronal 
PrP
C
 mRNA levels, which would explain the increase in surface PrP
C
 as shown by flow cytometry. Interestingly the 
6
th
 treatment, while not statistically significant from the untreated, resulted in neuronal PrP
C
 mRNA levels that are 
significantly decreased from the mRNA levels measured after the 4
th
 treatment (Figure 3.14E). This significance 
suggests that while the mRNA levels did rebound after the 3
rd
 treatment, they started to decrease again due to the 
repetitive LSPC treatments. Analysis of PrP
C
 mRNA levels in the kidney showed a statistically significant increase 
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in mRNA after the 1
st
 treatment and a decrease in mRNA levels after the 2
nd





 mRNA levels are not statistically different from the untreated control but seem to waver slightly up 
and down after LSPCs treatments. 
  
Figure 3.14. Flow cytometric and ddPCR analysis of a repeating two-week dosing regimen in FVB mice. 
A) Mice who received one to three LSPCs treatments every two weeks had lowered surface PrP
C
 levels in the 





levels start to rebound after three LPSCs treatments. B) None of the treatments resulted in a significant change in 
PrP
C
 protein levels in the kidney but three and six treatments are significantly different from one and four 
treatments, respectively. C) Western blot analysis of the brain did not reveal any significant difference between 
any of the untreated and LSPCs-treated mice. However, a trend of PrP
C
 protein levels being decreased and then 
increased at every other time point is observed. D) Fold change of western blot analysis more clearly shows the 
trend observed in PrP
C
 protein levels after one to six LSPCs treatments E) mRNA analysis of neuronal cells 
revealed a decrease in PrP
C
 mRNA after three LSPCs treatments and an increase in PrP
C
 mRNA levels after four 
LSPCs treatments. The PrP
C
 mRNA levels start to decrease again after four LSPCs treatments. F) mRNA 
analysis of kidney cells reveals a back and forth increase/decrease after subsequent LSPCs treatments. Error bars 
indicate SEM. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. ▲= statistically significant from 6 treatments. 
 = statistically significant from 3 treatments.  = statistically significant from 1 treatment. One-way ANOVA 













































































































































































































































































































































































































































































 The blood-brain barrier (BBB) is the rate-limiting step for delivery of therapeutics to the brain and remains 
the biggest challenge in producing effective therapeutics for neurodegenerative disorders. In physiological 
conditions, the BBB is meant to protect neurons, glia, and other neuronal cell types from serum proteins or toxins. 
The BBB produces its protective effect in a number of ways. The first is the organization of the endothelial layer 
that provides a physical barrier to the central nervous system (CNS). This physical barrier is composed of 
endothelial cells, pericytes, and foot processes of astrocytes. Tight junctions between endothelial cells do not permit 
most solutes from crossing between cells. In fact, transport through tight junctions, in physiological conditions, is 
negligible meaning that the only meaningful way to transport therapeutics across the BBB is by transport through 
the endothelial cells. Pericytes are the primary regulators of the vascular permeability, and certain permeabilizing 
receptors on these cells can be upregulated in disease processes. The second protective effect comes in the form of 
efflux pumps, which immediately transports out any molecule lucky enough to make it into the endothelial cells of 
the BBB. A third protective effect is the enzymatic BBB, which uses enzymes on the surface of the plasma 
membrane of endothelial cells to digest any unwanted proteins
62-64
. 
 While the structure of the BBB makes it sound like an impenetrable fortress, therapeutic drugs can still 
cross this membrane if designed smartly. Once across the membrane, the drug doesn’t have to traverse long 
distances as most neurons sit within 8-25 µm from a microvessel
64
. Countless strategies have been employed to 
transport drugs across the membrane, but perhaps the best-known approach is the ‘Trojan Horse’ method. The 
‘Trojan Horse’ method utilizes a targeting ligand bound to a drug or delivery system that binds to a cell-surface 
receptor on the endothelial cells of the BBB. The result of this binding is usually an internalization of the 
drug/delivery system. Care must be taken to avoid the endocytotic pathway of the endothelial cells in favor of the 
transcytotic pathway for transport
62,63
. Multiple ligands and their receptors have been used to transport drugs and 











, and brain-derived neurotrophic factor
63
. All of 
these ligands/receptors have shown success but still need optimization to become a part of the ‘next generation’ of 
delivery vehicles. 
 We have chosen to use the neuro-targeting peptide RVG-9r to guide our PrP
C
 siRNA therapeutic across the 
BBB. RVG-9r is a small peptide of the rabies virus glycoprotein that binds to the a7 subunit of nicotinic 
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acetylcholine receptors (nAchRs). These receptors are present in other tissues besides the CNS but neuronal cells 
within the CNS also highly express nAchRs. Kumar et al. showed that using RVG-9r bound to siRNA dramatically 
increased its delivery to the CNS. SiRNA bound to RVG-9r was able to decrease exogenous GFP by 40%, and anti-
viral siRNA against Japanese encephalitis virus increased survival times in mice infected with the virus
70
. Both the 
PrP
C
 siRNA and the RVG-9r, in our formulation, are protected by a liposomal delivery system to increase serum 
half-life and decrease nuclease attack by serum proteins. We have previously characterized the ability of our 
liposome-siRNA-peptide complexes (LSPCs) to deliver PrP
C
 siRNA to neuronal cells in vitro. LSPCs delivered 
PrP
C
 siRNA directly to mouse neuroblastoma cells without the need for lipofection reagents and decreased PrP
C
 
levels by 50-75% in these cells. The liposomes were able to protect the siRNA in increasing concentrations of 
serum, while the RVG-9r peptide delivered PrP
C
 siRNA specifically to cells that expressed nAchRs
58
. The next steps 
in characterizing these LSPCs was to determine their ability to deliver PrP
C
 siRNA to the brain in vivo, with the goal 
being, if successful, to determine an optimum dosing regimen of LSPCs in prion-infected mice. 
 The LSPCs delivered PrP
C
 siRNA to the brain, as shown by in vivo live imaging. We were able to detect 
PrP
C
 siRNA signal up to two hours after injection. Unfortunately, we did not detect any signal in the brains of any 
treated mice at 24 hours after injection during this experiment. However, in another experiment, we were able to 
detect PrP
C
 siRNA signal up to ten days after injection
71
. Several factors might explain the results seen during this 
experiment compared to the previous experiment, including different clearance rates, different metabolism of 
LSPCs, and less LSPCs being injected intravenously. At 48 hours after injection, PrP
C
 siRNA signal is seen in the 
bladders of all treated mice in this study (data not shown). The pooling in the bladder indicates a difference in 
clearance kinetics or metabolism among mice, as both of these would result in LSPCs being transported to the 
kidneys. The LSPC transport to the kidneys was seen to be a problem in about half of the mice that were treated, 





While initial results indicate that clearance kinetics have been altered in PALETS-treated mice (unpublished results), 
more studies are needed to determine if this is the case. 
 Control experiments were undertaken to determine if the LSPC treatment alone causes any alterations to 
PrP
C
 protein and mRNA levels. Mice were either treated with LSPCs with scrambled siRNA or LSPCs with the 
RVM control peptide. Surprisingly, the LSPCs treatment causes differences in PrP
C
 protein and mRNA levels. The 
slight decrease in neuronal PrP
C
 protein levels due to scrambled siRNA sequence might be due to the activation of 
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the RNAi machinery by the non-specific siRNA. The scrambled siRNA sequence does not have complementarity to 
the sequence of the prnp gene that encodes for PrP
C
, so theoretically it should not cause a decrease in mRNA or 
protein levels. However, if the scrambled siRNA is loaded into the RISC complex, it might just activate non-specific 
cleavage of PrP
C
. The reduction of PrP
C
 MFI in the kidney could be partially attributed to apoptosis of the treated 
cells as the number of PrP
C
-positive cells is decreased in the kidney for both scrambled and RVM LSPCs treatment 
(Figure A1.2). In the brain, apoptosis likely does not play a factor in the decrease in MFI because the number of 
PrP
C
-positive cells does not change with either scrambled LSPCs or RVM LSPCs treatment (Figure A1.2).  
 mRNA analysis of scrambled siRNA and RVM LSPCs treatment revealed a 1-fold increase in mRNA 
levels in treated mice compared to the untreated control. While this finding was unexpected, increased expression of 
PrP
C
 has been observed when certain immune cells are activated. Both T cells and follicular dendritic cells will 
upregulate the expression of PrP
C
 when the cells become activated by Toll-like receptor (TLR) ligands, such as 
lipopolysaccharide and CpG oligodeoxynucleotides
73-76
. While most of these immune studies assayed protein levels, 
it is entirely plausible that an upregulation of protein is preceded by an upregulation of mRNA levels. One study 
noted that they did not observe any mRNA changes of PrP
C
 in follicular dendritic cells. However, this observation 
could be due to a translational regulation of PrP
C
 in these cells or perhaps an early enough time point was not chosen 
to observe the mRNA increase. These studies indicate that PrP
C
 is upregulated during an immune response. There 
are several factors of the LPSCs treatment that could lead to the activation of immune cells/products, which could 
explain the increase in PrP
C
 mRNA that we detected in treated mice. 
 Early reports of siRNA indicated that the RNA molecules did not induce an immune response. Naked 
siRNAs injected into mice failed to produce an IL-12 or IFNa response
77
. However, later studies revealed that 
siRNA can signal through TLRs to increase cytokine production. This contradiction in results might be due to 
particular siRNA sequences, as some naked siRNA molecules do not activate an immune response while others 
do
77,78
. TLR 7 and 8, which recognize single-stranded RNA molecules, are the TLRs most commonly activated by 
siRNA
78-81
. Certain siRNA molecules will also activate TLR3, which recognizes dsRNA
82
. Activation of TLR 7 and 
8 occurs in the endosomal pathway, suggesting that any uptake of siRNA by endocytosis can lead to an immune 
response through these TLRs. While most siRNAs activate TLRs in the endocytotic pathway to produce cytokines, 
electroporation of siRNA directly into the cytoplasm also results in the production of inflammatory cytokines
79,83
. 




. Duplex siRNA causes less cytokine release from TLRs than does the single strands of the siRNA. 
Complexing the siRNA to delivery vehicles, such as liposomes, also increases cytokine production through TLR 
signaling. Though liposomes alone do not increase cytokine production
78,84
, siRNA and liposomes together produce 
a potent immune response. It is not known what component of the complex triggers the activation. Although, it is 
thought that perhaps the siRNA and liposome complex mimics a viral particle and thus induces a stronger immune 
response. Again, this immune response involves the secretion of TNFa, IL-6, and IL-12
85
.  
Another factor that could be causing an immune response is the rabies virus glycoprotein (RVG-9r) peptide 
that is used to target the LSPCs to the brain. The RVG peptide in its native form, without the nine arginine residues 
added to the COOH-terminus, does not elicit an immune response. Therefore, this peptide probably does not contain 
a proper recognition pattern for TLRs. An immune response does occur when the arginine residues are added to the 
end of the peptide. RVG-9r –siRNA exosomes were shown to increase IL-6 production in the mouse brain
86
. Again, 
it seems complexing two of the delivery vehicle factors together increases non-specific cytokine production. 
Due to the toxicity issues of complexing siRNA to cationic liposomes and complexing the RVG-9r peptide, 
it is possible that the increase in PrP
C
 mRNA levels is due to a non-specific immune response through the activation 
of TLR receptors. This reaction could be coming from either immune cells interacting with the LPSCs in the 
systemic circulation, and/or from microglia, astroglia, or neurons, which all contain TLRs 3, 7, and 8
87
. The 
cytokines produced by this non-specific response could be providing a third signal to activate immune cells
88
, such 
as T cells, that increases PrP
C
 mRNA levels. It is unknown whether a systemic T cell activation would affect PrP
C
 
levels in the brain. It would be prudent to treat mice with only cationic liposomes, naked siRNA, RVG-9r, liposomes 
+ siRNA, or liposomes + RVG to assess if the complexation of the siRNA and the cationic liposomes are causing 
the increase in mRNA levels. It is also necessary to determine the immune system profile of LSPCs treatment by 
measuring cytokine production in treated mice. 
We evaluated the pharmacodynamics (PD) of the LSPCs treatment in two different mouse models: CR1/2 
hemi transgenic mice and CD1 wild-type mice. We felt it necessary to assess the PD in two different mouse models 
to account for any treatment response differences in individual mice but also among different background strains of 
mice. The CR1/2 hemi transgenic mice express one allele of CD21 and one allele of CD35. The transgenic aspect of 
this mouse strain is not important to the studies in this report but the C57Bl/6 background enables us to assess 
LSPCs treatment in a different mouse model. The CR1/2 hemi mice have the same amount of PrP
C
 as their C57Bl/6 
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wild-type counterparts, so the transgenic nature of these mice should not have influenced the effects of the LSPCs 
treatment or the expression level of PrP
C
. 
Western blot analysis was utilized as another assay to evaluate PrP
C
 protein expression in the brains of 
LSPCs-treated mice treated at various time points. Samples were prepared in triplicate for each experiment, and the 
western blot was repeated. The densitometric analysis of the western blot showed very little statistical significance 
of PrP
C
 protein levels in LSPCs-treated mice. However, at 48 hours post-treatment in CR1/2 hemi mice and 21 days 
post-treatment in CD1 wild-type mice, there was a decrease in PrP
C
 protein fold change in two of the treated mice at 
those time points compared to the untreated control, which mimicked the flow cytometry and ddPCR results from 
the brain obtained at these time points. CR1/2 hemi LSPC-treated mice had a decrease in both PrP
C
 MFI and PrP
C
 
mRNA levels at 48 hours post-treatment. CD1 LSPC-treated mice at 21 days post-treatment do not have a 
statistically significant reduction in PrP
C
 MFI levels in the brain, but they do have a decrease in PrP
C
 mRNA levels 
at this time point. Because these two western blot results mimic the results seen from the other assays, we believe 
that the reason the western blots do not show a decrease in PrP
C
 levels at other time points is due to a low sensitivity 
of the western blot assay compared to the other tests. The discrepancy between the flow cytometry results and the 
western blot results could also be due to the difference between measuring surface PrP
C
 versus total PrP
C
 levels. Our 
flow cytometry protocol does not include a fixation and permeabilization step, which would allow the PrP
C
 antibody 
to label all cellular PrP
C
. Therefore, the antibody can only label surface PrP
C
 in our flow cytometry assay. The 
western blot protocol involves permeabilization of all cells, which would result in the measurement of total cellular 
PrP
C
. Though the reduction of total PrP
C
 would be optimal for a siRNA therapeutic against prion disease, reducing 
surface PrP
C
 might be more important and still have an impact on survival times of prion-infected mice as most 
PrP
Res
 formation likely occurs at the cell surface
89
. 
CR1/2 hemi mice responded well to the LSPCs treatment and had significant decreases in surface PrP
C
 in 
the brain at all time points tested. Most of the CR1/2 hemi mice also had decreases in mRNA levels in the brain. 
Interestingly, a pattern that presented in the treated mice revealed that most of the mice with the lowest amount of 
neuronal surface PrP
C
 had an increase in PrP
C
 mRNA levels above the untreated mouse. This discovery is interesting 
as it suggests that PrP
C
 has a tight transcriptional regulation over mRNA levels, and subsequently protein levels. 
PrP
C
 mRNA levels in the kidneys of CR1/2 hemi LPSC-treated mice had variable levels of PrP
C
 at different time 
points. The levels in the kidney are either increased at one time point or decreased at another time point. CD1 mice 
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show the same type of variability within treatment groups of PrP
C
 levels both in the brain and the kidney. At four 
days and fifteen days post-treatment, surface PrP
C
 in the brains of CD1 mice are decreased relative to the untreated 





 mRNA levels in the brains of LSPC-treated CD1 mice are also variable. Some mice with decreases in surface 
PrP
C
 have an increase in PrP
C
 mRNA levels. Again, at some time points, the mouse with the lowest MFI has the 
highest copy number and fold change of PrP
C
 mRNA levels compared to the untreated control. Most of the LSPC-
treated CD1 mice have decreased levels of surface PrP
C
 in the kidney, usually accompanied by a decrease in PrP
C
 
mRNA levels.  
The variability not only within the treated groups and between the two different background strains was not 
surprising given that siRNA response varies widely in individual mice. The striking feature of these experiments 
was that, in some cases, protein levels did not agree with mRNA levels. Some mice had increased protein and 
decreased mRNA levels, while other mice had the opposite. We can conclude from these two strains of mice that 
LSPCs can deliver PrP
C
 siRNA to the brains of two different mouse lines and that in both mouse lines delivery of 
siRNA usually results in a decrease of PrP
C
 levels. It is important to note that we anticipated off-target effects in the 
kidney due to the presence of nAchRs in that organ, but we did not expect the treatment itself (scrambled siRNA or 
RVM peptide) having such a dramatic effect on PrP
C
 levels in the kidney. All ddPCR results have been normalized 
to the non-specific increase caused solely by the LSPCs treatment. So, the fold change results observed in the kidney 
take into account the increase and show the increase/decrease caused only by the PrP
C
 siRNA. However, flow 
cytometry results for the kidney were not normalized towards the increase seen in control experiments. Therefore, 
the decrease in PrP
C
 levels in the kidney could either be caused by the PrP
C
 siRNA or by the presence of the LSPCs. 
The fold change of ddPCR results is shown as both individual mice and as a pooled group, due to the 
sensitivity of the ddPCR reaction. In ddPCR, every reaction has over 10,000 replicates in the form of droplets, 
which makes any change statistically significant. However, statistical significance does not imply biological 
significance. ddPCR results of individual mice are shown because it’s important to assess individual variability in 
mRNA levels due to the LSPC treatment. Biological significance is indicated by grouping the treated mice into a 
single mean. If the pooled data is statistically significant from the untreated control, we feel confident that this 
significant change in PrP
C
 mRNA levels might be biologically relevant. 
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We assessed whether multiple siRNA treatments would cause an even larger reduction in PrP
C
 during a 
two-week dosing regimen of LSPCs. Infected FVB mice were treated every two weeks starting at 2.5 months post 
inoculation. Again, the western blot analysis did not provide any statistical significance in neuronal PrP
C
 levels in 
treated mice compared to untreated mice. Conversely, flow cytometric analysis of both brain and kidney revealed 
that subsequent siRNA treatments with LSPCs result in even larger decreases of surface PrP
C
. Analysis of both 
organs shows a decline in surface PrP
C
 until the 3
rd
 LSPC treatment. After the 4
th
 treatment in the brain, there is a 
subsequent increase in PrP
C
 protein levels till the 6
th
 treatment even in the presence of PrP
C
 siRNA. In the brain, the 
6
th
 treatment is statistically significant from treatments 1-4, but not from the untreated, indicating that the 6
th
 
treatment has increased PrP
C
 levels relative to the earlier time points. The kidney shows a different trend where, 
again, the 4
th
 treatment increases surface PrP
C













 levels are dropping again. However, flow 
cytometry results could be due to a non-specific reduction of protein levels cause by the LSPCs treatment. The 
kidney mRNA levels show a back and forth trend of PrP
C
 levels, with the first two treatments being statistically 
significant. It’s interesting that the response of the kidney to the siRNA treatment is to upregulate both PrP
C
 mRNA 
and protein levels initially. The biological significance of this is unknown. Fold change of PrP
C
 mRNA levels in the 
brain decrease until the 3
rd
 treatment, where they dramatically increase at the 4
th





 mRNA levels start to drop again. 
The two-week regimen data, along with the CR1/2 hemi and CD1 mice pharmacodynamics data, suggest 
that PrP
C
 has some form of transcriptional regulation that tries to rebalance both the mRNA and protein levels to 
normal. PrP
C
 is considered to be a housekeeping gene and contains several CpG islands and transcription factor sites 
within non-coding regions of the prnp gene. Transcription factor binding sites include IL6, MyoD, and Sp1. The 
prnp gene is also very G/C rich on the 5’ end, which is indicative of a promoter region. The actual mechanism of 
transcriptional control of PrP
C
 is unknown. Given that the field of prion therapeutics has turned to PrP
C
 as a target, it 
would be beneficial to know the transcriptional regulation of PrP
C
 to design more effective therapeutics. Without 
knowledge of regulation, therapeutics that target PrP
C
 will continue to have the same complications we did with 
extreme variability and unpredictability of therapeutic response due to the targeting of PrP
C
. 
This report shows that LSPCs treatment in two different mouse models decreases surface PrP
C
 and mRNA 
levels in the brain. While there are off-target effects in the kidney, no animal died of treatment either in the PD 
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studies or the two-week regimen studies, indicating that LSPCs treatment is not overtly harmful to naïve mice. 
However, toxicity profiles, including immune response assays, need to be performed to evaluate the safety of 
LSPCs. Optimization of the LSPCs delivery vehicle might result in a better response than what was observed here. 
Since siRNA generates such variable and transient responses, it may not be the best therapeutic to use for a protein 
whose levels are tightly regulated. Therefore, it might be beneficial to test small molecules such as shRNA or 
CRISPR in the LSPC delivery vehicle that might prove more effective at decreasing PrP
C
 levels. Also, if RVG-9r 
generates too large of an immune response, another targeting peptide may be used with the delivery vehicle. With 
optimization, we feel that LSPCs still represent a viable therapeutic option for prion diseases. The next step would 
be to test the PrP
C
 siRNA LSPCs in prion-infected mice to determine if repeated siRNA treatments affect survival 
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Chapter 4:  
LSPCs do not increase the survival periods of prion-infected mice, but do improve 





 Prion diseases are devastating neurodegenerative diseases that affect both animals and humans. Currently, 
there is no known therapeutic that extends the survival period or alleviates disease in prion-infected 
animals/individuals. Prion diseases are also similar in pathogenesis to other protein misfolding diseases, such as 
Alzheimer’s and Parkinson’s disease. There is speculation that a therapeutic effective at treating prion diseases 
could also be applied to the treatment of other protein misfolding disorders. Therefore, we have investigated the use 
of RNA interference (RNAi) as a potential therapeutic for prion diseases. Our siRNA targets the host cellular prion 
protein (PrP
C
), which becomes misfolded during prion infection. Decreasing PrP
C
 via stereotaxic injection has 
proven successful in prolonging survival times and reversing prion neuropathology in prion-infected animals. Since 
repeated stereotaxic injections are not a feasible option for a clinical drug, we have packaged our PrP
C
 siRNA into 
liposomes bound to a neuro-targeting peptide. These liposome-siRNA-peptide complexes (LSPCs) can be 
administered intravenously, and can cross the blood-brain barrier to decrease neuronal PrP
C
. The aim of this study 
was to determine if LSPCs treatment could prolong the survival periods of prion-infected mice and alleviate clinical 
signs. Unfortunately, recurring LSPCs treatment does not increase survival times in prion-infected mice. However, it 
does improve the performance of these mice in burrowing and nesting behavioral tests. We also observed an 
increase in total IgG levels against RVG-9r of LSPCs-treated mice. This immune response might explain why there 
was no benefit to survival times with repetitive treatments. The immune reaction will need to be addressed via 
different dosing regimens, targeting peptides, and/or liposomal formulations before LSPCs become a viable 




The prion protein, PrP
C





 is widely expressed throughout the body, but the highest expression levels of mRNA 




 matures in the endoplasmic 
reticulum, where it becomes a 208-amino acid protein with a glycosylphosphatidylinositol anchor. Post-translational 
modification of PrP
C




 exists mostly as an 






 can change from an a-helical structure to a mostly b-sheet structure. When this secondary structure 
change occurs, PrP
C
 becomes infectious and is known as PrP
Res2,7,8
. The diseases that result from the conversion to 
PrP
Res
 are referred to as prion diseases. A misfolded protein that encodes its replicative instructions within the 
structure of the protein causes prion diseases
9
, unlike most diseases caused by microbiological agents, which are 
encoded by RNA or DNA. Prion diseases affect a broad range of species, from chronic wasting disease (CWD) in 
cervids to Creutzfeldt-Jakob disease (CJD) in humans.  
These diseases have multiple etiologies depending on the species and individuals that are afflicted. Several 
polymorphisms result in either susceptibility or resistance to acquiring prion disease. Individuals who possess 
susceptible polymorphisms have an increased likelihood of their PrP
C
 changing secondary structure and becoming 
infectious. Several prion diseases that have a genetic component include scrapie in sheep, and genetic CJD and fatal 
familial insomnia in humans. PrP
Res
 is also transmitted through the consumption of infected meat or exposure to 
infected bodily fluids. The diseases spread by these routes include bovine spongiform encephalopathy in cows, 
variant CJD in humans, and CWD in cervids, respectively. Incubation times of prion diseases vary between a few 
years to a couple of decades. However, progression of the disease, once clinical stage has been reached, is usually 
under six months. 
Once an individual is exposed, PrP
Res
 will first migrate to lymphoid tissues with the help from immune 




 replicates and accumulates within the spleen 
and lymph nodes that are part of the gut-associated lymphoid tissue. The replication eventually results in the 
migration of PrP
Res
 to nerve bundles within these tissues
11-13
. The leading theory on how PrP
Res
 reaches the brain is 
that it ascends nerve tracks originally located within these lymphoid tissues. Evidence to support this comes from 
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the pathology of prion diseases, which usually starts in the brain stem and migrates to the cerebellum and cerebrum, 
indicating that the first point-of-contact of PrP
Res
 molecules in the CNS is the brainstem
14,15
. Pathology includes 
PrP
Res





 began in the mid-1980s and has been ongoing for the last 30 years; however, the function of PrP
C
 
remains elusive. Evidence suggests that PrP
C
 might be neuroprotective through antioxidant
17-19
 and anti-apoptotic 
functions
20,21
. The regulation of Ca
2+







 is one way in which the protein can activate several cell-signaling pathways, such as 
MAPK/ERK, PKA, and STAT1, to modulate the response of oxidative and apoptotic damage
23,25,26
. The ability of 
PrP
C
 to bind to Cu
2+
 is also thought to mediate oxidative stress damage
18,27,28
. Another proposed function of PrP
C
 is 
to activate the immune system in the presence of certain immune stimulants, such as lipopolysaccharide and CpG 
oligodeoxynucleotides
29-31
. With these potential functions, it was anticipated that PrP-null mice would show an 
obvious phenotypic change. However, PrP-null mice do not show any deleterious effects from the elimination of 
PrP
C32
. PrP-null mice have slight circadian rhythm disruptions
33
 and reorganization of neuronal circuits
34
 but no 
overt loss-of-function phenotype. Some have argued that there is a redundant pathway that recovers the loss-of-




. Whatever the reason for no loss-of-function phenotype, mice with 
reduced or depleted PrP
C
 live long and healthy lives. 
Unfortunately, there is no known therapeutic that can improve the quality of life or the survival times of an 
individual afflicted with prion disease. Some therapeutics that targeted the mechanism of PrP
Res
 conversion or its 
accumulation resulted in longer survival times in animal models. However, a lot of these compounds were toxic or 
could not breach the blood-brain barrier. Also, most of these compounds were only successful, i.e. only extended 
survival periods, when given before or shortly after prion inoculation
36-41
. Since reducing or eliminating PrP
C
 was 
shown to have no deleterious effects, recent prion therapeutic research is focused on manipulating PrP
C
 to reduce 
PrP
Res
 and its pathology. Injections of short hairpin RNA directly into CNS tissue in prion-infected mice resulted in 
a decrease of neuronal PrP
Res




 after established prion 
infection using Cre/loxP mice also led to a reversal of prion pathology
44
. However, it is not feasible to create 
transgenic humans or to repeatedly inject therapeutic molecules into the CNS as it causes damage to the local tissue.  
We propose to use small interfering RNA (siRNA) to decrease the amount of neuronal PrP
C
 in vivo. Our 
PrP
C
 siRNA is packaged with cationic liposomes and a neuro-targeting peptide called RVG-9r. Together, these 
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complexes are referred to as liposome-siRNA-peptide complexes (LSPCs)
45
. We have previously shown that 
LSPCs, when injected intravenously, can cross the blood-brain barrier to decrease neuronal PrP
C
 in two different 
mouse models (unpublished results). Therefore, we treated prion-infected mice every two weeks or every four to six 
weeks starting at 120 days post inoculation all the way till terminal disease. These mice were also subjected to 
behavioral testing via burrowing and nesting tests every two weeks. We found that repeated siRNA treatments do 
not extend the survival times of mice infected with prions, but repeated treatments do improve the behavior of prion-
infected mice at certain time points. Treatment of mice every two weeks with LSPCs also increases total IgG levels, 
indicating that there is a significant immune response to our treatment. We conclude that although LSPCs are not 
able to extend survival times in prion-inoculated mice, behavioral scores are improved when LSPCs are 
administered every two weeks. Therefore, we postulate, with a little optimization, LPSCs may represent a new 
therapeutic option for prion diseases. 
 
Materials and Methods 
Mice 
 FVB mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and CD1 mice were purchased 
from Charles River Laboratories (Wilmington, MA). Mice were euthanized using CO2. All mice were bred and 
maintained at Lab Animal Resources, accredited by the Association for Assessment and Accreditation of Lab 
Animal Care International, in accordance with protocols approved by the Institutional Animal Care and Use 
Committee at Colorado State University. 
Generation of Liposomes 
DOTAP LSPCs 
 DOTAP LSPCs consist of a 1:1 DOTAP:cholesterol ratio in a 1:1 chloroform:methanol solution. Both 
lipids were purchased from Avanti Lipids (DOTAP - 1,2-dioleoyl-3-trimethylammonium-propane [chloride salt]). 
The solvents were evaporated using N2 gas and the resultant dry lipid film was placed under vacuum for a total of 8 
hours to remove any excess solvent. A stock solution of liposomes was made at an 8 mM (40 umole total) 
concentration, by resuspending the lipid film in 5 mL of 10% sucrose heated at 55°C. All components (lipid film 
and sucrose) were kept at this temperature during rehydration. The heated sucrose was added to the lipid cake 1 mL 
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every 10 minutes. The lipid film was swirled every 3 minutes to promote lipid mixing. Resulting liposomes were 
stored at 4°C. 
Generating LSPCs and treating mice with LSPCs 
PrP
C
 1672 siRNA sequence: ACATAAACTGCGATAGCTTC (Qiagen).  
PrP
C
 1578 siRNA sequence: GAAGTAGGCTCCATTCCAAA (Qiagen) 
RVG-9r peptide: YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGrrrrrrrrr (ChemPeptide) 
LSPCs 
 The DOTAP LSPCs liposomes were diluted 1:100 in 1X PBS and sonicated 4X with 2-3 minute rests in 
between. 50 uL (4 nmole total) of diluted/sonicated liposomes was mixed with 100 uL (4 nmole total) of 1672 
and/or 1578 siRNA. The siRNA/liposome solution was incubated for 10 minutes at 4°C. Then, 80 uL (40 nmole 
total) of RVG-9r peptide was added to the solution and allowed to incubate for 10 minutes on ice. Mice were placed 
under a heat lamp for 5 minutes and anesthetized with isofluorane. The mouse tails were disinfected using 70% 
EtOH. 200-300 µl LSPCs were injected into the tail veins of mice using a 29-gauge insulin syringe. Prion-infected 
mice were treated every 2 weeks in the first terminal study and every 3-5 weeks in the second terminal study. A 
small subset of mice were treated intranasally (IN). The IN mice were laid on their dorsal side (ventral side up) and 
the LSPCs were dripped into the nasal cavity 1-2 µL at a time for a total of 30-50 µL. 
Intraperitoneal inoculations and dissections 
 RML-5 prions were prepared as previously described46. 10% RML-5 brain homogenates were diluted 1:100 
(0.1%) in 1X PBS supplemented with 100 units/mL of Penicillin and 100 µg/mL of Streptomycin (Gibco) 
immediately before inoculation. Mice were scruffed and flipped upside down for inoculation. 100 µL of inoculum 
was injected in the left or right bottom quadrant of the intraperitoneal cavity with a 29-gauge insulin syringe (BD). 
Upon clinical stage, mice were scored based on a scoring rubric and euthanized if they reached a score of 10 or 
above. Brains, spleens, and serum were collected from each mouse. A hemisphere of brain and half of the spleen 
were frozen at -20°C for western blot analysis, and the other hemisphere of brain and spleen half were fixed in 4% 
paraformaldehyde. 
Behavioral Testing 
 Burrowing and nesting behavioral tests were performed on intraperitoneally prion-inoculated mice. 
Behavioral tests were started approximately 120 days post inoculation. For burrowing, mice were given 
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approximately 100 grams of food stuffed into a 6-inch plastic PVC pipe. Mice were allowed to burrow out the food 
for 30 minutes. Rate of burrowing was calculated by the number of grams of food burrowed out divided by total 
time burrowed. For nesting, mice were given a small cotton nestlet and allowed to build a nest overnight. Mice were 
scored on a scale from 0-4, with 0 being no nest built and 4 being a perfectly built nest. Average nesting scores were 
calculated for each treatment group. 
Normal brain homogenate (NBH) and Protein misfolding cyclic amplification (PMCA) 
Mice were euthanized and perfused with 30 mL of 5 mM EDTA in 1X PBS. Whole brains were removed. 
Brains were weighed and placed in 1.5 mL Eppendorf tubes with 2.5 mm glass beads. PMCA buffer (4 mM EDTA, 
150 mM NaCl in 1X PBS) with protease inhibitor tablets (Roche) was added to make a 20% weight/volume (w/v) 
solution. Samples were homogenized in a BeadBug homogenizer (Sigma). All NBH samples were pooled and 
diluted to a 10% w/v solution using PMCA conversion buffer containing 2% Triton-X 100. NBH was aliquoted and 
stored at -80°C. PMCA was performed as previously described
47
 with slight modifications. Samples were sonicated 
at power 20 for 40 seconds in a microplate horn sonicator (Qsonica), followed by a 30-minute incubation at 37°C 
repeated for 24 hours. This was equivalent to one round and a total of 6 rounds was completed on each sample. 
Proteinase K (PK) digestion and western blot were performed as described below. PMCA scores were calculated as 
previously described
48
. Briefly, PMCA scores were calculated based on the round that the samples first appeared, 
and a detection threshold based on the 99.9% confidence interval for designating NBH samples as negative was 
calculated from the mean PMCA score of 73 NBH samples using Student’s t-table. 
PK digestion and western blots 
A stock solution of PK was made using 500 µg/mL of proteinase K (Roche) with a 1:10 dilution of 0.5 M 
EDTA in 1X PBS. The PK stock solution was added to western blot samples at a 1:10 dilution for a final 
concentration of 50 µg/mL. PMCA samples were incubated at 37°C for 30 minutes with a 10-minute deactivation 
step at 95°C. Samples were stored at -20°C before running on western blot. Before starting western blots, samples 
were thawed on ice for 30 minutes and denatured at 95°C for 3 minutes. Proteins were electrophoretically separated 
using 12% sodium dodecyl sulfate polyacrylamide gels (Invitrogen). Proteins were then transferred to a 
polyvinylidene difluoride membrane (Millipore). Membranes were blocked using 5% non-fat dry milk for 1 hour. 
Membranes were washed 2X for 10 minutes each using 1X PBS with 0.2% Tween. Membranes were incubated with 
horseradish peroxidase-conjugated BAR-224 (SPI Bio) anti-PrP
C
 antibody diluted 1:20,000 overnight at 4°C. 
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Membranes were washed again 6X for 10 minutes each, and incubated with enhanced chemiluminescent substrate 
(Millipore) for 5 minutes. Membranes were photographed using an ImageQuant LAS 4000 (GE).  
Immunohistochemistry 
 Brains from prion-infected mice from the first terminal study were sent to Colorado State University’s 
Veterinary Diagnostic Laboratory for paraffin embedding and GFAP staining. The blank slides received from CSU’s 
VDL were then stained for PrP
Res
 using the following protocol. Slides were incubated at 53°C for 30 minutes before 
being immersed in xylene twice for 10 minutes. The slides were then rehydrated through an ethanol gradient 
consisting of 100%, 95% and 70% concentrations for 5 minutes each and then immersed in 88% formic acid for 10 
minutes. After washing the slides in running water for 10 minutes, the slides were processed through antigen 
retrieval while in a citrate buffer, pH of 7.4. The slides were allowed to cool before being washed twice in a 0.1% 
PBS-Triton buffer for 5 minutes on a rocker. In order to extinguish exogenous peroxidase activity of the tissues, the 
slides were immersed in a 3% hydrogen peroxide preparation in methanol for 30 minutes before undergoing another 
wash cycle. The tissues were then encircled in a DAP pen and allowed to incubate with Superblock for 30 minutes. 
The excess block was tapped off each slide and the slides incubated overnight in 4°C with D18 antibody at a 1:1000 
dilution. The next morning the slides were washed and incubated with a biotinylated anti-human Ig (1:1000) for 1 
hour at room temperature. They were then washed and incubated with an avidin-biotin complex for 30 minutes at 
room temperature. After 3 wash cycles, the slides were incubated with DAB reagent for 5 minutes in order to 
develop the staining. The slides were then briefly washed and counterstained in hematoxylin for 5 minutes, and then 
immersed in water for 10 minutes to deactivate the hematoxylin.  To complete the staining process the slides were 
dehydrated through the alcohol gradient and xylene before being mounted with a coverslip. All slides with either 
GFAP or PrP
Res
 staining were viewed by a lab member who was blinded to the LSPCs treatment groups 
ELISA for Total IgG Levels 
 Serum samples from terminally ill mice were collected by heart stick after euthanasia. Samples were stored 
at -20°C until assay was performed. 1 µg of RVG-9r was coated into 96-well Elisa plates (Nunc) using 
carbonate/bicarbonate buffer (Sigma) with 100 µL in each well. The plates incubated overnight at 4°C. Plates were 
washed 2X with 300 µL of Elisa wash buffer (1X PBS + 0.05% Tween). All wells were blocked with 100 µL 
SuperBlock (ThermoFisher) at room temperature for two hours. Plates were washed 2X with 300 µL of Elisa wash 
buffer. Plated 50 µL of the following serum dilutions from LSPCs treated mice: 1:50, 1:100, 1:250, 1:500, 1:1000, 
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and 1:2000. Serum incubated overnight at 4°C. All wells were washed 4X with 300 µL of Elisa wash buffer. A 
1:5000 dilution of an anti-mouse IgG horseradish peroxidase secondary antibody (Cell signaling) in SuperBlock was 
added to each well for a total volume of 100 µL per well and incubated at room temperature for two hours. All wells 
were washed with 300 µL of Elisa wash buffer. 100 µL of TMB substrate (Thermo) was added to each well and 
allowed to incubate until a deep blue color change developed. To stop the reaction, 100 µL of a stop solution (0.5 M 
H2SO4 in 1X PBS) was added to each well. Photometric analysis was performed at 450 nm using a Multiskan 
Spectrum plate reader (Thermo).  
Statistical Analysis 
 Statistical analyses were performed using GraphPad Prism and Excel. SD error bars are used to show the 
variability between technical replicates of individual treated mice. When mice are grouped together, SEM is used to 
show how closely the mean of the treated mice represents the population mean of all treated mice. 
 
Results 
Repetitive LSPCs treatments do not extend the survival times of prion-infected mice 
 FVB and CD1 mice were intraperitoneally inoculated with 0.1% RML-5 prions to assess whether repetitive 
LSPCs treatments affect survival times in prion-infected mice. Each treatment and control group contains between 
three and five mice. Mice were inoculated intraperitoneally with a lower dose of prions to mimic a more natural 
prion infection.  
 The 1
st
 terminal study involved FVB mice with the treatment groups listed in Table 4.1. The LSPCs 
treatment groups for the 1
st
 terminal study were treated every two weeks, starting at 119 days post-inoculation (dpi) 
and ending at 231 dpi (Table 4.2).  Most of the treated mice received the LSPCs intravenously (IV), but a small 
subset of mice received the LSPCs intranasally (IN). Half of the mice in the 1
st
 terminal study received seven LSPCs 




 treatments occurred after a significant number of mice were euthanized for clinical 
signs. Survival times of all treated mice were compared to the infected, untreated group. There was a perceived 
difference in development of clinical signs between male and female infected, untreated mice but the survival times 
calculated for each gender were not statistically significant (Figure 4.1A). The only significant difference in survival 
times observed in the 1
st
 terminal study was the infected, IV and IN group (Figure 4.1C). The IV and IN group, 
treated both intravenously and intranasally, were euthanized earlier than the infected, untreated group due to clinical 
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signs. The other treatment groups had no significant differences compared to the untreated group (Figure 4.1B and 




 LSPCs treatments (Table 
4.2 and Figure 4.1C). 
 The 2
nd
 terminal study involved prion-infected CD1 mice that were treated every 3-5 weeks for a total of 
four treatments (Table 4.4). Table 4.3 lists the groups of the CD1 treatment study. There was a significant difference 
between prion-infected, untreated CD1 male and female mice (Figure 4.2A). Therefore, survival times of the male 
and female treated groups were analyzed separately. A couple of the male treated mice died of intercurrent death and 
were thus excluded from analysis. Those deaths resulted in only two male mice per each treated group. There was no 
statistical difference between any of the male treated groups, although more numbers are needed to make any 
definite conclusions (Figure 4.2C). None of the female-treated groups had a statistical difference compared to the 









Infected, 1578 + 1672
Infected, Both IV and IN
Infected, IN














8 Treatments 217 1,2
9 Treatments 231 1,2
Table 4.2. Number of treatments and DPI treated 
in 1
st
 terminal study 
1
 Most mice euthanized by these treatments 
2















Table 4.3. Treatment groups of the 
2
nd
 terminal study 
Table 4.4. Number of treatments and DPI treated 
in 2
nd








Figure 4.1. Survival curves of LSPCs-treated FVB mice in 1
st
 terminal study. 
FVB mice were intraperitoneally infected with RML-5 prions and treated with LSPCs every two weeks starting 
half way through disease progression. A) Male and female prion-infected, untreated mice did not have 
significantly different survival times. B) The LSPCs-treated groups 1578, 1672, and 1578+1672 did not have 
statistically significant survival times compared to the infected, untreated group. C) The survival times of the 
LSPCs-treated groups infected, IN and uninfected, treated group were not different than the infected, untreated 
control. The infected, IV and IN did have significantly different survival times compared to the infected, 
untreated control in that the IV and IN group had shorter survival periods compared to control. * p<0.05. Log-










































































































LSPCs treatment causes an increase in activated astrocytes in treated mice compared to uninfected, untreated 
mice 
 Western blot analysis using the anti-PrP
C
 antibody BAR-224 conjugated to horseradish peroxidase and 
immunohistochemistry (IHC) using an anti-glial fibrillary acidic protein (GFAP) antibody were performed to 
analyze prion pathology within the brains of untreated and treated mice either uninfected or infected. 




 terminal study shows that all mice had prions in their brains at time 
of clinical disease, while uninfected mice did not (Figure 4.3A and B). IHC analysis reveals that all prion-infected 
mice, whether untreated or treated, have typical prion neuropathology, such as prion accumulation, vacuolation, and 
presence of reactive astrocytes by GFAP staining in the cerebellum and hippocampus (Figure 4.4 and 4.5). 
Surprisingly, the uninfected, treated group also had the presence of reactive astrocytes in both the cerebellum and  
Figure 4.2. Survival curves of LSPCs-treated CD1 mice in 2
nd
 terminal study. 
CD1 mice were intraperitoneally infected with RML-5 prions and treated every three to five weeks with LSPCs 
starting half way through disease progression. A) Female CD1 prion-infected mice had shorter survival times 
compared to their male counterparts.. B) Female mice in LSPCs-treated groups 1578, 1672, and 1578+1672 
compared did not have significantly different survival times compared to the female infected, untreated control. 
C) Male CD1 mice in LSPCs-treated groups 1578, 1672, and 1578+1672 did not have significantly different 
survival times compared to the male infected, untreated control. Multiple male mice were excluded from analysis 


















































































































the hippocampus compared to the age-matched uninfected, untreated group (Figure 4.5B). The uninfected, treated 
group did not have any prion accumulation as seen by both the western blot (Figure 4.3A) and IHC results (Figure 
4.4B). Therefore, the only difference between the uninfected, untreated and the uninfected, treated group was the 
repetitive LPSCs treatments.  
Repetitive LSPCs treatments result in a rescue of behavioral changes caused by prion infection 




 terminal studies were subjected to behavioral testing to determine if LSPCs 
treatment saves early behavioral deficits seen in prion-infected mice. Behavioral testing started one week before the 
LSPCs treatment and ended when all mice were euthanized. Both burrowing and nesting behavioral tests were 
chosen to assess behavioral deficits.  
 Since male and female mice had a difference in survival times in the 2
nd
 terminal study, the behavior of 
male mice was compared to female mice to assess if the behavior was different between the genders. No difference 
Figure 4.3. Analyzing PrP
Res
 deposition in prion-infected mice of the LSPCs terminal studies using western 
blot. 
A) All mice in the 1
st
 terminal study that were infected with RML-5 prions had PrP
Res
 deposition within their 
brains at terminal disease, regardless of treatment group. No difference in levels of PrPRes were observed 
between untreated and treated mice. B) All mice in the 2
nd
 terminal study that were infected with RML-5 prions 
had PrP
Res
 deposition in their brains at terminal disease, regardless of treatment groups. Again, no difference was 
observed in the amount of PrP
Res





Figure 4.4. Analysis of PrP
Res
 deposition in the brains of mice from the 1
st
 LSPCs treatment terminal study. 























Figure 4.5. Analysis of activated astrocytes using GFAP immunostain in the brains of mice from the 1
st
 LSPCs treatment terminal study. 






















	   
Figure 4.6. Burrowing rates of LSPCs-treated mice from the 1
st
 terminal study. 
A) The male and female untreated and treated groups were not statistically different from each other so male and 
female mice from each group were pooled and analyzed together. B) Burrowing rates of infected, 1578 treated 
mice were higher than the infected, untreated group at 141 dpi but not any other time point. C) Burrowing rates 
of infected, 1672 treated mice were lower than the infected, untreated group at most dpi. D) Burrowing rate of 
the infected, 1578+1672 treated mice were higher at 141 and 169 dpi compared to the infected, untreated control. 
The burrowing rates of the 1578+1672 mice are equal to those of the uninfected controls. E) Burrowing rates of 
infected, IV and IN are not any different than the infected, untreated group. F) Four out of the five mice in the 
infected, 1578+1672 treatment group have higher burrowing scores at 141 dpi than the infected, untreated 
control, although it’s not a statistically significant difference. No other treatment group shows an increase in 
burrowing at 141 dpi. G) At 169 dpi, both the uninfected control and the 1578+1672 treatment group have 
significantly higher burrowing rates than the infected, untreated control. H) At clinical disease stage (210 dpi), 
none of the LSPCs treatment groups are significantly different than the infected, untreated control. Error bars 













































































































































































































































































































































































































































































































































	   
Figure 4.7. Nesting scores of LSPCs-treated mice from the 1
st
 terminal study. 
A) The male and female untreated and treated mice did not have different nesting scores, so again the male and 
female mice of each treatment group were pooled for further analysis. B) The infected, 1578 treatment group had 
lower nesting scores than the infected, untreated control. C) Higher nesting scores at 141, 169, and 180 dpi were 
observed in mice treated with 1672 LSPCs compared to untreated control, so much so that the scores are similar 
to uninfected controls. D) The 1578+1672 treatment group performed equally as well as the uninfected control at 
most dpi and had higher nesting scores at all dpi compared to the infected, untreated control. E) The IV and IN 
treatment group had higher nesting scores at 169 dpi but no other dpi than the infected, untreated control. F) The 
1672 and 1578+1672 treatment groups both had higher nesting scores than the infected, untreated group at 141 
dpi, although not statistically significant. G) At 169 dpi, the 1672 treatment group had significantly higher 
nesting scores than the infected, untreated control. The 1578+1672 group also had a higher average nesting score 
at this dpi but it was not statistically significant. H) At clinical disease stage (210 dpi) none of the treated mice 












































































































































































































































































































































































































































































in either untreated or treated male and female mice was observed for either burrowing or nesting tests for the 1
st
 
terminal study (Figure 4.6A and 4.7A). Therefore, all treated mice were compared to the infected, untreated group. 
In the 1
st
 terminal study, both the uninfected, treated group and the infected, 1578+1672 group have significantly 
higher average rate of burrowing compared to the infected, untreated group at 169 dpi (Figure 4.6D and G). The 
1578+1672 group also performs higher at 141 dpi, although no statistical difference is seen (Figure 4.6F). While 
some mice in the other treated groups do have a higher average rate of burrowing than the untreated group, there is 
no other statistical difference between the infected, treated and untreated groups for burrowing (Figure 4.6B, C, E, 
and H).  
 Both the 1672 group and the 1578+1672 group perform as well as the uninfected treatment group in the 
nesting test, but only the 1672 group is significantly different from infected, untreated controls (Figure 4.7C, D, and 
G). The 1672 group has a higher average nesting score compared to the infected, untreated group at both 141 (Figure 
4.7F) and 169 dpi, but is only statistically significant at 169 dpi (Figure 4.7G). No other groups perform above the 
infected, untreated group in nesting (Figure 4.7B, E, and H). There is no difference in performance in any treated 
mice in either of the behavior tests compared to infected, untreated group at 210 dpi in the 1
st
 terminal study (Figure 
4.6H and 4.7H). 
 There is no difference in male versus female performance in the behavior tests of the 2
nd
 terminal study, so 
all treated mice were compared to the infected, untreated group (Figure 4.8A and 4.9A). No statistical difference is 
observed in the performance of treated mice in either the burrowing or nesting tests compared to the infected, 
untreated group in the 2
nd
 terminal study (Figure 4.8 and 4.9); however, the 1672 treated group has a trend in the 
burrowing test. The 1672 treated group has a higher average rate of burrowing compared to the infected, untreated 
group at 141 and 169 dpi (Figure 4.8C and G), although, this increase in performance is not statistically significant. 
No differences/trends or statistical significance were observed in any other treated groups in the nesting test in the 
2
nd
 terminal study (Figure 4.9). 
Total IgG levels against RVG-9r are elevated in LSPCs-treated prion-infected terminal mice 
 A surprising result from the 1
st
 terminal study was the death of the uninfected, treated controls (Figure 
4.1C) as the LSPCs treatment was thought to be relatively non-toxic. Observations upon necropsy, that included 
enlarged and darker spleens and severe ‘clotting’ of the blood, pointed to immune activation as being the cause of  
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Figure 4.8. Burrowing rates of LSPCs-treated mice from the 2
nd
 terminal study. 
A) While the survival times of male and female CD1 mice infected with RML-5 prions were found to be 
statistically different, the behavior of the genders was not statistically significant in untreated or treated mice. B) 
The 1578 treatment group did not have improved burrowing scores compared to the infected, untreated control. 
C) The burrowing rate of the 1672 treated mice was improved at 141 and 169 dpi compared to the untreated 
control. D) The burrowing rate of the 1578+1672 was not different from the infected, untreated control at most 
dpi. E) There was no difference in burrowing rates of the IN treatment group to the infected, untreated group. F) 
At 141 dpi, none of the treated mice had significantly different burrowing rates than the infected, untreated 
control. G) None of the treated mice had significantly different burrowing rates than the infected, untreated 
control at 169 dpi, although the 1672 treatment group has a slight improvement in burrowing rates at this time. 
H) At clinical disease stage (210 dpi), the treated mice have the same burrowing rates as the untreated control. 






















































































































































































































































































































































































































































































	   
Figure 4.9. Nesting scores of LSPCs-treated mice from the 2
nd
 terminal study. 
A) Comparison of nesting scores of CD1 male and female mice show no difference in either untreated or treated 
mice, so further analysis of treatment groups pools both genders. B) The 1578 treatment group does not perform 
any differently in the nesting test than the infected, untreated control. C) The 1672 treatment group is not 
significantly different than the infected, untreated control at any dpi. D) Nesting scores of the 1578+1672 
treatment group and the infected, untreated are not any different at any dpi. E) The IN treatment does not have 
significantly different nesting scores compared to the untreated control. F) At 141 dpi, none of the treated mice 
have different nesting scores compared to the infected, untreated control. G) At 169 dpi, none of the treated mice 
have different nesting scores compared to the untreated control. H) Nesting scores of treated mice at clinical 
disease stage (210 dpi) are not significantly different than the infected, untreated control. Error bars indicate 






























































































































































































































































































































































































































death of these animals. Therefore, to determine the extent of this immune response, total IgG levels against RVG-9r 
were measured using an indirect ELISA. Serum samples from clinically-ill mice were collected upon euthanasia. All 
treated mice were compared to the total IgG levels of infected, untreated mice. 
 Both the uninfected, treated group and the IV and IN groups in the 1
st
 terminal study had elevated levels of 
IgG against RVG-9r (Figure 4.10A). The 1578 group and the 1578+1672 group in the 2
nd
 terminal study also had  
elevated IgG levels against RVG-9r (Figure 4.10B). None of the other treated groups were statistically different, 
although, individual mice in the other groups had elevated levels of IgG compared to the infected, untreated group. 
LSPCs treatment results in an increase in prion load levels in the brain 
To determine why survival times are not affect but behavioral scores are of LSPCs-treated mice, PrP
Res
 
levels were assessed in the brains and spleens of treated mice. FVB mice were inoculated intraperitoneally 
	 
Figure 4.10. Total IgG levels against RVG-9r in LSPCs-treated terminal mice. 
A) Total IgG levels against RVG-9r in LSPCs-treated groups were elevated in the uninfected, treated group and 
the IV and IN treatment group of the 1
st
 terminal study. B) Total IgG levels against RVG-9r in the LSPCs-treated 
groups were elevated in the 1578 treatment group and the 1578+1672 treatment group of the 2
nd
 terminal study. 



































































































































































with 0.1% RML-5 prions and treated every two weeks at early time points in disease course. Early time points were 
used based on the observation that spleen prion loads increase until the 3
rd
 month after inoculation, where they peak 
and remain steady. At each time point (one week after LSPCs treatment), brains and spleens were collected from 
one untreated and one LSPCs-treated mouse after euthanasia. Mice were treated repetitively to determine if multiple 
siRNA treatments had a bigger effect on prion loads. The treated mouse at the ‘1 treatment’ time point only received 
one LSPCs treatment, whereas the treated mouse euthanized at the ‘6 treatment’ time point received a total of six 
LSPCs treatments. Table 4.5 lists the treatment and euthanasia dpi of early time point mice. The treatment protocol 
was not repeated. PMCA was performed to determine prion loads in the collected tissues by calculating a PMCA 
score based on when the tissue first amplified in the assay. Figure 4.11A shows a representative western blot of 
PrP
Res
 amplification in the brain using PMCA. After every LSPCs treatment, prion loads are increased in the brain in 
treated mice compared to the untreated control (Figure 4.11B and D). Spleen prion loads at each time point are 
statistically significant from the untreated controls, but no trend is observed as to an increase or decrease in levels 











LSPCs treatments in the spleen (Figure 4.11C). The prion levels of the untreated control at the 6
th
 LSPCs treatment 




Table 4.5. Repetitive LSPCs treatments of early time point mice indicating the dpi 
that mice were treated and euthanized 
DPI Treated DPI Euthanized
1 Treatment 75 89
2 Treatment 89 103
3 Treatment 103 110
4 Treatment 117 125
5 Treatment 132 139






Figure 4.11. PMCA amplification of PrP
Res
 in LSPCs-treated early time point mice. 
A) Representative western blot of PMCA amplified PrP
Res
 in the brain. B) At each of the time points (1 siRNA 
treatment or 6 siRNA treatments), there was an increase in levels of PrP
Res
 in the brain of all treated mice 
compared to the untreated control. C) PrP
Res
 levels in the spleens of treated mice are variable, with one and four 
siRNA treatments resulting in a decrease of PrP
Res
 levels and an increase in PrP
Res
 levels at all other time points. 
D) Cumulative PMCA scores of all untreated mice compared to all treated mice revealed a significant increase in 
PrP
Res
 levels in the brains of treated mice. E) Cumulative PMCA scores of all untreated mice compared to all 
treated mice did not reveal a difference in PrP
Res
 levels in the spleen. Error bars indicate SD for panels B and C 
and min to max for panels D and E. * p<0.05. *** p<0.001. **** p<0.0001. Two-way ANOVA with Sidak’s 
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LSPCs treatment increases total IgG levels against RVG-9r after the 3
rd
 repetitive treatment in early time point 
mice 
 Since total IgG levels were elevated in several treatment groups in the terminal studies, a question arose as 
to how many LSPCs treatments are needed to induce an IgG response towards RVG-9r. Therefore, early time point 
mice were euthanized one week after LSPCs treatment at which point serum was collected from each mouse. At 
each time point one untreated and one treated mouse were euthanized. The treated mouse euthanized at ‘one 
treatment received only one siRNA treatment, whereas the treated mouse euthanized at ‘six treatments’ received a 
total of six treatments given every two weeks. An ELISA was performed to determine total IgG levels compared to 





treatments (Figure 4.12). The decrease in IgG compared to the control could be due to either IgG being sequestered 
in immune complexes at these time points, or these two treated mice have lower IgG levels overall compared to the 
untreated mouse. IgG levels against RVG-9r are increased starting at the 3
rd
 LSPCs treatment and continue to 
elevate at subsequent treatments after that (Figure 4.12), indicating that three LSPCs treatments result in an overall 
increase in IgG against RVG-9r. 
 
  
Figure 4.12. Total IgG levels against RVG-9r in the brains of early time point mice repeatedly treated with 
LSPCs. 
Total IgG levels against RVG-9r increase after the third LSPCs treatment and keep increasing after subsequent 
treatments compared to untreated controls. Error bars indicate SD. ** p<0.01. **** p<0.0001. Two-way 








































































 Many compounds have been studied for their anti-prion effects, even before scientists understood the 
molecular basis of prion disease. These compounds are effective at decreasing prions in vitro but few have had 
success in vivo. Reasons for lack of in vivo efficacy include toxicity and an inability to cross the blood-brain 
barrier
41,49-51
. The anti-prion compounds that have worked in vivo extended survival times of prion-infected animals 
but did not alleviate clinical signs caused by prion neuropathology
36,39,52,53
. The one therapeutic that did both was 
RNA interference (RNAi) targeted towards PrP
C
. A single injection of short hairpin RNA resulted in an extension of 
survival times and a reversal of prion neuropathology
54
. Evidence supporting PrP
C
 as a target for therapeutics, 
instead of PrP
Res
, was shown by the lack of negative phenotype in PrP-null mice
32,33
. The numerous functional 
studies since then indicate that there is a redundant pathway in adult animals that compensates for the functional loss 
of PrP
C





, than their wild-type counterparts, but otherwise, have a normal phenotype. Several studies in the last 
decade have further proven that PrP
C
 might be a better therapeutic target than PrP
Res
. These studies have shown that 
by decreasing PrP
C
, the amount of PrP
Res
 declines, survival times increase, and neuropathology decreases
35,43,45,57
. 
Other advantages of targeting PrP
C
 include independence of scrapie strain type and host cell type.  
 Here we have attempted to alleviate prion disease through recurring treatments of our LSPC
45
 therapeutic 
that utilizes small interfering RNA (siRNA) targeted towards PrP
C
. We have previously shown that LSPCs can 
decrease the amount of neuronal PrP
C
 protein and mRNA levels between 15 and 21 days in wild-type mice 
(unpublished results). In this report, we wanted to assess not only the impact of LSPCs treatment on survival times 
but also on behavioral outcomes of prion-infected mice. We chose to use an intraperitoneal route of inoculation with  
a lower dose of prions to simulate a more natural infection. We also opted to start our LSPCs therapeutic midway 
through the prion disease course to determine whether the treatment could reverse the early neuronal changes seen in 
prion-infected mice. Unfortunately, repeated LSPCs treatments either every 2 or 3-5 weeks did not extend the 
survival times of prion-infected mice when started midway through the prion disease course. Survival periods 
decreased in mice that were treated every two weeks both intravenously (IV) and intranasally (IN). IN groups were 
incorporated into our design study to assess whether a different administration route, other than IV would alter 
clinical disease outcomes in LSPCs treated mice. Multiple reports have shown that IN administration of siRNA is 




Our behavior test results indicate that, while the LSPCs treatments may not be affecting survival times in 
prion-infected mice, they are improving behavioral scores in LSPCs-treated mice are certain days post inoculation. 
Several groups of treated mice had improved behavioral scores in both burrowing and nesting at 141 and 169 dpi. 
This improvement was not sustained until clinical disease, but it does raise the possibility that the LSPCs treatment 
could still be a potential therapeutic. The results of the behavior study of the 2
nd
 terminal study, for the most part, 
did not corroborate the results seen with behavior tests in the 1
st
 terminal study. This difference in behavior is most 
likely due to the use of two different wild-type mouse strains. The CD1 mice tend to have better behavioral scores in 
burrowing and nesting tests compared to the FVB mice, and are much more consistent with their behavior across 
time. The CD1 mice also have better performance in the behavioral tests right up until clinical disease stage. FVB 
mice are perhaps more useful because of the subtle behavioral variations, indicative of prion infection, that are more 
noticeable in this strain of mice than the CD1 mice. 
 The most obvious reason that the LSPCs treatment did not affect survival times is that the treatment was 
not given at the proper time or dose. While ineffective dosing might be an issue with the LSPCs treatment in this 
study, the amount of siRNA should be carefully increased as it is at the upper limit of the concentration that can be 
used in vivo safely
60
. Therefore, any dosing issues should be addressed to maximize the benefit of LSPCs treatment 
and minimize any toxic effects. It is not known at what time a prion therapeutic would be more efficient, early 
stages before clinical signs or after clinical stage manifestation. Early behavioral changes indicate that initial 
neuronal degeneration of prion disease occurs about halfway through disease course, which is why our study started 
treatment at this stage. This study is the first to assess multiple siRNA treatments for prion disease, so it is not 
known how effective siRNA is at different stages of disease. Recent work in our laboratory indicates that the LSPCs 
treatment affects clinical stages of disease as it extended the survival of transgenic mice that overexpress mouse 
PrP
C
 by 20% when administered three times close to the clinical disease stage (unpublished results). The results of 
that study do not necessarily contradict the results of this study, as it was performed in a different mouse model. It is 
possible that either the dosing regimen or the overexpression of mouse PrP
C
 affected the outcome of survival with 
LSPCs treatment. It has been proposed that a loss-of-function phenotype for PrP
C
 is responsible for prion 
neuropathology, instead of the accumulation of PrP
Res
 within the brain. Several studies have noted that 
neuropathology still predominates even with little to no detectable levels of PrP
Res44,61,62
. If the loss-of-function 
hypothesis is accurate, then the loss of PrP
C
 in wild-type mice would negate any positive effects caused by 
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decreasing the amount of PrP
Res
 in the brain. The overexpressing mice might be able to compensate for this loss-of-
function phenotype with the increased levels of PrP
C
.   
 The deaths of the uninfected control group in the 1
st
 terminal study were unexpected. Three out of the four 
mice in this group died or was euthanized one hour after LSPCs treatment due to severe morbidity. Two of the 
animals died after the 8
th
 treatment, and one was euthanized after the 9
th
 LSPCs treatment. The unaffected mouse in 
this group did not receive the 7
th
 treatment due to an inability to inject the LSPCs. This alteration in the treatment 
regimen probably resulted in the survival of this mouse upon subsequent treatments. Upon necropsy of the mice that 
died/were euthanized, it was noted that the spleens of these mice were larger than normal. Also, an attempt to collect 
serum from the mouse that was euthanized failed due to excessive clotting of the blood immediately after death. 
These observations indicate that these mice died of an acute Type III hypersensitivity. Therefore, ELISAs were 
performed to characterize the immune response in LSPCs-treated mice. Total IgG levels against RVG-9r were 
increased in several groups of treated mice, indicating that they are having an immune response to the peptide. 
Serum was collected at the time of euthanasia, which may be why more mice do not show an increase in IgG levels. 
The optimal time to collect serum for antibody measurement is seven to ten days after antigen exposure. IgG levels 
of the terminal mice might have already decreased by the time serum was collected since most mice were not 
euthanized seven to ten days after LSPC treatment. The presence of activated astrocytes in the uninfected, treated 
group points to an inflammatory response that could be caused by immune activation. Prion infection is known to 
cause activated astrocytes, and indeed infected, untreated mice have elevated levels of activated astrocytes compared 
to the uninfected, untreated control. Surprisingly, the uninfected, treated control mice had comparable levels of 
activated astrocytes to the prion-infected controls. 
 At this point, it is hard to determine the exact cause of the immune and inflammatory responses. The total 
IgG data indicates that there is, at the very minimum, an immune response to RVG-9r. The immune response 
towards the peptide is not too surprising as RVG-9r is known to activate levels of IL-6 when complexed with 
siRNA. RVG-9r is also a component of the rabies virus, so it could be recognized as an antigen by the immune 
system. However, native RVG alone does not stimulate the immune system, indicating that the addition of the nine 
arginine residues on the COOH-terminus of RVG might make the peptide more immunogenic
63
. Thus, removing the 
arginine residues and packaging the siRNA within the liposome might result in a reduction of the immune response. 
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Using a different targeting peptide, such as transferrin or a neuronal specific antibody, might also decrease the 
immune response to the LSPCs.  
The RVG-9r might not be the only component generating the immune activation. Liposomes and siRNA by 
themselves do not elicit an immune reaction, but once complexed together they can increase cytokine production 
such as TNFa and IFNa
60,64
. The prevailing hypothesis as to why these components only elicit an immune response 
when complexed together is that they resemble viral particles with a membrane and nucleic acid. Cationic 
liposome/siRNA complexes are also known to bind to serum proteins, which generates large immune complexes 
that can stimulate the immune system. SiRNA is also known to activate Toll-like receptors (TLRs) in the endosomal 
pathway and increase production of cytokines
64-66
. Thus, all three components of the LSPCs treatment, when used 
together, could be involved in immune activation. Modifications of the LSPCs can decrease the immune response to 
the treatment, but there will probably always be a low level of activation by the immune system towards LSPCs. 
Alterations include using modified siRNA with locked nucleic acids, 2’-O-methyl, or 2’-fluro modifications. 
Variations to siRNA reduce the activation of TLRs but may reduce silencing activity depending on the location and 
number of modifications
65,67,68
. Therefore, the benefit of the modified siRNA should be measured carefully to its 
optimal silencing activity. As noted above, different targeting peptides that are less immunogenic can be utilized 
instead of RVG-9r. Liposome modifications include adding PEGylated groups to the liposomes, which make them 
less available to bind to serum proteins and generate immune complexes
69
. To address some of these concerns, we 
have designed other liposomal delivery vehicles that package the siRNA within the liposome and use PEGylated 
lipid groups (PALETS)
70
. Thus, these PALETS, with a few modifications to increase RNAi activity, may prove to 
be a useful alternative to LSPCs treatment. 
 Nicotinic acetylcholine receptors (nAchRs) are extremely abundant in the central nervous system and are 
used to control the release of neurotransmitters at the synapse, such as glutamate and acetylcholine. RVG-9r 
specifically binds to the a7 subunit of nAchRs to mediate its entry into neuronal cells
71
. The activation of the a7 
subunit of nAchRs by RVG-9r must be taken into consideration as the activation has been implicated in multiple 
cellular processes. Activation of this subunit results in a decrease in inflammation of neuronal cells
72
. This may be 
beneficial for LSPCs treatment, as not only would the binding of RVG-9r to neuronal cells deliver the PrP
C
 siRNA 
to the brain, but it could also decrease inflammation caused by either the treatment or prion infection. Activation of 




 levels. Some drugs that bind to the a7 subunit can cause neuronal death, autonomic dysfunction, and seizures 




. Therefore, while activation of nAchRs can be beneficial, too much 
can lead to the exact problems that the treatment is trying to solve. The increase in cytosolic Ca
2+
 may not be an 
issue in the prion disease model with LSPCs treatment, as PrP
C
 is known to modulate cytosolic Ca
2+
 levels. PrP-null 
cells have been shown to have a decrease in cytosolic Ca
2+
 levels due to an increased removal of Ca
2+
 from the 
cells
22-24
. By decreasing PrP
C
, the treatment could affect Ca
2+
 stores within the cell. However, if RVG-9r is over-
activating nAchRs, then these Ca
2+




Activation of the a7 subunit of nAchRs also increases cognition and memory retention
74,75
. The behavioral 
test results observed in this study may be reflective of either a benefit of the LSPCs treatment or the activation of 
nAchRs. The increase in behavioral scores is most likely due to a benefit from the treatment rather than activation of 
nAchRs because the behavior of LSPCs-treated mice is only improved at certain time points. If the increased 
performance was due to the activation of nAchRs, then the behavior should be enhanced at all time points. Also, 
burrowing and nesting does not rely on memory or cognition skills. So, if these two processes are increased in 
treated mice it would not necessarily be measured using these behavioral tests. There is limited statistical 
significance in the behavioral studies, but an argument can be made that there is biological significance in the 
behavior of some of the LSPCs-treated groups. Any treatment group that performs as well or better than the 
uninfected, untreated group may not be statistically significant, but is biologically significant in that behavior was 
rescued to non-prion-infected levels. 
 The last point that will be made involves the observation from the pharmacodynamics study that PrP
C
 
protein and mRNA levels can increase substantially with LSPCs treatment (unpublished results). PrP
C
 levels can 
increase due to an immune reaction through the activation of TLRs
30,76
. The immune response observed in this study 
could be the cause of the increase in PrP
C
 protein levels after treatment. PrP
C
 levels could also be tightly regulated at 
either the transcriptional or translational level leading to an increase in PrP
C
 levels after LSPCs treatment. However, 
it is also possible that the activation of nAchRs leads to an increase in PrP
C
 levels. Activation of nAchRs by a-
bungarotoxin leads to an increase in the transcription of several genes, including the proto-oncogene c-fos and 
actin
77
. If the activation of the nAchRs is causing an increase in PrP
C
 levels, then another targeting peptide can be 
chosen to alleviate this problem. 
	 150	
 Although the results of the present study were somewhat disappointing, all is not lost. As noted above, 
multiple modifications can be utilized to try to alleviate some of the effects seen due to the recurring LSPCs 
treatments.  If it is determined that RNAi is not the best therapy for prion diseases, the LSPCs and the PALETS 
(without the siRNA) still represent delivery vehicles capable of delivering cargo past the blood-brain barrier. 
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 RNA interference, such as small interfering RNA (siRNA), has been proposed as a possible therapeutic for 
protein misfolding diseases. This technology has the potential to reduce the amount of misfolded protein that 
accumulates in the brains of affected individuals. However, crossing the blood-brain barrier remains the main 
challenge for delivering any small molecule drug to the central nervous system (CNS). Liposomes offer an attractive 
option as a small molecule delivery system. These liposomal delivery systems can protect the siRNA from serum 
nucleases and can be targeted directly to the brain using targeting peptides. We have previously generated liposome-
siRNA-peptide complexes (LSPCs) that employ the RVG-9r peptide from the rabies virus glycoprotein to target 
PrP
C
 siRNA to nicotinic acetylcholine receptors in the brain. PrP
C
, cellular prion protein, has been implicated to 
misfold into an infectious isomer, PrP
Res
, during prion infection. In half of the mice treated with LSPCs, the PrP
C
 
siRNA is delivered to the brain and decreases surface neuronal PrP
C
 by 40-50%. There was no decrease in PrP
C
 
mRNA levels in the brain when assayed four days after treatment. In the other half of mice, LSPCs were cleared by 
the kidneys within hours after injection. To try to improve the biodistribution of PrP
C
 siRNA in the brain, we 
designed two other delivery vehicles, cationic (DOTAP) and anionic (DSPE) PALETS, which can encapsulate the 
siRNA within the liposome and covalently modify the RVG-9r peptide to the lipid groups. To achieve encapsulation 
of the anionic siRNA into anionic DSPE PALETS, we utilized the cation protamine sulfate. Protamine sulfate 
results in encapsulation of 80-90% of the PrP
C
 siRNA in DSPE PALETS. At least one PALETS-treated mouse had a 
decrease in neuronal surface PrP
C
 out of the three treated mice for each PALETS formulation four days after 
injection, although grouped there was no difference between the three treated and the untreated mice. DOTAP 
PALETS also decreased the number of PrP
C
-positive cells within the brain. PrP
C
 was also measured in the kidneys 
of all treated mice to assess any off-target effects and clearance kinetics. Both DOTAP LSPCs and DSPE PALETS 
had a significant reduction in the amount of surface PrP
C
 in the kidney, indicating that these two delivery systems 
are cleared through the kidneys four days after treatment. DOTAP PALETS do not result in a decrease in surface 
PrP
C
 in the kidney. DOTAP LSPCs and DOTAP PALETS have a 2-fold reduction in PrP
C
 mRNA levels in the 
kidney, while DSPE PALETS have a 2-fold increase. 
 We have previously characterized the ability of the LSPCs treatment to deliver PrP
C
 siRNA to mouse 
neuroblastoma cells and to decrease the amount of surface PrP
C
 on these cells. The decrease in surface PrP
C
 lead to a 
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‘curing’ of prion-infected cells. Therefore, in chapter three, we characterized the ability of LSPCs to deliver PrP
C
 
siRNA to the CNS in two different mouse models, one on a C57Bl/6 background and the other on a CD1 
background. The control LSPCs using either scrambled LSPCs or the RVM control peptide that does not target 
nicotinic acetylcholine receptors resulted in changes in PrP
C
 protein and mRNA levels. The scrambled LSPCs 
resulted in a 14% reduction in surface PrP
C
 and a 1.5 increase in PrP
C
 mRNA. The RVM LSPCs resulted in a slight 
increase of surface PrP
C
 and a 1.5 increase in mRNA. Therefore, we normalized all the mRNA analyses by the 
increase caused by the non-specific LSPCs treatment. In the C57Bl/6 background mice, surface PrP
C
 in the brain 
was decreased at 24, 48 hours and 4 days after LSPCs treatment. Neuronal PrP
C
 mRNA levels were variable, with 
the highest mRNA levels usually occurring in the mouse with the lowest surface PrP
C
 protein levels. CD1 mice had 
a decrease in surface PrP
C
 in the brain at 4 and 15 days after LSPCs treatment but not 48 hours or 21 days after 
treatment. Again, PrP
C
 mRNA levels were variable but the same trend was observed where the mouse with the 




 protein and mRNA levels were assessed in the 
kidney for any off-target effects and toxicity issues. Since PrP
C
 protein levels are severely decreased with control 
LSPCs, no conclusions can be made regarding the decreases observed using flow cytometry. However, as stated, 
mRNA analyses in the brain and kidney were normalized to the effects of the control LSPCs to ascertain the effect 
of the PrP
C
 siRNA only. In the kidneys of C57Bl/6 and CD1 mice, PrP
C
 mRNA levels are variable with most mice 
showing a decrease in mRNA levels and a few showing an increase in mRNA levels. We hypothesize that the 
increases observed in both the brain and kidney of LSPCs-treated mice are caused by an immune reaction to the 
LSPCs, a transcriptional regulation mechanism, or both. We also assessed the ability of repetitive LSPCs treatment 
to reduce PrP
C
 protein and mRNA levels. PrP
C
 protein levels are reduced 70% and mRNA levels are reduced 3-fold 
in the brain by the third LSPCs treatment occurring every two weeks. Subsequent treatments result in an increase in 
both PrP
C
 protein and mRNA levels in the brain. 
 Prion diseases are characterized by neuronal degeneration, astrogliosis, and vacuolation within the CNS. 
These diseases affect humans, and captive and free-ranging animals. Prion diseases result when PrP
C
 misfolds into 
the infectious isomer PrP
Res
. The field of prion therapeutics has turned towards gene therapies that target PrP
C
, as 
molecules that target PrP
Res
 or the mechanism of conversion have not shown any promise in clinical trials. RNAi has 
been postulated to be a potential therapeutic of prion diseases as it can result in the decrease of misfolded protein by 
targeting the mRNA of the normal cellular protein. A single treatment of RNAi injected into the hippocampus of 
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prion-infected mice showed that not only can RNAi increase survival times by decreasing PrP
C
 but it can also 
reverse prion neuropathology. Therefore, in chapter four of this thesis, we investigated whether a repetitive PrP
C
 
siRNA therapeutic can increase the survival times of prion-infected mice when administered intravascularly or 
intranasally. Mice were treated every two to 3-5 weeks intravascularly/intranasally with LSPCs starting at 120 days 
post inoculation. These mice were also subjected to burrowing and nesting behavioral tests to determine if multiple 
LSPCs can affect behavioral outcomes. The repeated LSPCs treatments, either two or 3-5 weeks, did not alter 
survival times of prion-infected mice. The survival times of the group treated both intravascularly and intranasally 
actually decreased compared to the infected, untreated control. While survival times were not affected by multiple 
LSPCs treatment, several treated groups did perform better in the behavioral tests at 141 and 169 days post 
inoculation than the infected, untreated control. No treated mice had increased behavioral scores at time of terminal 
disease. These results show that the LSPCs treatment improved the behavioral scores for treated mice at certain time 
points. Since the LSPCs treatment resulted in an improvement in behavior, we assessed whether the treatment 
decreased the amount of PrP
Res
 in prion-infected mice, even though survival times were not affected. Surprisingly, 
LSPCs treatment results in an increase of PrP
Res
 in the brain after one to six LSPCs treatments every two weeks. We 
speculate that, even though LSPCs result in an initial decrease in PrP
C
 at certain time points, the protein actually 
increases overall, which leads to an increase of PrP
Res
. The overall increase of PrP
C
 could be due to either an 
immune reaction towards the LSPCs treatment or a transcriptional regulation mechanism of PrP
C
. Several of the 
uninfected, treated controls died shortly after LSPCs treatment of an apparent Type III hypersensitivity. Total IgG 
levels against RVG-9r were measured and found to be elevated in several of the treated groups. The increase in total 
IgG levels occurred after the third LSPCs treatment, when administered every two weeks. In this study, total IgG 
levels against RVG-9r were measured and found to be elevated but the siRNA/liposome complexes are also capable 







 In the seoncd chapter of this dissertation, we generated three liposomal delivery vehicles capable of 
crossing the blood-brain barrier. More pharmacodynamics studies are needed to determine which delivery vehicle 
results in the greatest reduction of PrP
C
. Our results at four days after treatment indicate the LSPCs vehicle is more 
effective at reducing PrP
C
. However, the addition of the PEG groups to the PALETS formulations should result in 
an increase in circulation times so the activity of the PALETS formulations should be assessed past four days after 
treatment. While the non-specific response to the LSPCs treatment confounds any flow cytometry analysis in the 
kidney, it is still important to observe PALETS behavior in the kidney at certain time points to assess clearance 
kinetics. DOTAP PALETS, at four days after treatment, showed no decrease in PrP
C
 in the kidney, indicating that 
clearance kinetics of this vehicle changed from the LSPCs. This finding could mean that more DOTAP PALETS are 
able to make it to the brain than are LSPCs. 
 In the fourth chapter of this dissertation, no difference was seen between prion-infected, untreated and 
LSPCs-treated mice. If all the LSPCs-treated mice injected intravenously are pooled together as one large treatment 
group with a difference of means of 3.6 from the untreated group, the power of this study is 0.1298. This power 
value indicates that, using the current mouse numbers, the observed effect would only be seen 12% of the time if 
this experiment was repeated. Thus, it is important to repeat the survival experiments using a larger number of mice. 
To achieve 80% power, where the data is observed 80% of the time, with a true difference of means of 3.6, and 
standard deviations of 5.74 for the untreated group and 11.42 for the treated group, 103 mice will be needed for the 
next treatment terminal study. 
 The formulations, targeting peptide, and therapeutic can all be altered if future studies determine that the 
vehicles are not optimal. If the RVG-9r peptide is causing the largest immune reaction amongst the three 
components of the vehicles then it can be replaced with another neuronal targeting peptide. Many different 
ligands/receptors have been utilized to target delivery vehicles to the central nervous system, including transferrin, 
leptin, low-density lipoprotein, brain-derived neurotrophic factor, and antibodies to neuronal receptors. We are 
currently in the process of generating camelid antibodies against PrP
C
 that have the potential to target either the 
LSPCs or the PALETS to the brain. The native form of RVG-9r, RVG, might also be a better targeting ligand as, 
alone, it does not elicit an immune response. Multiple ligands might need to be examined to determine which one 
	 158	
results in the greatest amount of PrP
C
 siRNA being delivered to the brain. The DOTAP PALETS utilized a 
carbodiimide reaction to covalently link the RVG-9r to the PEG lipids. This reaction catalyzes a covalent bond 
between an amine and a hydroxyl group. While this reaction is commonly used to link peptides to other molecules, 
its effect on the RVG-9r peptide is unknown. Therefore, it would be prudent to assess whether the activity of RVG-
9r remains intact after the reaction. Also, it might be possible to alter the RVG-9r primary structure by changing the 
cysteine residue to a serine to provide a better covalent linkage between RVG-9r and the PEG groups. The lipid 
formulations can also be adjusted to increase circulation times. Depending on toxicity issues from using liposomes, 
it may be necessary to try a different vehicle altogether. Exosomes are gaining momentum as a new delivery vehicle 
that is less immunogenic than other vehicles. Exosome vehicles are able to encapsulate siRNA and target specific 
cell types with a targeting peptide. A different therapeutic, other than siRNA, might result in a more profound 
decrease of PrP
C
. An explanation for the results of the terminal studies and the PMCA experiments is that transiently 
decreasing PrP
C
 allows time for the protein levels to rebound, which results in an increase in PrP
Res
 and no increase 
in survival times. Therefore, a more permanent decrease of PrP
C
 with either short hairpin RNA or CRISPR 
technology might affect survival times of prion-infected mice. 
 Perhaps the most important future direction is to characterize the immune response to the LSPCs. There 
will always be some immune activation towards the LSPCs, as each component is a TLR agonist, but it may be 
possible to alter the LSPCs so that the immune activation is lessened. Since each of the components of the LSPCs 
activates TLR signaling and the signaling causes cytokine and chemokine release, it would be important to measure 
cytokine/chemokine levels in naïve mice in response to repetitive LSPCs treatment. This would give a more 
complete picture as to the whole immune response towards the treatment rather than just measuring IgG levels. 
Cytokines can be measured using a multiplex bead assay. Naïve mice should be treated with each individual LSPCs 
component to assess activation due to the siRNA, peptide, or liposome. Modifications (as described above) can be 
made to any of the components if it is found that one component activates an immune response more than another 
component. Once the immune response to individual components has been measured, then naïve mice should be 
treated with the entire LSPCs complex both one time and multiple times to assess cytokine/chemokine release due to 
LSPCs treatment. 
 Another idea that developed in response to the data observed in this project was to understand the 
transcriptional control of PrP
C
. If researchers keep using PrP
C
 as a therapeutic target for prion diseases, especially 
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with gene therapies that may result in alteration of transcription, then it would be necessary to elucidate the 
mechanisms of control of PrP
C
 to optimize future therapeutics to their full potential. Otherwise, future therapeutics 
may have efficacy problems due to not getting around the transcriptional control. First, it should be determined 
whether the results seen in these studies were the result of immune activation or transcriptional regulation. The 
above immune assays should help tease that out but it would also be necessary to do an in vitro assay with a purified 
population of cells to assess mRNA levels at different time points. When we first assessed mRNA levels in vitro 
after LSPCs treatment, we only looked at one time point. Therefore, a purified population of neuronal cells (without 
any immune cells) should be treated with LSPCs and mRNA levels assessed every couple of hours to 6-12 hour 
increments. This experiment could also be done in vivo, using mice with no immune system, such as NOD SCID 
gamma mice. These mice can be treated with LSPCs to assess PrP
C
 mRNA/protein levels at different time points 
after treatment. If the same trend is seen (with PrP
C
 protein being low and PrP
C
 mRNA levels being high) with the 
above experiments then the data observed in the present study was most likely due to a regulational mechanism of 
PrP
C
. Another drug that is known to decrease PrP
C
 can be used as a control to determine if the response is due to the 
siRNA or is a general response to any drug that affects PrP
C
. If a regulational mechanism is responsible for the 
dichotomy in PrP
C
 protein and mRNA levels, then techniques such as CHIP-seq and mobility shift assays can be 
performed to elucidate the mechanism of control. 
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Figure A.1. In vivo live imaging of LSPCs-treated mice 24 hours after treatment. 
Mice were injected intravenously with LSPCs and imaged for up to 24 hours after treatment. siRNA 
signal was imaged on 500/540 nm filter. 24 hours after treatment there is no siRNA signal in the brain. 





















































































































Figure A.2. Percent of PrP
C
-positive cells using scrambled siRNA and RVM peptide.  
A) Percent of PrP
C
-positive cells in the brain. B) Percent of PrP
C
-positive cells in the kidney. Error bars 






































































































































Figure A.3. Comparison of PrP
C
 levels in C57Bl/6 and CR1/2 hemi mice. 
A) Median fluorescent intensity (MFI) of PrP
C
 in the brain. B) PrP+ cells in the brain. C) MFI of PrP
C
 
in the kidney. D) PrP+ cells in the kidney. Error bars indicate SEM. * p<0.05, ** p<0.01. t test 
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TSE Transmissible spongiform encephalopathy 
CNS Central nervous system 
CJD Creutzfeldt-Jakob disease 
UV Ultraviolet 
GSS Gerstmann-Sträussler-Scheinker syndrome 
PrP
C
 Cellular prion protein (non-infectious) 
PrP
Res
 Proteinase K resistant cellular prion protein (infectious) 
ER Endoplasmic reticulum 
GPI Glycosylphosphatidylinositol 
BSE Bovine spongiform encephalopathy 




LRP 37 kDa/67 kDa laminin receptor 
Kd Dissociation constant 
SOD Superoxide dismutase 
HSC Hematopoietic stem cells 
DC Dendritic cells 
GALT Gut-associated lymphoid tissue 
MBM Meat and bone meal 
CWD Chronic wasting disease 
LRS Lymphoreticular system 
TME Transmissible mink encephalopathy 
FSE Feline spongiform encephalopathy 
CJD Creutzfeldt-Jakob disease 
sCJD Sporadic Creutzfeldt-Jakob disease 
f/gCJD Familial/genetic Creutzfeldt-Jakob disease 
iCJD Iatrogenic Creutzfeldt-Jakob disease 
vCJD Variant Creutzfeldt-Jakob disease 
FFI Fatal familial insomnia 
AD Alzheimer’s disease 
PD Parkinson’s disease 
HD Huntington’s disease 
APP Amyloid precursor protein 
Ab Amyloid b 
APLP1 Amyloid-like precursor protein 1 
AmB Amphotericin B 
PEI Polyethyleneimine 
PPI Polypropyleneimine 
N2a Neuroblastoma cells 
BBB Blood-brain barrier 
GAGs Glycosaminoglycans 
DS-500 Dextran sulfate 500 
HS Heparan sulfate 
CR Congo red 
CFA Complete Freund’s adjuvant 
RNAi RNA interference 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
LSPCs Liposome-siRNA-peptide complexes 
dsRNA Double-stranded RNA 
ssRNA Single-stranded RNA 
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Dcr Dicer 
RISC RNA-induced silencing complex 
Ago Argonaute 
PS Phosphorothioate 
LNAs Locked nucleic acids 
CPPs Cell-penetrating peptides 
MPPs Membrane-penetrating peptides 
TLR Toll-like receptor 
RVG Rabies virus glycoprotein 
RVG-9r Rabies virus glycoprotein with nine arginine residues 
SNALP Stable nucleic acid lipid particle 
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) 
DOTMA 1,2-di-O-octadecenyl-3-trimethylammonium propane (chloride salt) 
DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
OTEs Off-target effects 
miRNA Micro RNAs 
PALETS Peptide-addressed liposome-encapsulated therapeutic siRNA 
MPS Mononuclear phagocyte system 
DSPE 1,2-distearoyl-sn-glycero-3-phosphoethanolamine 
ddPCR Digital droplet polymerase chain reaction 
SEM Standard error of the mean 
SD Standard deviation 
MFI Median fluorescent intensity 
PEG Pegylated lipids 




NBH Normal brain homogenate 
PMCA Protein misfolding cyclic amplification 
PK Proteinase K 




GFAP Glial fibrillary acidic protein 
ELISA Enzyme-linked immunosorbent assay 
	
	
